

16.2.8 Listing of Individual Laboratory Measurements by Participant, When Required by Regulatory Authorities

Listing 13: Abnormal Clinical Laboratory Results – Chemistry

Listing 14: Abnormal Clinical Laboratory Results – Hematology

**Listing 13:
Abnormal Clinical Laboratory Results - Chemistry**

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM007	100 µg (18-55 years)	MALE	46	-1	-4	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	1	1	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	8	7	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	29	28	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	36	34	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	-1	-4	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	1	1	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	8	7	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	29	28	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	36	34	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	-1	-4	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM007	100 µg (18-55 years)	MALE	46	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	8	7	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	29	28	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	36	34	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	-1	-4	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	1	1	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	8	7	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	29	28	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	36	34	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	-1	-4	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	8	7	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	29	28	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM007	100 µg (18-55 years)	MALE	46	36	34	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	-1	-4	Total Bilirubin (mg/dL)	1.5 (Mild)	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	-1	-2	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	1	1	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	8	7	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	29	28	Total Bilirubin (mg/dL)	1.4 (Mild)	NOT RELATED	Grade 1 Similar to baseline bilirubin	NC- DOSE NOT CHANGED	No
CV01EM007	100 µg (18-55 years)	MALE	46	36	34	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	57	55	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	-1	-4	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	8	8	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	29	29	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM010	100 µg (18-55 years)	FEMALE	23	36	35	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	-1	-4	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	1	1	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	8	8	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	29	29	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	36	35	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	-1	-4	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	1	1	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	8	8	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	36	35	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	-1	-4	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM010	100 µg (18-55 years)	FEMALE	23	8	8	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	29	29	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	36	35	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	-1	-4	Serum Lipase (U/L)	53.0	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	1	1	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	8	8	Serum Lipase (U/L)	53.0	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	29	29	Serum Lipase (U/L)	78.0 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01EM010	100 µg (18-55 years)	FEMALE	23	36	35	Serum Lipase (U/L)	70.0 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01EM010	100 µg (18-55 years)	FEMALE	23	57	56	Serum Lipase (U/L)	77.0 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01EM010	100 µg (18-55 years)	FEMALE	23	119	113	Serum Lipase (U/L)	44.0	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	-1	-4	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	8	8	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	36	35	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM020	250 µg (18-55 years)	MALE	51	-1	-11	Alanine Aminotransferase (U/L)	33	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	1	1	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	8	7	Alanine Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	29	29	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	36	35	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	57	56	Alanine Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	-1	-11	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	1	1	Alkaline Phosphatase (U/L)	72	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	8	7	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	29	29	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	36	35	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	-1	-11	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM020	250 µg (18-55 years)	MALE	51	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	8	7	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	29	29	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	36	35	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	57	56	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	-1	-11	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	1	1	Creatinine (mg/dL)	1.12	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	8	7	Creatinine (mg/dL)	1.16	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	29	29	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	36	35	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	-1	-11	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	1	1	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	8	7	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM020	250 µg (18-55 years)	MALE	51	29	29	Serum Lipase (U/L)	39.0	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	36	35	Serum Lipase (U/L)	112.0 (Moderate)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01EM020	250 µg (18-55 years)	MALE	51	43	43	Serum Lipase (U/L)	72.0 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01EM020	250 µg (18-55 years)	MALE	51	57	56	Serum Lipase (U/L)	240.0 (Severe)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01EM020	250 µg (18-55 years)	MALE	51	-1	-11	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	36	35	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	57	56	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	-1	-5	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	8	7	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM032	100 µg (56-70 years)	FEMALE	64	29	28	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	36	36	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	-1	-5	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	1	1	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	8	7	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	29	28	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	36	36	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	-1	-5	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	8	7	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	29	28	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	36	36	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM032	100 µg (56-70 years)	FEMALE	64	-1	-5	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	1	1	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	8	7	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	29	28	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	36	36	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	-1	-5	Serum Lipase (U/L)	57.0	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	1	1	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	8	7	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	29	28	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	36	36	Serum Lipase (U/L)	72.0 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01EM032	100 µg (56-70 years)	FEMALE	64	43	44	Serum Lipase (U/L)	68.0 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01EM032	100 µg (56-70 years)	FEMALE	64	57	58	Serum Lipase (U/L)	70.0 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01EM032	100 µg (56-70 years)	FEMALE	64	119	114	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM032	100 µg (56-70 years)	FEMALE	64	8	7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	36	36	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	-1	-2	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	8	9	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	29	27	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	36	35	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	-1	-2	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	1	1	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	8	9	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	29	27	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	36	35	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM054	50 µg (18-55 years)	FEMALE	54	-1	-2	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	1	1	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	8	9	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	29	27	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	36	35	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	-1	-2	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	8	9	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	29	27	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	36	35	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	-1	-2	Serum Lipase (U/L)	51.0	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	1	1	Serum Lipase (U/L)	118.0 (Moderate)	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	8	9	Serum Lipase (U/L)	44.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM054	50 µg (18-55 years)	FEMALE	54	29	27	Serum Lipase (U/L)	57.0	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	36	35	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	-1	-2	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	29	27	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	36	35	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	-1	-4	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	1	1	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	8	9	Alanine Aminotransferase (U/L)	39	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	29	29	Alanine Aminotransferase (U/L)	52 (Mild)	NOT RELATED	Related to Alcohol	NA- NOT APPLICABLE	No
CV01HC003	100 µg (18-55 years)	MALE	22	36	35	Alanine Aminotransferase (U/L)	37	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	-1	-4	Alkaline Phosphatase (U/L)	86	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC003	100 µg (18-55 years)	MALE	22	1	1	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	8	9	Alkaline Phosphatase (U/L)	90	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	29	29	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	36	35	Alkaline Phosphatase (U/L)	81	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	-1	-4	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	8	9	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	29	29	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	36	35	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	-1	-4	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	1	1	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	8	9	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	29	29	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC003	100 µg (18-55 years)	MALE	22	36	35	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	-1	-4	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	1	1	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	8	9	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	29	29	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	36	35	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	-1	-4	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	8	9	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	36	35	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	-1	-4	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	1	1	Alanine Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	8	8	Alanine Aminotransferase (U/L)	88 (Mild)	NOT RELATED	subject confirmed alcohol use	NC- DOSE NOT CHANGED	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC004	100 µg (18-55 years)	MALE	34	29	29	Alanine Aminotransferase (U/L)	39	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	36	36	Alanine Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	-1	-4	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	1	1	Alkaline Phosphatase (U/L)	91	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	8	8	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	29	29	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	36	36	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	-1	-4	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	1	1	Aspartate Aminotransferase (U/L)	29	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	8	8	Aspartate Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	29	29	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	36	36	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC004	100 µg (18-55 years)	MALE	34	-1	-4	Creatinine (mg/dL)	1.18	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	1	1	Creatinine (mg/dL)	1.17	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	8	8	Creatinine (mg/dL)	1.20	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	29	29	Creatinine (mg/dL)	1.14	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	36	36	Creatinine (mg/dL)	1.26	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	-1	-4	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	1	1	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	8	8	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	29	29	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	36	36	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	-1	-4	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	8	8	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	29	29	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	36	36	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC027	25 µg (56-70 years)	FEMALE	69	-1	-2	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	1	1	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	8	8	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	29	29	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	36	36	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	-1	-2	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	8	8	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	29	29	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	36	36	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	-1	-2	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC027	25 µg (56-70 years)	FEMALE	69	8	8	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	29	29	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	36	36	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	-1	-2	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	1	1	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	8	8	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	29	29	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	36	36	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	-1	-2	Serum Lipase (U/L)	60.0	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	1	1	Serum Lipase (U/L)	67.0 (Mild)	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	8	8	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	29	29	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	36	36	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	-1	-2	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC027	25 µg (56-70 years)	FEMALE	69	1	1	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	8	8	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	29	29	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	36	36	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	-1	-5	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	1	1	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	8	9	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	29	28	Alanine Aminotransferase (U/L)	32	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	36	36	Alanine Aminotransferase (U/L)	37	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	-1	-5	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	1	1	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	8	9	Alkaline Phosphatase (U/L)	81	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	29	28	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC038	100 µg (56-70 years)	MALE	56	36	36	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	-1	-5	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	1	1	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	8	9	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	29	28	Aspartate Aminotransferase (U/L)	54 (Mild)	NOT RELATED	alcohol consumption	NC- DOSE NOT CHANGED	No
CV01HC038	100 µg (56-70 years)	MALE	56	36	36	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	-1	-5	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	1	1	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	8	9	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	29	28	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	36	36	Creatinine (mg/dL)	0.89	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	-1	-5	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	1	1	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC038	100 µg (56-70 years)	MALE	56	8	9	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	29	28	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	36	36	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	-1	-5	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	36	36	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	-1	-11	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	1	1	Alanine Aminotransferase (U/L)	53 (Mild)	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	8	8	Alanine Aminotransferase (U/L)	43	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	29	30	Alanine Aminotransferase (U/L)	44	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	36	38	Alanine Aminotransferase (U/L)	46	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP001	25 µg (18-55 years)	MALE	46	-1	-11	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	1	1	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	8	8	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	29	30	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	36	38	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	-1	-11	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	8	8	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	29	30	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	36	38	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	-1	-11	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	1	1	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	8	8	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP001	25 µg (18-55 years)	MALE	46	29	30	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	36	38	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	-1	-11	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	1	1	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	8	8	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	29	30	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	36	38	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	-1	-11	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	29	30	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	36	38	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	-1	-15	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	1	1	Alanine Aminotransferase (U/L)	38	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP011	25 µg (18-55 years)	MALE	37	8	9	Alanine Aminotransferase (U/L)	66 (Mild)	NOT RELATED	increased alcohol night before	NC- DOSE NOT CHANGED	No
CV01KP011	25 µg (18-55 years)	MALE	37	29	29	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	36	37	Alanine Aminotransferase (U/L)	42	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	-1	-15	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	1	1	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	8	9	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	29	29	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	36	37	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	-1	-15	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	8	9	Aspartate Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP011	25 µg (18-55 years)	MALE	37	36	37	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	-1	-15	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	1	1	Creatinine (mg/dL)	1.22	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	8	9	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	36	37	Creatinine (mg/dL)	1.02	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	-1	-15	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	1	1	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	8	9	Serum Lipase (U/L)	8.0	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	29	29	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	36	37	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	-1	-15	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP011	25 µg (18-55 years)	MALE	37	36	37	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	-1	-11	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	8	9	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	29	29	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	36	37	Alanine Aminotransferase (U/L)	45	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	-1	-11	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	1	1	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	8	9	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	29	29	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	36	37	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	-1	-11	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP027	25 µg (18-55 years)	MALE	53	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	8	9	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	29	29	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	36	37	Aspartate Aminotransferase (U/L)	45 (Mild)	NOT RELATED	Alcohol intake	NA- NOT APPLICABLE	No
CV01KP027	25 µg (18-55 years)	MALE	53	-1	-11	Creatinine (mg/dL)	0.71	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	1	1	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	8	9	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	29	29	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	36	37	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	-1	-11	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	8	9	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	29	29	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP027	25 µg (18-55 years)	MALE	53	36	37	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	-1	-11	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	8	9	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	36	37	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	-1	-26	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	1	1	Alanine Aminotransferase (U/L)	53 (Mild)	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	8	8	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	29	28	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	36	35	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	-1	-26	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	1	1	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP030	250 µg (18-55 years)	MALE	22	8	8	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	29	28	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	36	35	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	-1	-26	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	1	1	Aspartate Aminotransferase (U/L)	38	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	8	8	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	29	28	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	36	35	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	-1	-26	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	1	1	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	8	8	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	29	28	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	36	35	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP030	250 µg (18-55 years)	MALE	22	-1	-26	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	1	1	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	29	28	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	36	35	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	-1	-26	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	36	35	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	-1	-8	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	1	1	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	8	9	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP032	25 µg (18-55 years)	MALE	27	29	29	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	36	37	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	-1	-8	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	1	1	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	8	9	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	29	29	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	36	37	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	-1	-8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	8	9	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	29	29	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	36	37	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP032	25 µg (18-55 years)	MALE	27	-1	-8	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	1	1	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	8	9	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	29	29	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	36	37	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	-1	-8	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	1	1	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	8	9	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	29	29	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	36	37	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	-1	-8	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	1	1	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	8	9	Total Bilirubin (mg/dL)	1.6 (Mild)	NOT RELATED	suspected gilberts	NC- DOSE NOT CHANGED	No
CV01KP032	25 µg (18-55 years)	MALE	27	29	29	Total Bilirubin (mg/dL)	2.1 (Moderate)	NOT RELATED	suspected Gilberts	NA- NOT APPLICABLE	No
CV01KP032	25 µg (18-55 years)	MALE	27	36	37	Total Bilirubin (mg/dL)	1.8 (Mild)	NOT RELATED	Other	NA- NOT APPLICABLE	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP036	250 µg (18-55 years)	MALE	33	-1	-26	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	8	8	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	29	29	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	36	36	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	-1	-26	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	8	8	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	29	29	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	36	36	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	-1	-26	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP036	250 µg (18-55 years)	MALE	33	8	8	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	36	36	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	-1	-26	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	8	8	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	29	29	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	36	36	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	-1	-26	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	1	1	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	8	8	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	29	29	Serum Lipase (U/L)	58.0	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	36	36	Serum Lipase (U/L)	61.0	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	-1	-26	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP036	250 µg (18-55 years)	MALE	33	1	1	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	8	8	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	29	29	Total Bilirubin (mg/dL)	1.5 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP036	250 µg (18-55 years)	MALE	33	36	36	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	-1	-17	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	8	9	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	29	29	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	36	37	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	-1	-17	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	1	1	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	8	9	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	29	29	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP061	25 µg (≥71 years)	MALE	72	36	37	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	-1	-17	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	8	9	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	29	29	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	36	37	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	-1	-17	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	1	1	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	8	9	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	29	29	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	36	37	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	-1	-17	Serum Lipase (U/L)	44.0	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	1	1	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP061	25 µg (≥71 years)	MALE	72	8	9	Serum Lipase (U/L)	67.0 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01KP061	25 µg (≥71 years)	MALE	72	29	29	Serum Lipase (U/L)	52.0	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	36	37	Serum Lipase (U/L)	53.0	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	-1	-17	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	36	37	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	-1	-15	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	8	9	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	29	29	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	36	36	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP067	100 µg (≥71 years)	FEMALE	73	-1	-15	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	1	1	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	8	9	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	29	29	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	36	36	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	-1	-15	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	8	9	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	29	29	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	36	36	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	-1	-15	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	1	1	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	8	9	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP067	100 µg (≥71 years)	FEMALE	73	29	29	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	36	36	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	-1	-15	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	1	1	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	8	9	Serum Lipase (U/L)	67.0 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01KP067	100 µg (≥71 years)	FEMALE	73	29	29	Serum Lipase (U/L)	46.0	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	36	36	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	-1	-15	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	36	36	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	-1	-19	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP078	100 µg (≥71 years)	FEMALE	73	8	8	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	29	29	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	36	36	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	-1	-19	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	1	1	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	8	8	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	29	29	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	36	36	Alkaline Phosphatase (U/L)	61	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	-1	-19	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	8	8	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	29	29	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP078	100 µg (≥71 years)	FEMALE	73	36	36	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	-1	-19	Creatinine (mg/dL)	0.71	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	1	1	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	8	8	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	29	29	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	36	36	Creatinine (mg/dL)	0.61	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	-1	-19	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	1	1	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	29	29	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	36	36	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	-1	-19	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	1	1	Total Bilirubin (mg/dL)	1.4 (Mild)	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	29	29	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP078	100 µg (≥71 years)	FEMALE	73	36	36	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	-1	-24	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	1	1	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	8	7	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	29	27	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	36	35	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	-1	-24	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	1	1	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	8	7	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	29	27	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	36	35	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	-1	-24	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR035	50 µg (≥71 years)	FEMALE	77	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	8	7	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	29	27	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	36	35	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	-1	-24	Creatinine (mg/dL)	0.89	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	1	1	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	8	7	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	29	27	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	36	35	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	-1	-24	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	1	1	Serum Lipase (U/L)	181.0 (Severe)	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	8	7	Serum Lipase (U/L)	336.0 (Severe)	NOT RELATED	Baseline lipase elevated	NC- DOSE NOT CHANGED	No
CV01VR035	50 µg (≥71 years)	FEMALE	77	15	13	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR035	50 µg (≥71 years)	FEMALE	77	29	27	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	36	35	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	-1	-24	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	8	7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	29	27	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	36	35	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

**Listing 14:
Abnormal Clinical Laboratory Results - Hematology**

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM003	250 µg (18-55 years)	MALE	30	-1	-22	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
CV01EM003	250 µg (18-55 years)	MALE	30	1	1	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
CV01EM003	250 µg (18-55 years)	MALE	30	8	8	Hemoglobin (g/dL)	14.9	N/A	N/A	N/A	N/A
CV01EM003	250 µg (18-55 years)	MALE	30	29	29	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
CV01EM003	250 µg (18-55 years)	MALE	30	36	36	Hemoglobin (g/dL)	14.0 (Mild)	NOT RELATED	Grade 1, due to phlebotomy procedure	NA- NOT APPLICABLE	No
CV01EM003	250 µg (18-55 years)	MALE	30	-1	-22	PT (seconds)	11.8 (Mild)	N/A	N/A	N/A	N/A
CV01EM003	250 µg (18-55 years)	MALE	30	-1	-14	PT (seconds)	10.5	N/A	N/A	N/A	N/A
CV01EM003	250 µg (18-55 years)	MALE	30	-1	-22	PTT (seconds)	34.0 (Mild)	N/A	N/A	N/A	N/A
CV01EM003	250 µg (18-55 years)	MALE	30	-1	-22	Platelets (10 ³ /uL)	190	N/A	N/A	N/A	N/A
CV01EM003	250 µg (18-55 years)	MALE	30	1	1	Platelets (10 ³ /uL)	182	N/A	N/A	N/A	N/A
CV01EM003	250 µg (18-55 years)	MALE	30	8	8	Platelets (10 ³ /uL)	204	N/A	N/A	N/A	N/A
CV01EM003	250 µg (18-55 years)	MALE	30	29	29	Platelets (10 ³ /uL)	197	N/A	N/A	N/A	N/A
CV01EM003	250 µg (18-55 years)	MALE	30	36	36	Platelets (10 ³ /uL)	212	N/A	N/A	N/A	N/A
CV01EM003	250 µg (18-55 years)	MALE	30	-1	-22	WBC (10 ³ /uL)	3.70	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM003	250 µg (18-55 years)	MALE	30	-1	-15	WBC (10 ³ /uL)	4.50	N/A	N/A	N/A	N/A
CV01EM003	250 µg (18-55 years)	MALE	30	1	1	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01EM003	250 µg (18-55 years)	MALE	30	8	8	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A
CV01EM003	250 µg (18-55 years)	MALE	30	29	29	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A
CV01EM003	250 µg (18-55 years)	MALE	30	36	36	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A
CV01EM004	100 µg (18-55 years)	MALE	32	-1	-4	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
CV01EM004	100 µg (18-55 years)	MALE	32	1	1	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A
CV01EM004	100 µg (18-55 years)	MALE	32	8	7	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
CV01EM004	100 µg (18-55 years)	MALE	32	29	28	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Grade 1 Due to study procedures phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM004	100 µg (18-55 years)	MALE	32	36	35	Hemoglobin (g/dL)	14.7 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM004	100 µg (18-55 years)	MALE	32	-1	-4	PT (seconds)	10.5	N/A	N/A	N/A	N/A
CV01EM004	100 µg (18-55 years)	MALE	32	-1	-4	PTT (seconds)	32.0	N/A	N/A	N/A	N/A
CV01EM004	100 µg (18-55 years)	MALE	32	-1	-4	Platelets (10 ³ /uL)	332	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM004	100 µg (18-55 years)	MALE	32	1	1	Platelets (10 ³ /uL)	334	N/A	N/A	N/A	N/A
CV01EM004	100 µg (18-55 years)	MALE	32	8	7	Platelets (10 ³ /uL)	358	N/A	N/A	N/A	N/A
CV01EM004	100 µg (18-55 years)	MALE	32	29	28	Platelets (10 ³ /uL)	343	N/A	N/A	N/A	N/A
CV01EM004	100 µg (18-55 years)	MALE	32	36	35	Platelets (10 ³ /uL)	366	N/A	N/A	N/A	N/A
CV01EM004	100 µg (18-55 years)	MALE	32	-1	-4	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A
CV01EM004	100 µg (18-55 years)	MALE	32	1	1	WBC (10 ³ /uL)	6.20	N/A	N/A	N/A	N/A
CV01EM004	100 µg (18-55 years)	MALE	32	8	7	WBC (10 ³ /uL)	6.20	N/A	N/A	N/A	N/A
CV01EM004	100 µg (18-55 years)	MALE	32	29	28	WBC (10 ³ /uL)	6.40	N/A	N/A	N/A	N/A
CV01EM004	100 µg (18-55 years)	MALE	32	36	35	WBC (10 ³ /uL)	5.70	N/A	N/A	N/A	N/A
CV01EM005	100 µg (18-55 years)	FEMALE	28	-1	-4	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
CV01EM005	100 µg (18-55 years)	FEMALE	28	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
CV01EM005	100 µg (18-55 years)	FEMALE	28	8	8	Hemoglobin (g/dL)	13.7 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM005	100 µg (18-55 years)	FEMALE	28	29	28	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Grade 1 Due to study procedures phlebotomy	NC- DOSE NOT CHANGED	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM005	100 µg (18-55 years)	FEMALE	28	36	35	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM005	100 µg (18-55 years)	FEMALE	28	-1	-4	PT (seconds)	10.6	N/A	N/A	N/A	N/A
CV01EM005	100 µg (18-55 years)	FEMALE	28	-1	-4	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01EM005	100 µg (18-55 years)	FEMALE	28	-1	-4	Platelets (10 ³ /uL)	201	N/A	N/A	N/A	N/A
CV01EM005	100 µg (18-55 years)	FEMALE	28	1	1	Platelets (10 ³ /uL)	200	N/A	N/A	N/A	N/A
CV01EM005	100 µg (18-55 years)	FEMALE	28	8	8	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A
CV01EM005	100 µg (18-55 years)	FEMALE	28	29	28	Platelets (10 ³ /uL)	206	N/A	N/A	N/A	N/A
CV01EM005	100 µg (18-55 years)	FEMALE	28	36	35	Platelets (10 ³ /uL)	238	N/A	N/A	N/A	N/A
CV01EM005	100 µg (18-55 years)	FEMALE	28	-1	-4	WBC (10 ³ /uL)	7.80	N/A	N/A	N/A	N/A
CV01EM005	100 µg (18-55 years)	FEMALE	28	1	1	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01EM005	100 µg (18-55 years)	FEMALE	28	8	8	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01EM005	100 µg (18-55 years)	FEMALE	28	29	28	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A
CV01EM005	100 µg (18-55 years)	FEMALE	28	36	35	WBC (10 ³ /uL)	5.30	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	-1	-4	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM007	100 µg (18-55 years)	MALE	46	1	1	Hemoglobin (g/dL)	15.7	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	8	7	Hemoglobin (g/dL)	15.6 (Mild)	NOT RELATED	Due to phlebotomy (study procedure)	NC- DOSE NOT CHANGED	No
CV01EM007	100 µg (18-55 years)	MALE	46	29	28	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM007	100 µg (18-55 years)	MALE	46	36	34	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM007	100 µg (18-55 years)	MALE	46	-1	-4	PT (seconds)	10.7	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	-1	-4	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	-1	-4	Platelets (10 ³ /uL)	163	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	1	1	Platelets (10 ³ /uL)	185	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	8	7	Platelets (10 ³ /uL)	195	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	29	28	Platelets (10 ³ /uL)	170	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	36	34	Platelets (10 ³ /uL)	162	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	-1	-4	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	1	1	WBC (10 ³ /uL)	5.10	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM007	100 µg (18-55 years)	MALE	46	8	7	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	29	28	WBC (10 ³ /uL)	5.30	N/A	N/A	N/A	N/A
CV01EM007	100 µg (18-55 years)	MALE	46	36	34	WBC (10 ³ /uL)	3.90	N/A	N/A	N/A	N/A
CV01EM009	100 µg (18-55 years)	MALE	32	-1	-4	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
CV01EM009	100 µg (18-55 years)	MALE	32	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
CV01EM009	100 µg (18-55 years)	MALE	32	8	8	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM009	100 µg (18-55 years)	MALE	32	29	29	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
CV01EM009	100 µg (18-55 years)	MALE	32	36	36	Hemoglobin (g/dL)	14.3 (Mild)	NOT RELATED	study procedure phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM009	100 µg (18-55 years)	MALE	32	-1	-4	PT (seconds)	11.2	N/A	N/A	N/A	N/A
CV01EM009	100 µg (18-55 years)	MALE	32	-1	-4	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01EM009	100 µg (18-55 years)	MALE	32	-1	-4	Platelets (10 ³ /uL)	215	N/A	N/A	N/A	N/A
CV01EM009	100 µg (18-55 years)	MALE	32	1	1	Platelets (10 ³ /uL)	206	N/A	N/A	N/A	N/A
CV01EM009	100 µg (18-55 years)	MALE	32	8	8	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
CV01EM009	100 µg (18-55 years)	MALE	32	29	29	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM009	100 µg (18-55 years)	MALE	32	36	36	Platelets (10 ³ /uL)	237	N/A	N/A	N/A	N/A
CV01EM009	100 µg (18-55 years)	MALE	32	-1	-4	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01EM009	100 µg (18-55 years)	MALE	32	1	1	WBC (10 ³ /uL)	5.30	N/A	N/A	N/A	N/A
CV01EM009	100 µg (18-55 years)	MALE	32	8	8	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01EM009	100 µg (18-55 years)	MALE	32	29	29	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01EM009	100 µg (18-55 years)	MALE	32	36	36	WBC (10 ³ /uL)	5.10	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	-1	-4	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	1	1	Hemoglobin (g/dL)	12.2	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	8	8	Hemoglobin (g/dL)	12.5	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	29	29	Hemoglobin (g/dL)	12.6	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	36	35	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM010	100 µg (18-55 years)	FEMALE	23	-1	-4	PT (seconds)	11.2	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	-1	-4	PTT (seconds)	27.0	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	-1	-4	Platelets (10 ³ /uL)	222	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM010	100 µg (18-55 years)	FEMALE	23	1	1	Platelets (10 ³ /uL)	226	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	8	8	Platelets (10 ³ /uL)	252	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	29	29	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	36	35	Platelets (10 ³ /uL)	231	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	-1	-4	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	1	1	WBC (10 ³ /uL)	3.20 (Mild)	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	8	8	WBC (10 ³ /uL)	2.80 (Mild)	NOT RELATED	Grade I - similar to Grade I that was present prior to receipt of vaccine	NC- DOSE NOT CHANGED	No
CV01EM010	100 µg (18-55 years)	FEMALE	23	29	29	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A
CV01EM010	100 µg (18-55 years)	FEMALE	23	36	35	WBC (10 ³ /uL)	3.00 (Mild)	NOT RELATED	Grade 1 Similar to her baseline	NC- DOSE NOT CHANGED	No
CV01EM010	100 µg (18-55 years)	FEMALE	23	57	56	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01EM012	100 µg (18-55 years)	MALE	21	-1	-4	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
CV01EM012	100 µg (18-55 years)	MALE	21	1	1	Hemoglobin (g/dL)	16.7	N/A	N/A	N/A	N/A
CV01EM012	100 µg (18-55 years)	MALE	21	8	8	Hemoglobin (g/dL)	15.5 (Mild)	NOT RELATED	Due to study - phlebotomy	NC- DOSE NOT CHANGED	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM012	100 µg (18-55 years)	MALE	21	29	29	Hemoglobin (g/dL)	15.3 (Mild)	NOT RELATED	Grade 1 Due to study procedures phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM012	100 µg (18-55 years)	MALE	21	36	36	Hemoglobin (g/dL)	15.9 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM012	100 µg (18-55 years)	MALE	21	-1	-4	PT (seconds)	10.9	N/A	N/A	N/A	N/A
CV01EM012	100 µg (18-55 years)	MALE	21	-1	-4	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01EM012	100 µg (18-55 years)	MALE	21	-1	-4	Platelets (10 ³ /uL)	175	N/A	N/A	N/A	N/A
CV01EM012	100 µg (18-55 years)	MALE	21	1	1	Platelets (10 ³ /uL)	168	N/A	N/A	N/A	N/A
CV01EM012	100 µg (18-55 years)	MALE	21	8	8	Platelets (10 ³ /uL)	174	N/A	N/A	N/A	N/A
CV01EM012	100 µg (18-55 years)	MALE	21	29	29	Platelets (10 ³ /uL)	170	N/A	N/A	N/A	N/A
CV01EM012	100 µg (18-55 years)	MALE	21	36	36	Platelets (10 ³ /uL)	189	N/A	N/A	N/A	N/A
CV01EM012	100 µg (18-55 years)	MALE	21	-1	-4	WBC (10 ³ /uL)	5.70	N/A	N/A	N/A	N/A
CV01EM012	100 µg (18-55 years)	MALE	21	1	1	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01EM012	100 µg (18-55 years)	MALE	21	8	8	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01EM012	100 µg (18-55 years)	MALE	21	29	29	WBC (10 ³ /uL)	5.60	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM012	100 µg (18-55 years)	MALE	21	36	36	WBC (10 ³ /uL)	5.00	N/A	N/A	N/A	N/A
CV01EM016	250 µg (18-55 years)	FEMALE	24	-1	-21	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
CV01EM016	250 µg (18-55 years)	FEMALE	24	1	1	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
CV01EM016	250 µg (18-55 years)	FEMALE	24	8	7	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM016	250 µg (18-55 years)	FEMALE	24	29	28	Hemoglobin (g/dL)	13.4 (Mild)	NOT RELATED	Grade I due to study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM016	250 µg (18-55 years)	FEMALE	24	36	35	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM016	250 µg (18-55 years)	FEMALE	24	-1	-21	PT (seconds)	9.9	N/A	N/A	N/A	N/A
CV01EM016	250 µg (18-55 years)	FEMALE	24	-1	-21	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01EM016	250 µg (18-55 years)	FEMALE	24	-1	-21	Platelets (10 ³ /uL)	291	N/A	N/A	N/A	N/A
CV01EM016	250 µg (18-55 years)	FEMALE	24	1	1	Platelets (10 ³ /uL)	275	N/A	N/A	N/A	N/A
CV01EM016	250 µg (18-55 years)	FEMALE	24	8	7	Platelets (10 ³ /uL)	282	N/A	N/A	N/A	N/A
CV01EM016	250 µg (18-55 years)	FEMALE	24	29	28	Platelets (10 ³ /uL)	281	N/A	N/A	N/A	N/A
CV01EM016	250 µg (18-55 years)	FEMALE	24	36	35	Platelets (10 ³ /uL)	318	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM016	250 µg (18-55 years)	FEMALE	24	-1	-21	WBC (10 ³ /uL)	5.20	N/A	N/A	N/A	N/A
CV01EM016	250 µg (18-55 years)	FEMALE	24	1	1	WBC (10 ³ /uL)	5.00	N/A	N/A	N/A	N/A
CV01EM016	250 µg (18-55 years)	FEMALE	24	8	7	WBC (10 ³ /uL)	5.00	N/A	N/A	N/A	N/A
CV01EM016	250 µg (18-55 years)	FEMALE	24	29	28	WBC (10 ³ /uL)	5.10	N/A	N/A	N/A	N/A
CV01EM016	250 µg (18-55 years)	FEMALE	24	36	35	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	-1	-11	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	1	1	Hemoglobin (g/dL)	16.5	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	8	7	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM020	250 µg (18-55 years)	MALE	51	29	29	Hemoglobin (g/dL)	15.4 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM020	250 µg (18-55 years)	MALE	51	36	35	Hemoglobin (g/dL)	14.7 (Moderate)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01EM020	250 µg (18-55 years)	MALE	51	-1	-11	PT (seconds)	10.0	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	-1	-11	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	-1	-11	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	1	1	Platelets (10 ³ /uL)	266	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM020	250 µg (18-55 years)	MALE	51	8	7	Platelets (10 ³ /uL)	266	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	29	29	Platelets (10 ³ /uL)	241	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	36	35	Platelets (10 ³ /uL)	253	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	-1	-11	WBC (10 ³ /uL)	5.80	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	1	1	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	8	7	WBC (10 ³ /uL)	5.40	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	29	29	WBC (10 ³ /uL)	6.20	N/A	N/A	N/A	N/A
CV01EM020	250 µg (18-55 years)	MALE	51	36	35	WBC (10 ³ /uL)	6.30	N/A	N/A	N/A	N/A
CV01EM023	100 µg (56-70 years)	MALE	69	-1	-7	Hemoglobin (g/dL)	16.1	N/A	N/A	N/A	N/A
CV01EM023	100 µg (56-70 years)	MALE	69	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
CV01EM023	100 µg (56-70 years)	MALE	69	8	7	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM023	100 µg (56-70 years)	MALE	69	29	28	Hemoglobin (g/dL)	14.0 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM023	100 µg (56-70 years)	MALE	69	36	36	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	Grade 1 -Due to study procedure-phlebotomy	NA- NOT APPLICABLE	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM023	100 µg (56-70 years)	MALE	69	-1	-7	PT (seconds)	11.5 (Mild)	N/A	N/A	N/A	N/A
CV01EM023	100 µg (56-70 years)	MALE	69	-1	-4	PT (seconds)	10.6	N/A	N/A	N/A	N/A
CV01EM023	100 µg (56-70 years)	MALE	69	-1	-7	PTT (seconds)	36.0 (Mild)	N/A	N/A	N/A	N/A
CV01EM023	100 µg (56-70 years)	MALE	69	-1	-4	PTT (seconds)	34.0 (Mild)	N/A	N/A	N/A	N/A
CV01EM023	100 µg (56-70 years)	MALE	69	-1	-7	Platelets (10 ³ /uL)	304	N/A	N/A	N/A	N/A
CV01EM023	100 µg (56-70 years)	MALE	69	1	1	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
CV01EM023	100 µg (56-70 years)	MALE	69	8	7	Platelets (10 ³ /uL)	283	N/A	N/A	N/A	N/A
CV01EM023	100 µg (56-70 years)	MALE	69	29	28	Platelets (10 ³ /uL)	277	N/A	N/A	N/A	N/A
CV01EM023	100 µg (56-70 years)	MALE	69	36	36	Platelets (10 ³ /uL)	313	N/A	N/A	N/A	N/A
CV01EM023	100 µg (56-70 years)	MALE	69	-1	-7	WBC (10 ³ /uL)	8.60	N/A	N/A	N/A	N/A
CV01EM023	100 µg (56-70 years)	MALE	69	1	1	WBC (10 ³ /uL)	6.90	N/A	N/A	N/A	N/A
CV01EM023	100 µg (56-70 years)	MALE	69	8	7	WBC (10 ³ /uL)	6.70	N/A	N/A	N/A	N/A
CV01EM023	100 µg (56-70 years)	MALE	69	29	28	WBC (10 ³ /uL)	6.70	N/A	N/A	N/A	N/A
CV01EM023	100 µg (56-70 years)	MALE	69	36	36	WBC (10 ³ /uL)	6.60	N/A	N/A	N/A	N/A
CV01EM024	100 µg (56-70 years)	MALE	67	-1	-5	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM024	100 µg (56-70 years)	MALE	67	1	1	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
CV01EM024	100 µg (56-70 years)	MALE	67	8	9	Hemoglobin (g/dL)	14.7 (Mild)	NOT RELATED	study procedures -phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM024	100 µg (56-70 years)	MALE	67	29	30	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
CV01EM024	100 µg (56-70 years)	MALE	67	36	38	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Grade 1- Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM024	100 µg (56-70 years)	MALE	67	-1	-5	PT (seconds)	11.3	N/A	N/A	N/A	N/A
CV01EM024	100 µg (56-70 years)	MALE	67	-1	-5	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01EM024	100 µg (56-70 years)	MALE	67	-1	-5	Platelets (10 ³ /uL)	213	N/A	N/A	N/A	N/A
CV01EM024	100 µg (56-70 years)	MALE	67	1	1	Platelets (10 ³ /uL)	228	N/A	N/A	N/A	N/A
CV01EM024	100 µg (56-70 years)	MALE	67	8	9	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A
CV01EM024	100 µg (56-70 years)	MALE	67	29	30	Platelets (10 ³ /uL)	203	N/A	N/A	N/A	N/A
CV01EM024	100 µg (56-70 years)	MALE	67	36	38	Platelets (10 ³ /uL)	228	N/A	N/A	N/A	N/A
CV01EM024	100 µg (56-70 years)	MALE	67	-1	-5	WBC (10 ³ /uL)	6.30	N/A	N/A	N/A	N/A
CV01EM024	100 µg (56-70 years)	MALE	67	1	1	WBC (10 ³ /uL)	6.70	N/A	N/A	N/A	N/A
CV01EM024	100 µg (56-70 years)	MALE	67	8	9	WBC (10 ³ /uL)	6.70	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM024	100 µg (56-70 years)	MALE	67	29	30	WBC (10 ³ /uL)	5.60	N/A	N/A	N/A	N/A
CV01EM024	100 µg (56-70 years)	MALE	67	36	38	WBC (10 ³ /uL)	9.10	N/A	N/A	N/A	N/A
CV01EM025	25 µg (56-70 years)	FEMALE	65	-1	-5	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
CV01EM025	25 µg (56-70 years)	FEMALE	65	1	1	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A
CV01EM025	25 µg (56-70 years)	FEMALE	65	8	8	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM025	25 µg (56-70 years)	FEMALE	65	29	29	Hemoglobin (g/dL)	13.9 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM025	25 µg (56-70 years)	FEMALE	65	36	37	Hemoglobin (g/dL)	13.7 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM025	25 µg (56-70 years)	FEMALE	65	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A
CV01EM025	25 µg (56-70 years)	FEMALE	65	-1	-5	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01EM025	25 µg (56-70 years)	FEMALE	65	-1	-5	Platelets (10 ³ /uL)	199	N/A	N/A	N/A	N/A
CV01EM025	25 µg (56-70 years)	FEMALE	65	1	1	Platelets (10 ³ /uL)	181	N/A	N/A	N/A	N/A
CV01EM025	25 µg (56-70 years)	FEMALE	65	8	8	Platelets (10 ³ /uL)	196	N/A	N/A	N/A	N/A
CV01EM025	25 µg (56-70 years)	FEMALE	65	29	29	Platelets (10 ³ /uL)	204	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM025	25 µg (56-70 years)	FEMALE	65	36	37	Platelets (10 ³ /uL)	206	N/A	N/A	N/A	N/A
CV01EM025	25 µg (56-70 years)	FEMALE	65	-1	-5	WBC (10 ³ /uL)	6.10	N/A	N/A	N/A	N/A
CV01EM025	25 µg (56-70 years)	FEMALE	65	1	1	WBC (10 ³ /uL)	5.80	N/A	N/A	N/A	N/A
CV01EM025	25 µg (56-70 years)	FEMALE	65	8	8	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A
CV01EM025	25 µg (56-70 years)	FEMALE	65	29	29	WBC (10 ³ /uL)	6.00	N/A	N/A	N/A	N/A
CV01EM025	25 µg (56-70 years)	FEMALE	65	36	37	WBC (10 ³ /uL)	6.60	N/A	N/A	N/A	N/A
CV01EM027	25 µg (56-70 years)	FEMALE	68	-1	-5	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
CV01EM027	25 µg (56-70 years)	FEMALE	68	1	1	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
CV01EM027	25 µg (56-70 years)	FEMALE	68	8	8	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM027	25 µg (56-70 years)	FEMALE	68	29	29	Hemoglobin (g/dL)	12.1 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM027	25 µg (56-70 years)	FEMALE	68	36	37	Hemoglobin (g/dL)	11.4 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01EM027	25 µg (56-70 years)	FEMALE	68	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A
CV01EM027	25 µg (56-70 years)	FEMALE	68	-1	-5	PTT (seconds)	29.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM027	25 µg (56-70 years)	FEMALE	68	-1	-5	Platelets (10 ³ /uL)	209	N/A	N/A	N/A	N/A
CV01EM027	25 µg (56-70 years)	FEMALE	68	1	1	Platelets (10 ³ /uL)	192	N/A	N/A	N/A	N/A
CV01EM027	25 µg (56-70 years)	FEMALE	68	8	8	Platelets (10 ³ /uL)	189	N/A	N/A	N/A	N/A
CV01EM027	25 µg (56-70 years)	FEMALE	68	29	29	Platelets (10 ³ /uL)	185	N/A	N/A	N/A	N/A
CV01EM027	25 µg (56-70 years)	FEMALE	68	36	37	Platelets (10 ³ /uL)	187	N/A	N/A	N/A	N/A
CV01EM027	25 µg (56-70 years)	FEMALE	68	-1	-5	WBC (10 ³ /uL)	6.50	N/A	N/A	N/A	N/A
CV01EM027	25 µg (56-70 years)	FEMALE	68	1	1	WBC (10 ³ /uL)	4.20	N/A	N/A	N/A	N/A
CV01EM027	25 µg (56-70 years)	FEMALE	68	8	8	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01EM027	25 µg (56-70 years)	FEMALE	68	29	29	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A
CV01EM027	25 µg (56-70 years)	FEMALE	68	36	37	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01EM029	25 µg (56-70 years)	FEMALE	68	-1	-5	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A
CV01EM029	25 µg (56-70 years)	FEMALE	68	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
CV01EM029	25 µg (56-70 years)	FEMALE	68	8	8	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
CV01EM029	25 µg (56-70 years)	FEMALE	68	29	29	Hemoglobin (g/dL)	14.7 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM029	25 µg (56-70 years)	FEMALE	68	36	37	Hemoglobin (g/dL)	14.5 (Mild)	NOT RELATED	Grade 1 Due to study procedures	NA- NOT APPLICABLE	No
CV01EM029	25 µg (56-70 years)	FEMALE	68	-1	-5	PT (seconds)	10.0	N/A	N/A	N/A	N/A
CV01EM029	25 µg (56-70 years)	FEMALE	68	-1	-5	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01EM029	25 µg (56-70 years)	FEMALE	68	-1	-5	Platelets (10 ³ /uL)	320	N/A	N/A	N/A	N/A
CV01EM029	25 µg (56-70 years)	FEMALE	68	1	1	Platelets (10 ³ /uL)	332	N/A	N/A	N/A	N/A
CV01EM029	25 µg (56-70 years)	FEMALE	68	8	8	Platelets (10 ³ /uL)	337	N/A	N/A	N/A	N/A
CV01EM029	25 µg (56-70 years)	FEMALE	68	29	29	Platelets (10 ³ /uL)	352	N/A	N/A	N/A	N/A
CV01EM029	25 µg (56-70 years)	FEMALE	68	36	37	Platelets (10 ³ /uL)	361	N/A	N/A	N/A	N/A
CV01EM029	25 µg (56-70 years)	FEMALE	68	-1	-5	WBC (10 ³ /uL)	8.60	N/A	N/A	N/A	N/A
CV01EM029	25 µg (56-70 years)	FEMALE	68	1	1	WBC (10 ³ /uL)	8.60	N/A	N/A	N/A	N/A
CV01EM029	25 µg (56-70 years)	FEMALE	68	8	8	WBC (10 ³ /uL)	9.90	N/A	N/A	N/A	N/A
CV01EM029	25 µg (56-70 years)	FEMALE	68	29	29	WBC (10 ³ /uL)	8.60	N/A	N/A	N/A	N/A
CV01EM029	25 µg (56-70 years)	FEMALE	68	36	37	WBC (10 ³ /uL)	8.50	N/A	N/A	N/A	N/A
CV01EM030	25 µg (56-70 years)	FEMALE	69	-1	-5	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
CV01EM030	25 µg (56-70 years)	FEMALE	69	1	1	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM030	25 µg (56-70 years)	FEMALE	69	8	8	Hemoglobin (g/dL)	14.3 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM030	25 µg (56-70 years)	FEMALE	69	29	30	Hemoglobin (g/dL)	13.1 (Moderate)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01EM030	25 µg (56-70 years)	FEMALE	69	36	37	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM030	25 µg (56-70 years)	FEMALE	69	-1	-5	PT (seconds)	10.6	N/A	N/A	N/A	N/A
CV01EM030	25 µg (56-70 years)	FEMALE	69	-1	-5	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01EM030	25 µg (56-70 years)	FEMALE	69	-1	-5	Platelets (10 ³ /uL)	206	N/A	N/A	N/A	N/A
CV01EM030	25 µg (56-70 years)	FEMALE	69	1	1	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
CV01EM030	25 µg (56-70 years)	FEMALE	69	8	8	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A
CV01EM030	25 µg (56-70 years)	FEMALE	69	29	30	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
CV01EM030	25 µg (56-70 years)	FEMALE	69	36	37	Platelets (10 ³ /uL)	246	N/A	N/A	N/A	N/A
CV01EM030	25 µg (56-70 years)	FEMALE	69	-1	-5	WBC (10 ³ /uL)	5.30	N/A	N/A	N/A	N/A
CV01EM030	25 µg (56-70 years)	FEMALE	69	1	1	WBC (10 ³ /uL)	5.30	N/A	N/A	N/A	N/A
CV01EM030	25 µg (56-70 years)	FEMALE	69	8	8	WBC (10 ³ /uL)	6.40	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM030	25 µg (56-70 years)	FEMALE	69	29	30	WBC (10 ³ /uL)	6.00	N/A	N/A	N/A	N/A
CV01EM030	25 µg (56-70 years)	FEMALE	69	36	37	WBC (10 ³ /uL)	5.40	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	-1	-5	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	1	1	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	8	7	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM032	100 µg (56-70 years)	FEMALE	64	29	28	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM032	100 µg (56-70 years)	FEMALE	64	36	36	Hemoglobin (g/dL)	12.5 (Moderate)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01EM032	100 µg (56-70 years)	FEMALE	64	43	44	Hemoglobin (g/dL)	12.4 (Moderate)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01EM032	100 µg (56-70 years)	FEMALE	64	57	58	Hemoglobin (g/dL)	12.4 (Moderate)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01EM032	100 µg (56-70 years)	FEMALE	64	119	114	Hemoglobin (g/dL)	12.3 (Severe)	NOT RELATED	Grade 3. Due to study procedures Abnormally high baseline hemoglobin	NA- NOT APPLICABLE	No
CV01EM032	100 µg (56-70 years)	FEMALE	64	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	-1	-5	PTT (seconds)	21.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM032	100 µg (56-70 years)	FEMALE	64	-1	-5	Platelets (10 ³ /uL)	216	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	1	1	Platelets (10 ³ /uL)	199	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	8	7	Platelets (10 ³ /uL)	216	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	29	28	Platelets (10 ³ /uL)	202	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	36	36	Platelets (10 ³ /uL)	229	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	-1	-5	WBC (10 ³ /uL)	5.60	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	1	1	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	8	7	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	29	28	WBC (10 ³ /uL)	5.20	N/A	N/A	N/A	N/A
CV01EM032	100 µg (56-70 years)	FEMALE	64	36	36	WBC (10 ³ /uL)	8.20	N/A	N/A	N/A	N/A
CV01EM033	100 µg (56-70 years)	FEMALE	63	-1	-5	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
CV01EM033	100 µg (56-70 years)	FEMALE	63	1	1	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
CV01EM033	100 µg (56-70 years)	FEMALE	63	8	8	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	study procedures - phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM033	100 µg (56-70 years)	FEMALE	63	29	29	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	Grade 1, due to phlebotomy	NA- NOT APPLICABLE	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM033	100 µg (56-70 years)	FEMALE	63	36	36	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM033	100 µg (56-70 years)	FEMALE	63	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
CV01EM033	100 µg (56-70 years)	FEMALE	63	-1	-5	PTT (seconds)	31.0	N/A	N/A	N/A	N/A
CV01EM033	100 µg (56-70 years)	FEMALE	63	-1	-5	Platelets (10 ³ /uL)	371	N/A	N/A	N/A	N/A
CV01EM033	100 µg (56-70 years)	FEMALE	63	1	1	Platelets (10 ³ /uL)	355	N/A	N/A	N/A	N/A
CV01EM033	100 µg (56-70 years)	FEMALE	63	8	8	Platelets (10 ³ /uL)	370	N/A	N/A	N/A	N/A
CV01EM033	100 µg (56-70 years)	FEMALE	63	29	29	Platelets (10 ³ /uL)	352	N/A	N/A	N/A	N/A
CV01EM033	100 µg (56-70 years)	FEMALE	63	36	36	Platelets (10 ³ /uL)	379	N/A	N/A	N/A	N/A
CV01EM033	100 µg (56-70 years)	FEMALE	63	-1	-5	WBC (10 ³ /uL)	6.30	N/A	N/A	N/A	N/A
CV01EM033	100 µg (56-70 years)	FEMALE	63	1	1	WBC (10 ³ /uL)	6.60	N/A	N/A	N/A	N/A
CV01EM033	100 µg (56-70 years)	FEMALE	63	8	8	WBC (10 ³ /uL)	7.30	N/A	N/A	N/A	N/A
CV01EM033	100 µg (56-70 years)	FEMALE	63	29	29	WBC (10 ³ /uL)	7.60	N/A	N/A	N/A	N/A
CV01EM033	100 µg (56-70 years)	FEMALE	63	36	36	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A
CV01EM039	100 µg (56-70 years)	MALE	66	-1	-5	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM039	100 µg (56-70 years)	MALE	66	1	1	Hemoglobin (g/dL)	15.7	N/A	N/A	N/A	N/A
CV01EM039	100 µg (56-70 years)	MALE	66	8	8	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	study procedure phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM039	100 µg (56-70 years)	MALE	66	29	29	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM039	100 µg (56-70 years)	MALE	66	36	37	Hemoglobin (g/dL)	14.7 (Mild)	NOT RELATED	Grade 1- due to study procedure - phlebotomy.	NA- NOT APPLICABLE	No
CV01EM039	100 µg (56-70 years)	MALE	66	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
CV01EM039	100 µg (56-70 years)	MALE	66	-1	-5	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01EM039	100 µg (56-70 years)	MALE	66	-1	-5	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
CV01EM039	100 µg (56-70 years)	MALE	66	1	1	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
CV01EM039	100 µg (56-70 years)	MALE	66	8	8	Platelets (10 ³ /uL)	256	N/A	N/A	N/A	N/A
CV01EM039	100 µg (56-70 years)	MALE	66	29	29	Platelets (10 ³ /uL)	250	N/A	N/A	N/A	N/A
CV01EM039	100 µg (56-70 years)	MALE	66	36	37	Platelets (10 ³ /uL)	289	N/A	N/A	N/A	N/A
CV01EM039	100 µg (56-70 years)	MALE	66	-1	-5	WBC (10 ³ /uL)	7.20	N/A	N/A	N/A	N/A
CV01EM039	100 µg (56-70 years)	MALE	66	1	1	WBC (10 ³ /uL)	6.70	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM039	100 µg (56-70 years)	MALE	66	8	8	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A
CV01EM039	100 µg (56-70 years)	MALE	66	29	29	WBC (10 ³ /uL)	4.50	N/A	N/A	N/A	N/A
CV01EM039	100 µg (56-70 years)	MALE	66	36	37	WBC (10 ³ /uL)	5.20	N/A	N/A	N/A	N/A
CV01EM041	25 µg (56-70 years)	FEMALE	60	-1	-3	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
CV01EM041	25 µg (56-70 years)	FEMALE	60	1	1	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
CV01EM041	25 µg (56-70 years)	FEMALE	60	8	9	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	study procedures -phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM041	25 µg (56-70 years)	FEMALE	60	29	30	Hemoglobin (g/dL)	12.2 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM041	25 µg (56-70 years)	FEMALE	60	36	37	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
CV01EM041	25 µg (56-70 years)	FEMALE	60	-1	-3	PT (seconds)	10.3	N/A	N/A	N/A	N/A
CV01EM041	25 µg (56-70 years)	FEMALE	60	-1	-3	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01EM041	25 µg (56-70 years)	FEMALE	60	-1	-3	Platelets (10 ³ /uL)	361	N/A	N/A	N/A	N/A
CV01EM041	25 µg (56-70 years)	FEMALE	60	1	1	Platelets (10 ³ /uL)	395	N/A	N/A	N/A	N/A
CV01EM041	25 µg (56-70 years)	FEMALE	60	8	9	Platelets (10 ³ /uL)	388	N/A	N/A	N/A	N/A
CV01EM041	25 µg (56-70 years)	FEMALE	60	29	30	Platelets (10 ³ /uL)	350	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM041	25 µg (56-70 years)	FEMALE	60	36	37	Platelets (10 ³ /uL)	379	N/A	N/A	N/A	N/A
CV01EM041	25 µg (56-70 years)	FEMALE	60	-1	-3	WBC (10 ³ /uL)	5.20	N/A	N/A	N/A	N/A
CV01EM041	25 µg (56-70 years)	FEMALE	60	1	1	WBC (10 ³ /uL)	6.50	N/A	N/A	N/A	N/A
CV01EM041	25 µg (56-70 years)	FEMALE	60	8	9	WBC (10 ³ /uL)	6.20	N/A	N/A	N/A	N/A
CV01EM041	25 µg (56-70 years)	FEMALE	60	29	30	WBC (10 ³ /uL)	5.20	N/A	N/A	N/A	N/A
CV01EM041	25 µg (56-70 years)	FEMALE	60	36	37	WBC (10 ³ /uL)	7.70	N/A	N/A	N/A	N/A
CV01EM045	100 µg (56-70 years)	FEMALE	68	-1	-7	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
CV01EM045	100 µg (56-70 years)	FEMALE	68	1	1	Hemoglobin (g/dL)	13.0	N/A	N/A	N/A	N/A
CV01EM045	100 µg (56-70 years)	FEMALE	68	8	7	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM045	100 µg (56-70 years)	FEMALE	68	29	28	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM045	100 µg (56-70 years)	FEMALE	68	36	35	Hemoglobin (g/dL)	12.1 (Mild)	NOT RELATED	Grade 1- due to study procedure - phlebotomy.	NA- NOT APPLICABLE	No
CV01EM045	100 µg (56-70 years)	FEMALE	68	-1	-7	PT (seconds)	10.7	N/A	N/A	N/A	N/A
CV01EM045	100 µg (56-70 years)	FEMALE	68	-1	-7	PTT (seconds)	30.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM045	100 µg (56-70 years)	FEMALE	68	-1	-7	Platelets (10 ³ /uL)	350	N/A	N/A	N/A	N/A
CV01EM045	100 µg (56-70 years)	FEMALE	68	1	1	Platelets (10 ³ /uL)	352	N/A	N/A	N/A	N/A
CV01EM045	100 µg (56-70 years)	FEMALE	68	8	7	Platelets (10 ³ /uL)	346	N/A	N/A	N/A	N/A
CV01EM045	100 µg (56-70 years)	FEMALE	68	29	28	Platelets (10 ³ /uL)	358	N/A	N/A	N/A	N/A
CV01EM045	100 µg (56-70 years)	FEMALE	68	36	35	Platelets (10 ³ /uL)	356	N/A	N/A	N/A	N/A
CV01EM045	100 µg (56-70 years)	FEMALE	68	-1	-7	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A
CV01EM045	100 µg (56-70 years)	FEMALE	68	1	1	WBC (10 ³ /uL)	6.20	N/A	N/A	N/A	N/A
CV01EM045	100 µg (56-70 years)	FEMALE	68	8	7	WBC (10 ³ /uL)	6.10	N/A	N/A	N/A	N/A
CV01EM045	100 µg (56-70 years)	FEMALE	68	29	28	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A
CV01EM045	100 µg (56-70 years)	FEMALE	68	36	35	WBC (10 ³ /uL)	5.60	N/A	N/A	N/A	N/A
CV01EM049	50 µg (18-55 years)	MALE	42	-1	-2	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
CV01EM049	50 µg (18-55 years)	MALE	42	1	1	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
CV01EM049	50 µg (18-55 years)	MALE	42	8	7	Hemoglobin (g/dL)	14.9 (Mild)	NOT RELATED	Grade 1 = phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM049	50 µg (18-55 years)	MALE	42	29	29	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NA- NOT APPLICABLE	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM049	50 µg (18-55 years)	MALE	42	36	35	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM049	50 µg (18-55 years)	MALE	42	-1	-2	PT (seconds)	10.6	N/A	N/A	N/A	N/A
CV01EM049	50 µg (18-55 years)	MALE	42	-1	-2	PTT (seconds)	31.0	N/A	N/A	N/A	N/A
CV01EM049	50 µg (18-55 years)	MALE	42	-1	-2	Platelets (10 ³ /uL)	220	N/A	N/A	N/A	N/A
CV01EM049	50 µg (18-55 years)	MALE	42	1	1	Platelets (10 ³ /uL)	241	N/A	N/A	N/A	N/A
CV01EM049	50 µg (18-55 years)	MALE	42	8	7	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A
CV01EM049	50 µg (18-55 years)	MALE	42	29	29	Platelets (10 ³ /uL)	224	N/A	N/A	N/A	N/A
CV01EM049	50 µg (18-55 years)	MALE	42	36	35	Platelets (10 ³ /uL)	231	N/A	N/A	N/A	N/A
CV01EM049	50 µg (18-55 years)	MALE	42	-1	-2	WBC (10 ³ /uL)	6.50	N/A	N/A	N/A	N/A
CV01EM049	50 µg (18-55 years)	MALE	42	1	1	WBC (10 ³ /uL)	6.60	N/A	N/A	N/A	N/A
CV01EM049	50 µg (18-55 years)	MALE	42	8	7	WBC (10 ³ /uL)	6.20	N/A	N/A	N/A	N/A
CV01EM049	50 µg (18-55 years)	MALE	42	29	29	WBC (10 ³ /uL)	5.60	N/A	N/A	N/A	N/A
CV01EM049	50 µg (18-55 years)	MALE	42	36	35	WBC (10 ³ /uL)	6.70	N/A	N/A	N/A	N/A
CV01EM051	50 µg (18-55 years)	MALE	50	-1	-2	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM051	50 µg (18-55 years)	MALE	50	1	1	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
CV01EM051	50 µg (18-55 years)	MALE	50	8	8	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Grade 1 - phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM051	50 µg (18-55 years)	MALE	50	29	27	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	Study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM051	50 µg (18-55 years)	MALE	50	36	35	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Grade 1 Due to study procedure Phlebotomy	NA- NOT APPLICABLE	No
CV01EM051	50 µg (18-55 years)	MALE	50	-1	-2	PT (seconds)	11.1	N/A	N/A	N/A	N/A
CV01EM051	50 µg (18-55 years)	MALE	50	-1	-2	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01EM051	50 µg (18-55 years)	MALE	50	-1	-2	Platelets (10 ³ /uL)	273	N/A	N/A	N/A	N/A
CV01EM051	50 µg (18-55 years)	MALE	50	1	1	Platelets (10 ³ /uL)	273	N/A	N/A	N/A	N/A
CV01EM051	50 µg (18-55 years)	MALE	50	8	8	Platelets (10 ³ /uL)	270	N/A	N/A	N/A	N/A
CV01EM051	50 µg (18-55 years)	MALE	50	29	27	Platelets (10 ³ /uL)	243	N/A	N/A	N/A	N/A
CV01EM051	50 µg (18-55 years)	MALE	50	36	35	Platelets (10 ³ /uL)	297	N/A	N/A	N/A	N/A
CV01EM051	50 µg (18-55 years)	MALE	50	-1	-2	WBC (10 ³ /uL)	6.70	N/A	N/A	N/A	N/A
CV01EM051	50 µg (18-55 years)	MALE	50	1	1	WBC (10 ³ /uL)	8.70	N/A	N/A	N/A	N/A
CV01EM051	50 µg (18-55 years)	MALE	50	8	8	WBC (10 ³ /uL)	8.00	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM051	50 µg (18-55 years)	MALE	50	29	27	WBC (10 ³ /uL)	6.10	N/A	N/A	N/A	N/A
CV01EM051	50 µg (18-55 years)	MALE	50	36	35	WBC (10 ³ /uL)	7.10	N/A	N/A	N/A	N/A
CV01EM053	50 µg (18-55 years)	FEMALE	27	-1	-2	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
CV01EM053	50 µg (18-55 years)	FEMALE	27	1	1	Hemoglobin (g/dL)	13.5	N/A	N/A	N/A	N/A
CV01EM053	50 µg (18-55 years)	FEMALE	27	8	9	Hemoglobin (g/dL)	14.9	N/A	N/A	N/A	N/A
CV01EM053	50 µg (18-55 years)	FEMALE	27	29	27	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
CV01EM053	50 µg (18-55 years)	FEMALE	27	36	35	Hemoglobin (g/dL)	13.4 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM053	50 µg (18-55 years)	FEMALE	27	-1	-2	PT (seconds)	10.5	N/A	N/A	N/A	N/A
CV01EM053	50 µg (18-55 years)	FEMALE	27	-1	-2	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01EM053	50 µg (18-55 years)	FEMALE	27	-1	-2	Platelets (10 ³ /uL)	240	N/A	N/A	N/A	N/A
CV01EM053	50 µg (18-55 years)	FEMALE	27	1	1	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A
CV01EM053	50 µg (18-55 years)	FEMALE	27	8	9	Platelets (10 ³ /uL)	256	N/A	N/A	N/A	N/A
CV01EM053	50 µg (18-55 years)	FEMALE	27	29	27	Platelets (10 ³ /uL)	258	N/A	N/A	N/A	N/A
CV01EM053	50 µg (18-55 years)	FEMALE	27	36	35	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM053	50 µg (18-55 years)	FEMALE	27	-1	-2	WBC (10 ³ /uL)	9.20	N/A	N/A	N/A	N/A
CV01EM053	50 µg (18-55 years)	FEMALE	27	1	1	WBC (10 ³ /uL)	8.20	N/A	N/A	N/A	N/A
CV01EM053	50 µg (18-55 years)	FEMALE	27	8	9	WBC (10 ³ /uL)	5.70	N/A	N/A	N/A	N/A
CV01EM053	50 µg (18-55 years)	FEMALE	27	29	27	WBC (10 ³ /uL)	7.50	N/A	N/A	N/A	N/A
CV01EM053	50 µg (18-55 years)	FEMALE	27	36	35	WBC (10 ³ /uL)	5.20	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	-1	-2	Hemoglobin (g/dL)	13.2	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	1	1	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	8	9	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
CV01EM054	50 µg (18-55 years)	FEMALE	54	29	27	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	study procedure phlebotomy	NA- NOT APPLICABLE	No
CV01EM054	50 µg (18-55 years)	FEMALE	54	36	35	Hemoglobin (g/dL)	13.4	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	-1	-2	PT (seconds)	10.2	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	-1	-2	PTT (seconds)	27.0	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	-1	-2	Platelets (10 ³ /uL)	220	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	1	1	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01EM054	50 µg (18-55 years)	FEMALE	54	8	9	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	29	27	Platelets (10 ³ /uL)	207	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	36	35	Platelets (10 ³ /uL)	234	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	-1	-2	WBC (10 ³ /uL)	6.30	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	1	1	WBC (10 ³ /uL)	6.40	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	8	9	WBC (10 ³ /uL)	6.40	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	29	27	WBC (10 ³ /uL)	6.10	N/A	N/A	N/A	N/A
CV01EM054	50 µg (18-55 years)	FEMALE	54	36	35	WBC (10 ³ /uL)	6.70	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	-1	-4	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	1	1	Hemoglobin (g/dL)	13.4 (Mild)	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	8	9	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	29	29	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	36	35	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	-1	-4	PT (seconds)	9.9	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	-1	-4	PTT (seconds)	33.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC003	100 µg (18-55 years)	MALE	22	-1	-4	Platelets (10 ³ /uL)	367	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	1	1	Platelets (10 ³ /uL)	321	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	8	9	Platelets (10 ³ /uL)	379	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	29	29	Platelets (10 ³ /uL)	367	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	36	35	Platelets (10 ³ /uL)	345	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	-1	-4	WBC (10 ³ /uL)	6.10	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	1	1	WBC (10 ³ /uL)	5.30	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	8	9	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	29	29	WBC (10 ³ /uL)	6.30	N/A	N/A	N/A	N/A
CV01HC003	100 µg (18-55 years)	MALE	22	36	35	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	-1	-4	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	1	1	Hemoglobin (g/dL)	13.1 (Mild)	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	8	8	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	29	29	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	36	36	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC004	100 µg (18-55 years)	MALE	34	-1	-4	PT (seconds)	10.3	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	-1	-4	PTT (seconds)	27.0	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	-1	-4	Platelets (10 ³ /uL)	359	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	1	1	Platelets (10 ³ /uL)	321	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	8	8	Platelets (10 ³ /uL)	328	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	29	29	Platelets (10 ³ /uL)	302	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	36	36	Platelets (10 ³ /uL)	348	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	-1	-4	WBC (10 ³ /uL)	8.20	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	1	1	WBC (10 ³ /uL)	7.90	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	8	8	WBC (10 ³ /uL)	7.40	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	29	29	WBC (10 ³ /uL)	6.90	N/A	N/A	N/A	N/A
CV01HC004	100 µg (18-55 years)	MALE	34	36	36	WBC (10 ³ /uL)	6.90	N/A	N/A	N/A	N/A
CV01HC007	100 µg (18-55 years)	MALE	32	-1	-3	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
CV01HC007	100 µg (18-55 years)	MALE	32	1	1	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
CV01HC007	100 µg (18-55 years)	MALE	32	8	8	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC007	100 µg (18-55 years)	MALE	32	29	28	Hemoglobin (g/dL)	14.9	N/A	N/A	N/A	N/A
CV01HC007	100 µg (18-55 years)	MALE	32	36	35	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
CV01HC007	100 µg (18-55 years)	MALE	32	-1	-3	PT (seconds)	10.3	N/A	N/A	N/A	N/A
CV01HC007	100 µg (18-55 years)	MALE	32	-1	-3	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01HC007	100 µg (18-55 years)	MALE	32	-1	-3	Platelets (10 ³ /uL)	265	N/A	N/A	N/A	N/A
CV01HC007	100 µg (18-55 years)	MALE	32	1	1	Platelets (10 ³ /uL)	245	N/A	N/A	N/A	N/A
CV01HC007	100 µg (18-55 years)	MALE	32	8	8	Platelets (10 ³ /uL)	260	N/A	N/A	N/A	N/A
CV01HC007	100 µg (18-55 years)	MALE	32	29	28	Platelets (10 ³ /uL)	235	N/A	N/A	N/A	N/A
CV01HC007	100 µg (18-55 years)	MALE	32	36	35	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
CV01HC007	100 µg (18-55 years)	MALE	32	-1	-3	WBC (10 ³ /uL)	6.30	N/A	N/A	N/A	N/A
CV01HC007	100 µg (18-55 years)	MALE	32	1	1	WBC (10 ³ /uL)	4.70	N/A	N/A	N/A	N/A
CV01HC007	100 µg (18-55 years)	MALE	32	8	8	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01HC007	100 µg (18-55 years)	MALE	32	29	28	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01HC007	100 µg (18-55 years)	MALE	32	36	35	WBC (10 ³ /uL)	5.10	N/A	N/A	N/A	N/A
CV01HC008	100 µg (18-55 years)	FEMALE	26	-1	-5	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC008	100 µg (18-55 years)	FEMALE	26	1	1	Hemoglobin (g/dL)	13.4	N/A	N/A	N/A	N/A
CV01HC008	100 µg (18-55 years)	FEMALE	26	8	8	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
CV01HC008	100 µg (18-55 years)	FEMALE	26	29	29	Hemoglobin (g/dL)	12.1 (Mild)	NOT RELATED	Normal variation	NC- DOSE NOT CHANGED	No
CV01HC008	100 µg (18-55 years)	FEMALE	26	36	36	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	normal lab variation	NA- NOT APPLICABLE	No
CV01HC008	100 µg (18-55 years)	FEMALE	26	-1	-5	PT (seconds)	11.0	N/A	N/A	N/A	N/A
CV01HC008	100 µg (18-55 years)	FEMALE	26	-1	-5	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01HC008	100 µg (18-55 years)	FEMALE	26	-1	-5	Platelets (10 ³ /uL)	247	N/A	N/A	N/A	N/A
CV01HC008	100 µg (18-55 years)	FEMALE	26	1	1	Platelets (10 ³ /uL)	222	N/A	N/A	N/A	N/A
CV01HC008	100 µg (18-55 years)	FEMALE	26	8	8	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A
CV01HC008	100 µg (18-55 years)	FEMALE	26	29	29	Platelets (10 ³ /uL)	211	N/A	N/A	N/A	N/A
CV01HC008	100 µg (18-55 years)	FEMALE	26	36	36	Platelets (10 ³ /uL)	249	N/A	N/A	N/A	N/A
CV01HC008	100 µg (18-55 years)	FEMALE	26	-1	-5	WBC (10 ³ /uL)	5.10	N/A	N/A	N/A	N/A
CV01HC008	100 µg (18-55 years)	FEMALE	26	1	1	WBC (10 ³ /uL)	5.10	N/A	N/A	N/A	N/A
CV01HC008	100 µg (18-55 years)	FEMALE	26	8	8	WBC (10 ³ /uL)	4.20	N/A	N/A	N/A	N/A
CV01HC008	100 µg (18-55 years)	FEMALE	26	29	29	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC008	100 µg (18-55 years)	FEMALE	26	36	36	WBC (10 ³ /uL)	4.70	N/A	N/A	N/A	N/A
CV01HC012	250 µg (18-55 years)	FEMALE	41	-1	-15	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
CV01HC012	250 µg (18-55 years)	FEMALE	41	1	1	Hemoglobin (g/dL)	12.0 (Mild)	N/A	N/A	N/A	N/A
CV01HC012	250 µg (18-55 years)	FEMALE	41	8	7	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
CV01HC012	250 µg (18-55 years)	FEMALE	41	29	29	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
CV01HC012	250 µg (18-55 years)	FEMALE	41	36	36	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
CV01HC012	250 µg (18-55 years)	FEMALE	41	-1	-15	PT (seconds)	10.4	N/A	N/A	N/A	N/A
CV01HC012	250 µg (18-55 years)	FEMALE	41	-1	-15	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01HC012	250 µg (18-55 years)	FEMALE	41	-1	-15	Platelets (10 ³ /uL)	354	N/A	N/A	N/A	N/A
CV01HC012	250 µg (18-55 years)	FEMALE	41	1	1	Platelets (10 ³ /uL)	373	N/A	N/A	N/A	N/A
CV01HC012	250 µg (18-55 years)	FEMALE	41	8	7	Platelets (10 ³ /uL)	420	N/A	N/A	N/A	N/A
CV01HC012	250 µg (18-55 years)	FEMALE	41	29	29	Platelets (10 ³ /uL)	415	N/A	N/A	N/A	N/A
CV01HC012	250 µg (18-55 years)	FEMALE	41	36	36	Platelets (10 ³ /uL)	407	N/A	N/A	N/A	N/A
CV01HC012	250 µg (18-55 years)	FEMALE	41	-1	-15	WBC (10 ³ /uL)	6.30	N/A	N/A	N/A	N/A
CV01HC012	250 µg (18-55 years)	FEMALE	41	1	1	WBC (10 ³ /uL)	5.10	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC012	250 µg (18-55 years)	FEMALE	41	8	7	WBC (10 ³ /uL)	6.10	N/A	N/A	N/A	N/A
CV01HC012	250 µg (18-55 years)	FEMALE	41	29	29	WBC (10 ³ /uL)	5.60	N/A	N/A	N/A	N/A
CV01HC012	250 µg (18-55 years)	FEMALE	41	36	36	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A
CV01HC013	250 µg (18-55 years)	FEMALE	34	-1	-15	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
CV01HC013	250 µg (18-55 years)	FEMALE	34	1	1	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
CV01HC013	250 µg (18-55 years)	FEMALE	34	8	8	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	study procedures - phlebotomy	NC- DOSE NOT CHANGED	No
CV01HC013	250 µg (18-55 years)	FEMALE	34	29	29	Hemoglobin (g/dL)	13.3 (Mild)	NOT RELATED	related to study procedure	NA- NOT APPLICABLE	No
CV01HC013	250 µg (18-55 years)	FEMALE	34	36	36	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	change due to frequent blood draws or normal variation	NA- NOT APPLICABLE	No
CV01HC013	250 µg (18-55 years)	FEMALE	34	-1	-15	PT (seconds)	10.6	N/A	N/A	N/A	N/A
CV01HC013	250 µg (18-55 years)	FEMALE	34	-1	-15	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01HC013	250 µg (18-55 years)	FEMALE	34	-1	-15	Platelets (10 ³ /uL)	211	N/A	N/A	N/A	N/A
CV01HC013	250 µg (18-55 years)	FEMALE	34	1	1	Platelets (10 ³ /uL)	187	N/A	N/A	N/A	N/A
CV01HC013	250 µg (18-55 years)	FEMALE	34	8	8	Platelets (10 ³ /uL)	186	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC013	250 µg (18-55 years)	FEMALE	34	29	29	Platelets (10 ³ /uL)	195	N/A	N/A	N/A	N/A
CV01HC013	250 µg (18-55 years)	FEMALE	34	36	36	Platelets (10 ³ /uL)	199	N/A	N/A	N/A	N/A
CV01HC013	250 µg (18-55 years)	FEMALE	34	-1	-15	WBC (10 ³ /uL)	8.10	N/A	N/A	N/A	N/A
CV01HC013	250 µg (18-55 years)	FEMALE	34	1	1	WBC (10 ³ /uL)	6.20	N/A	N/A	N/A	N/A
CV01HC013	250 µg (18-55 years)	FEMALE	34	8	8	WBC (10 ³ /uL)	5.10	N/A	N/A	N/A	N/A
CV01HC013	250 µg (18-55 years)	FEMALE	34	29	29	WBC (10 ³ /uL)	7.90	N/A	N/A	N/A	N/A
CV01HC013	250 µg (18-55 years)	FEMALE	34	36	36	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01HC016	250 µg (18-55 years)	FEMALE	38	-1	-14	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
CV01HC016	250 µg (18-55 years)	FEMALE	38	1	1	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
CV01HC016	250 µg (18-55 years)	FEMALE	38	8	8	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	study procedures - phlebotomy	NC- DOSE NOT CHANGED	No
CV01HC016	250 µg (18-55 years)	FEMALE	38	29	28	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
CV01HC016	250 µg (18-55 years)	FEMALE	38	36	35	Hemoglobin (g/dL)	12.2 (Moderate)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
CV01HC016	250 µg (18-55 years)	FEMALE	38	-1	-14	PT (seconds)	10.3	N/A	N/A	N/A	N/A
CV01HC016	250 µg (18-55 years)	FEMALE	38	-1	-14	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01HC016	250 µg (18-55 years)	FEMALE	38	-1	-14	Platelets (10 ³ /uL)	270	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC016	250 µg (18-55 years)	FEMALE	38	1	1	Platelets (10 ³ /uL)	278	N/A	N/A	N/A	N/A
CV01HC016	250 µg (18-55 years)	FEMALE	38	8	8	Platelets (10 ³ /uL)	285	N/A	N/A	N/A	N/A
CV01HC016	250 µg (18-55 years)	FEMALE	38	29	28	Platelets (10 ³ /uL)	273	N/A	N/A	N/A	N/A
CV01HC016	250 µg (18-55 years)	FEMALE	38	36	35	Platelets (10 ³ /uL)	238	N/A	N/A	N/A	N/A
CV01HC016	250 µg (18-55 years)	FEMALE	38	-1	-14	WBC (10 ³ /uL)	8.00	N/A	N/A	N/A	N/A
CV01HC016	250 µg (18-55 years)	FEMALE	38	1	1	WBC (10 ³ /uL)	7.20	N/A	N/A	N/A	N/A
CV01HC016	250 µg (18-55 years)	FEMALE	38	8	8	WBC (10 ³ /uL)	8.10	N/A	N/A	N/A	N/A
CV01HC016	250 µg (18-55 years)	FEMALE	38	29	28	WBC (10 ³ /uL)	7.60	N/A	N/A	N/A	N/A
CV01HC016	250 µg (18-55 years)	FEMALE	38	36	35	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A
CV01HC026	25 µg (56-70 years)	FEMALE	57	-1	-2	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
CV01HC026	25 µg (56-70 years)	FEMALE	57	1	1	Hemoglobin (g/dL)	13.2	N/A	N/A	N/A	N/A
CV01HC026	25 µg (56-70 years)	FEMALE	57	8	7	Hemoglobin (g/dL)	12.7 (Mild)	NOT RELATED	related to study blood draws	NC- DOSE NOT CHANGED	No
CV01HC026	25 µg (56-70 years)	FEMALE	57	29	29	Hemoglobin (g/dL)	12.1 (Mild)	NOT RELATED	normal variation	NA- NOT APPLICABLE	No
CV01HC026	25 µg (56-70 years)	FEMALE	57	36	35	Hemoglobin (g/dL)	12.2 (Mild)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
CV01HC026	25 µg (56-70 years)	FEMALE	57	-1	-2	PT (seconds)	9.7	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC026	25 µg (56-70 years)	FEMALE	57	-1	-2	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01HC026	25 µg (56-70 years)	FEMALE	57	-1	-2	Platelets (10 ³ /uL)	332	N/A	N/A	N/A	N/A
CV01HC026	25 µg (56-70 years)	FEMALE	57	1	1	Platelets (10 ³ /uL)	324	N/A	N/A	N/A	N/A
CV01HC026	25 µg (56-70 years)	FEMALE	57	8	7	Platelets (10 ³ /uL)	343	N/A	N/A	N/A	N/A
CV01HC026	25 µg (56-70 years)	FEMALE	57	29	29	Platelets (10 ³ /uL)	308	N/A	N/A	N/A	N/A
CV01HC026	25 µg (56-70 years)	FEMALE	57	36	35	Platelets (10 ³ /uL)	320	N/A	N/A	N/A	N/A
CV01HC026	25 µg (56-70 years)	FEMALE	57	-1	-2	WBC (10 ³ /uL)	7.50	N/A	N/A	N/A	N/A
CV01HC026	25 µg (56-70 years)	FEMALE	57	1	1	WBC (10 ³ /uL)	6.20	N/A	N/A	N/A	N/A
CV01HC026	25 µg (56-70 years)	FEMALE	57	8	7	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A
CV01HC026	25 µg (56-70 years)	FEMALE	57	29	29	WBC (10 ³ /uL)	8.00	N/A	N/A	N/A	N/A
CV01HC026	25 µg (56-70 years)	FEMALE	57	36	35	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	-1	-2	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	8	8	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	study procedure (phlebotomy)	NC- DOSE NOT CHANGED	No
CV01HC027	25 µg (56-70 years)	FEMALE	69	29	29	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC027	25 µg (56-70 years)	FEMALE	69	36	36	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	-1	-2	PT (seconds)	10.3	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	-1	-2	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	-1	-2	Platelets (10 ³ /uL)	173	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	1	1	Platelets (10 ³ /uL)	180	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	8	8	Platelets (10 ³ /uL)	159	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	29	29	Platelets (10 ³ /uL)	180	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	36	36	Platelets (10 ³ /uL)	188	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	-1	-2	WBC (10 ³ /uL)	5.80	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	1	1	WBC (10 ³ /uL)	5.80	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	8	8	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	29	29	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A
CV01HC027	25 µg (56-70 years)	FEMALE	69	36	36	WBC (10 ³ /uL)	4.10	N/A	N/A	N/A	N/A
CV01HC031	100 µg (56-70 years)	MALE	65	-1	-6	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
CV01HC031	100 µg (56-70 years)	MALE	65	1	1	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC031	100 µg (56-70 years)	MALE	65	8	8	Hemoglobin (g/dL)	15.0 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01HC031	100 µg (56-70 years)	MALE	65	29	29	Hemoglobin (g/dL)	15.4 (Mild)	NOT RELATED	normal variation	NA- NOT APPLICABLE	No
CV01HC031	100 µg (56-70 years)	MALE	65	36	36	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	study procedure or normal variation	NA- NOT APPLICABLE	No
CV01HC031	100 µg (56-70 years)	MALE	65	-1	-6	PT (seconds)	10.6	N/A	N/A	N/A	N/A
CV01HC031	100 µg (56-70 years)	MALE	65	-1	-6	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01HC031	100 µg (56-70 years)	MALE	65	-1	-6	Platelets (10 ³ /uL)	232	N/A	N/A	N/A	N/A
CV01HC031	100 µg (56-70 years)	MALE	65	1	1	Platelets (10 ³ /uL)	226	N/A	N/A	N/A	N/A
CV01HC031	100 µg (56-70 years)	MALE	65	8	8	Platelets (10 ³ /uL)	215	N/A	N/A	N/A	N/A
CV01HC031	100 µg (56-70 years)	MALE	65	29	29	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A
CV01HC031	100 µg (56-70 years)	MALE	65	36	36	Platelets (10 ³ /uL)	234	N/A	N/A	N/A	N/A
CV01HC031	100 µg (56-70 years)	MALE	65	-1	-6	WBC (10 ³ /uL)	5.30	N/A	N/A	N/A	N/A
CV01HC031	100 µg (56-70 years)	MALE	65	1	1	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A
CV01HC031	100 µg (56-70 years)	MALE	65	8	8	WBC (10 ³ /uL)	5.10	N/A	N/A	N/A	N/A
CV01HC031	100 µg (56-70 years)	MALE	65	29	29	WBC (10 ³ /uL)	5.60	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC031	100 µg (56-70 years)	MALE	65	36	36	WBC (10 ³ /uL)	5.00	N/A	N/A	N/A	N/A
CV01HC032	25 µg (56-70 years)	MALE	71	-1	-5	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
CV01HC032	25 µg (56-70 years)	MALE	71	1	1	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
CV01HC032	25 µg (56-70 years)	MALE	71	8	8	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	Normal variation or phlebotomy	NC- DOSE NOT CHANGED	No
CV01HC032	25 µg (56-70 years)	MALE	71	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
CV01HC032	25 µg (56-70 years)	MALE	71	36	37	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
CV01HC032	25 µg (56-70 years)	MALE	71	-1	-5	PT (seconds)	10.6	N/A	N/A	N/A	N/A
CV01HC032	25 µg (56-70 years)	MALE	71	-1	-5	PTT (seconds)	27.0	N/A	N/A	N/A	N/A
CV01HC032	25 µg (56-70 years)	MALE	71	-1	-5	Platelets (10 ³ /uL)	279	N/A	N/A	N/A	N/A
CV01HC032	25 µg (56-70 years)	MALE	71	1	1	Platelets (10 ³ /uL)	278	N/A	N/A	N/A	N/A
CV01HC032	25 µg (56-70 years)	MALE	71	8	8	Platelets (10 ³ /uL)	269	N/A	N/A	N/A	N/A
CV01HC032	25 µg (56-70 years)	MALE	71	29	29	Platelets (10 ³ /uL)	278	N/A	N/A	N/A	N/A
CV01HC032	25 µg (56-70 years)	MALE	71	36	37	Platelets (10 ³ /uL)	296	N/A	N/A	N/A	N/A
CV01HC032	25 µg (56-70 years)	MALE	71	-1	-5	WBC (10 ³ /uL)	7.10	N/A	N/A	N/A	N/A
CV01HC032	25 µg (56-70 years)	MALE	71	1	1	WBC (10 ³ /uL)	6.80	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC032	25 µg (56-70 years)	MALE	71	8	8	WBC (10 ³ /uL)	8.40	N/A	N/A	N/A	N/A
CV01HC032	25 µg (56-70 years)	MALE	71	29	29	WBC (10 ³ /uL)	7.20	N/A	N/A	N/A	N/A
CV01HC032	25 µg (56-70 years)	MALE	71	36	37	WBC (10 ³ /uL)	6.20	N/A	N/A	N/A	N/A
CV01HC033	25 µg (56-70 years)	MALE	65	-1	-5	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
CV01HC033	25 µg (56-70 years)	MALE	65	1	1	Hemoglobin (g/dL)	16.8	N/A	N/A	N/A	N/A
CV01HC033	25 µg (56-70 years)	MALE	65	8	8	Hemoglobin (g/dL)	14.8 (Moderate)	NOT RELATED	Large volume phlebotomy at V01	NC- DOSE NOT CHANGED	No
CV01HC033	25 µg (56-70 years)	MALE	65	29	29	Hemoglobin (g/dL)	14.1 (Severe)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
CV01HC033	25 µg (56-70 years)	MALE	65	36	37	Hemoglobin (g/dL)	15.5 (Mild)	NOT RELATED	normal variation	NA- NOT APPLICABLE	No
CV01HC033	25 µg (56-70 years)	MALE	65	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
CV01HC033	25 µg (56-70 years)	MALE	65	-1	-5	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01HC033	25 µg (56-70 years)	MALE	65	-1	-5	Platelets (10 ³ /uL)	280	N/A	N/A	N/A	N/A
CV01HC033	25 µg (56-70 years)	MALE	65	1	1	Platelets (10 ³ /uL)	312	N/A	N/A	N/A	N/A
CV01HC033	25 µg (56-70 years)	MALE	65	8	8	Platelets (10 ³ /uL)	273	N/A	N/A	N/A	N/A
CV01HC033	25 µg (56-70 years)	MALE	65	29	29	Platelets (10 ³ /uL)	271	N/A	N/A	N/A	N/A
CV01HC033	25 µg (56-70 years)	MALE	65	36	37	Platelets (10 ³ /uL)	291	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC033	25 µg (56-70 years)	MALE	65	-1	-5	WBC (10 ³ /uL)	6.50	N/A	N/A	N/A	N/A
CV01HC033	25 µg (56-70 years)	MALE	65	1	1	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A
CV01HC033	25 µg (56-70 years)	MALE	65	8	8	WBC (10 ³ /uL)	6.80	N/A	N/A	N/A	N/A
CV01HC033	25 µg (56-70 years)	MALE	65	29	29	WBC (10 ³ /uL)	6.30	N/A	N/A	N/A	N/A
CV01HC033	25 µg (56-70 years)	MALE	65	36	37	WBC (10 ³ /uL)	6.90	N/A	N/A	N/A	N/A
CV01HC034	100 µg (56-70 years)	FEMALE	58	-1	-5	Hemoglobin (g/dL)	13.0	N/A	N/A	N/A	N/A
CV01HC034	100 µg (56-70 years)	FEMALE	58	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
CV01HC034	100 µg (56-70 years)	FEMALE	58	8	8	Hemoglobin (g/dL)	12.8 (Mild)	NOT RELATED	Large volume phlebotomy at V01	NC- DOSE NOT CHANGED	No
CV01HC034	100 µg (56-70 years)	FEMALE	58	29	30	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	frequent blood draws	NC- DOSE NOT CHANGED	No
CV01HC034	100 µg (56-70 years)	FEMALE	58	36	37	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	study procedures or normal variation	NA- NOT APPLICABLE	No
CV01HC034	100 µg (56-70 years)	FEMALE	58	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A
CV01HC034	100 µg (56-70 years)	FEMALE	58	-1	-5	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01HC034	100 µg (56-70 years)	FEMALE	58	-1	-5	Platelets (10 ³ /uL)	310	N/A	N/A	N/A	N/A
CV01HC034	100 µg (56-70 years)	FEMALE	58	1	1	Platelets (10 ³ /uL)	320	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC034	100 µg (56-70 years)	FEMALE	58	8	8	Platelets (10 ³ /uL)	316	N/A	N/A	N/A	N/A
CV01HC034	100 µg (56-70 years)	FEMALE	58	29	30	Platelets (10 ³ /uL)	287	N/A	N/A	N/A	N/A
CV01HC034	100 µg (56-70 years)	FEMALE	58	36	37	Platelets (10 ³ /uL)	351	N/A	N/A	N/A	N/A
CV01HC034	100 µg (56-70 years)	FEMALE	58	-1	-5	WBC (10 ³ /uL)	8.00	N/A	N/A	N/A	N/A
CV01HC034	100 µg (56-70 years)	FEMALE	58	1	1	WBC (10 ³ /uL)	7.40	N/A	N/A	N/A	N/A
CV01HC034	100 µg (56-70 years)	FEMALE	58	8	8	WBC (10 ³ /uL)	5.20	N/A	N/A	N/A	N/A
CV01HC034	100 µg (56-70 years)	FEMALE	58	29	30	WBC (10 ³ /uL)	5.10	N/A	N/A	N/A	N/A
CV01HC034	100 µg (56-70 years)	FEMALE	58	36	37	WBC (10 ³ /uL)	6.40	N/A	N/A	N/A	N/A
CV01HC035	25 µg (56-70 years)	MALE	66	-1	-5	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
CV01HC035	25 µg (56-70 years)	MALE	66	1	1	Hemoglobin (g/dL)	15.2	N/A	N/A	N/A	N/A
CV01HC035	25 µg (56-70 years)	MALE	66	8	8	Hemoglobin (g/dL)	13.6 (Moderate)	NOT RELATED	Large volume phlebotomy at V01	NC- DOSE NOT CHANGED	No
CV01HC035	25 µg (56-70 years)	MALE	66	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
CV01HC035	25 µg (56-70 years)	MALE	66	36	37	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	study procedure or normal variation	NA- NOT APPLICABLE	No
CV01HC035	25 µg (56-70 years)	MALE	66	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC035	25 µg (56-70 years)	MALE	66	-1	-5	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01HC035	25 µg (56-70 years)	MALE	66	-1	-5	Platelets (10 ³ /uL)	167	N/A	N/A	N/A	N/A
CV01HC035	25 µg (56-70 years)	MALE	66	1	1	Platelets (10 ³ /uL)	167	N/A	N/A	N/A	N/A
CV01HC035	25 µg (56-70 years)	MALE	66	8	8	Platelets (10 ³ /uL)	159	N/A	N/A	N/A	N/A
CV01HC035	25 µg (56-70 years)	MALE	66	29	29	Platelets (10 ³ /uL)	163	N/A	N/A	N/A	N/A
CV01HC035	25 µg (56-70 years)	MALE	66	36	37	Platelets (10 ³ /uL)	206	N/A	N/A	N/A	N/A
CV01HC035	25 µg (56-70 years)	MALE	66	-1	-5	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A
CV01HC035	25 µg (56-70 years)	MALE	66	1	1	WBC (10 ³ /uL)	5.40	N/A	N/A	N/A	N/A
CV01HC035	25 µg (56-70 years)	MALE	66	8	8	WBC (10 ³ /uL)	5.70	N/A	N/A	N/A	N/A
CV01HC035	25 µg (56-70 years)	MALE	66	29	29	WBC (10 ³ /uL)	6.30	N/A	N/A	N/A	N/A
CV01HC035	25 µg (56-70 years)	MALE	66	36	37	WBC (10 ³ /uL)	6.60	N/A	N/A	N/A	N/A
CV01HC037	100 µg (56-70 years)	FEMALE	61	-1	-6	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
CV01HC037	100 µg (56-70 years)	FEMALE	61	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
CV01HC037	100 µg (56-70 years)	FEMALE	61	8	8	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01HC037	100 µg (56-70 years)	FEMALE	61	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	normal variation	NA- NOT APPLICABLE	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC037	100 µg (56-70 years)	FEMALE	61	36	36	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	study procedure or normal variation	NA- NOT APPLICABLE	No
CV01HC037	100 µg (56-70 years)	FEMALE	61	-1	-6	PT (seconds)	10.7	N/A	N/A	N/A	N/A
CV01HC037	100 µg (56-70 years)	FEMALE	61	-1	-6	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01HC037	100 µg (56-70 years)	FEMALE	61	-1	-6	Platelets (10 ³ /uL)	287	N/A	N/A	N/A	N/A
CV01HC037	100 µg (56-70 years)	FEMALE	61	1	1	Platelets (10 ³ /uL)	284	N/A	N/A	N/A	N/A
CV01HC037	100 µg (56-70 years)	FEMALE	61	8	8	Platelets (10 ³ /uL)	287	N/A	N/A	N/A	N/A
CV01HC037	100 µg (56-70 years)	FEMALE	61	29	29	Platelets (10 ³ /uL)	283	N/A	N/A	N/A	N/A
CV01HC037	100 µg (56-70 years)	FEMALE	61	36	36	Platelets (10 ³ /uL)	278	N/A	N/A	N/A	N/A
CV01HC037	100 µg (56-70 years)	FEMALE	61	-1	-6	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01HC037	100 µg (56-70 years)	FEMALE	61	1	1	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01HC037	100 µg (56-70 years)	FEMALE	61	8	8	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A
CV01HC037	100 µg (56-70 years)	FEMALE	61	29	29	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A
CV01HC037	100 µg (56-70 years)	FEMALE	61	36	36	WBC (10 ³ /uL)	3.90	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	-1	-5	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC038	100 µg (56-70 years)	MALE	56	1	1	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	8	9	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	29	28	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
CV01HC038	100 µg (56-70 years)	MALE	56	36	36	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	study procedure	NA- NOT APPLICABLE	No
CV01HC038	100 µg (56-70 years)	MALE	56	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	-1	-5	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	-1	-5	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	1	1	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	8	9	Platelets (10 ³ /uL)	240	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	29	28	Platelets (10 ³ /uL)	222	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	36	36	Platelets (10 ³ /uL)	226	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	-1	-5	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	1	1	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	8	9	WBC (10 ³ /uL)	4.70	N/A	N/A	N/A	N/A
CV01HC038	100 µg (56-70 years)	MALE	56	29	28	WBC (10 ³ /uL)	4.00	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC038	100 µg (56-70 years)	MALE	56	36	36	WBC (10 ³ /uL)	4.50	N/A	N/A	N/A	N/A
CV01HC048	50 µg (18-55 years)	MALE	33	-1	-4	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
CV01HC048	50 µg (18-55 years)	MALE	33	1	1	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
CV01HC048	50 µg (18-55 years)	MALE	33	8	8	Hemoglobin (g/dL)	15.4 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01HC048	50 µg (18-55 years)	MALE	33	29	29	Hemoglobin (g/dL)	16.1	N/A	N/A	N/A	N/A
CV01HC048	50 µg (18-55 years)	MALE	33	36	35	Hemoglobin (g/dL)	14.0 (Moderate)	NOT RELATED	related to phlebotomy	NC- DOSE NOT CHANGED	No
CV01HC048	50 µg (18-55 years)	MALE	33	-1	-4	PT (seconds)	9.8	N/A	N/A	N/A	N/A
CV01HC048	50 µg (18-55 years)	MALE	33	-1	-4	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01HC048	50 µg (18-55 years)	MALE	33	-1	-4	Platelets (10 ³ /uL)	248	N/A	N/A	N/A	N/A
CV01HC048	50 µg (18-55 years)	MALE	33	1	1	Platelets (10 ³ /uL)	233	N/A	N/A	N/A	N/A
CV01HC048	50 µg (18-55 years)	MALE	33	8	8	Platelets (10 ³ /uL)	241	N/A	N/A	N/A	N/A
CV01HC048	50 µg (18-55 years)	MALE	33	29	29	Platelets (10 ³ /uL)	265	N/A	N/A	N/A	N/A
CV01HC048	50 µg (18-55 years)	MALE	33	36	35	Platelets (10 ³ /uL)	233	N/A	N/A	N/A	N/A
CV01HC048	50 µg (18-55 years)	MALE	33	-1	-4	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A
CV01HC048	50 µg (18-55 years)	MALE	33	1	1	WBC (10 ³ /uL)	6.30	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC048	50 µg (18-55 years)	MALE	33	8	8	WBC (10 ³ /uL)	6.70	N/A	N/A	N/A	N/A
CV01HC048	50 µg (18-55 years)	MALE	33	29	29	WBC (10 ³ /uL)	5.70	N/A	N/A	N/A	N/A
CV01HC048	50 µg (18-55 years)	MALE	33	36	35	WBC (10 ³ /uL)	6.60	N/A	N/A	N/A	N/A
CV01HC050	50 µg (18-55 years)	FEMALE	31	-1	-3	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
CV01HC050	50 µg (18-55 years)	FEMALE	31	1	1	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
CV01HC050	50 µg (18-55 years)	FEMALE	31	8	8	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
CV01HC050	50 µg (18-55 years)	FEMALE	31	29	29	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	normal variation	NA- NOT APPLICABLE	No
CV01HC050	50 µg (18-55 years)	FEMALE	31	36	36	Hemoglobin (g/dL)	12.4 (Moderate)	NOT RELATED	related to phlebotomy	NA- NOT APPLICABLE	No
CV01HC050	50 µg (18-55 years)	FEMALE	31	-1	-3	PT (seconds)	10.4	N/A	N/A	N/A	N/A
CV01HC050	50 µg (18-55 years)	FEMALE	31	-1	-3	PTT (seconds)	27.0	N/A	N/A	N/A	N/A
CV01HC050	50 µg (18-55 years)	FEMALE	31	-1	-3	Platelets (10 ³ /uL)	208	N/A	N/A	N/A	N/A
CV01HC050	50 µg (18-55 years)	FEMALE	31	1	1	Platelets (10 ³ /uL)	206	N/A	N/A	N/A	N/A
CV01HC050	50 µg (18-55 years)	FEMALE	31	8	8	Platelets (10 ³ /uL)	194	N/A	N/A	N/A	N/A
CV01HC050	50 µg (18-55 years)	FEMALE	31	29	29	Platelets (10 ³ /uL)	207	N/A	N/A	N/A	N/A
CV01HC050	50 µg (18-55 years)	FEMALE	31	36	36	Platelets (10 ³ /uL)	224	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC050	50 µg (18-55 years)	FEMALE	31	-1	-3	WBC (10 ³ /uL)	4.50	N/A	N/A	N/A	N/A
CV01HC050	50 µg (18-55 years)	FEMALE	31	1	1	WBC (10 ³ /uL)	4.70	N/A	N/A	N/A	N/A
CV01HC050	50 µg (18-55 years)	FEMALE	31	8	8	WBC (10 ³ /uL)	5.10	N/A	N/A	N/A	N/A
CV01HC050	50 µg (18-55 years)	FEMALE	31	29	29	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A
CV01HC050	50 µg (18-55 years)	FEMALE	31	36	36	WBC (10 ³ /uL)	4.00	N/A	N/A	N/A	N/A
CV01HC051	50 µg (18-55 years)	FEMALE	26	-1	-4	Hemoglobin (g/dL)	13.1	N/A	N/A	N/A	N/A
CV01HC051	50 µg (18-55 years)	FEMALE	26	1	1	Hemoglobin (g/dL)	13.4	N/A	N/A	N/A	N/A
CV01HC051	50 µg (18-55 years)	FEMALE	26	8	8	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
CV01HC051	50 µg (18-55 years)	FEMALE	26	29	27	Hemoglobin (g/dL)	11.5 (Mild)	NOT RELATED	related to phlebotomy	NC- DOSE NOT CHANGED	No
CV01HC051	50 µg (18-55 years)	FEMALE	26	36	34	Hemoglobin (g/dL)	11.9 (Mild)	NOT RELATED	related to blood draws	NC- DOSE NOT CHANGED	No
CV01HC051	50 µg (18-55 years)	FEMALE	26	-1	-4	PT (seconds)	10.3	N/A	N/A	N/A	N/A
CV01HC051	50 µg (18-55 years)	FEMALE	26	-1	-4	PTT (seconds)	31.0	N/A	N/A	N/A	N/A
CV01HC051	50 µg (18-55 years)	FEMALE	26	-1	-4	Platelets (10 ³ /uL)	311	N/A	N/A	N/A	N/A
CV01HC051	50 µg (18-55 years)	FEMALE	26	1	1	Platelets (10 ³ /uL)	330	N/A	N/A	N/A	N/A
CV01HC051	50 µg (18-55 years)	FEMALE	26	8	8	Platelets (10 ³ /uL)	316	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC051	50 µg (18-55 years)	FEMALE	26	29	27	Platelets (10 ³ /uL)	289	N/A	N/A	N/A	N/A
CV01HC051	50 µg (18-55 years)	FEMALE	26	36	34	Platelets (10 ³ /uL)	306	N/A	N/A	N/A	N/A
CV01HC051	50 µg (18-55 years)	FEMALE	26	-1	-4	WBC (10 ³ /uL)	7.90	N/A	N/A	N/A	N/A
CV01HC051	50 µg (18-55 years)	FEMALE	26	1	1	WBC (10 ³ /uL)	5.30	N/A	N/A	N/A	N/A
CV01HC051	50 µg (18-55 years)	FEMALE	26	8	8	WBC (10 ³ /uL)	6.60	N/A	N/A	N/A	N/A
CV01HC051	50 µg (18-55 years)	FEMALE	26	29	27	WBC (10 ³ /uL)	6.50	N/A	N/A	N/A	N/A
CV01HC051	50 µg (18-55 years)	FEMALE	26	36	34	WBC (10 ³ /uL)	6.30	N/A	N/A	N/A	N/A
CV01HC054	50 µg (18-55 years)	MALE	38	-1	-3	Hemoglobin (g/dL)	14.9	N/A	N/A	N/A	N/A
CV01HC054	50 µg (18-55 years)	MALE	38	1	1	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
CV01HC054	50 µg (18-55 years)	MALE	38	8	8	Hemoglobin (g/dL)	13.4 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
CV01HC054	50 µg (18-55 years)	MALE	38	29	27	Hemoglobin (g/dL)	13.4 (Mild)	NOT RELATED	related to phlebotomy	NC- DOSE NOT CHANGED	No
CV01HC054	50 µg (18-55 years)	MALE	38	36	34	Hemoglobin (g/dL)	13.4 (Mild)	NOT RELATED	related to phlebotomy	NC- DOSE NOT CHANGED	No
CV01HC054	50 µg (18-55 years)	MALE	38	-1	-3	PT (seconds)	10.0	N/A	N/A	N/A	N/A
CV01HC054	50 µg (18-55 years)	MALE	38	-1	-3	PTT (seconds)	25.0	N/A	N/A	N/A	N/A
CV01HC054	50 µg (18-55 years)	MALE	38	-1	-3	Platelets (10 ³ /uL)	258	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01HC054	50 µg (18-55 years)	MALE	38	1	1	Platelets (10 ³ /uL)	243	N/A	N/A	N/A	N/A
CV01HC054	50 µg (18-55 years)	MALE	38	8	8	Platelets (10 ³ /uL)	256	N/A	N/A	N/A	N/A
CV01HC054	50 µg (18-55 years)	MALE	38	29	27	Platelets (10 ³ /uL)	236	N/A	N/A	N/A	N/A
CV01HC054	50 µg (18-55 years)	MALE	38	36	34	Platelets (10 ³ /uL)	249	N/A	N/A	N/A	N/A
CV01HC054	50 µg (18-55 years)	MALE	38	-1	-3	WBC (10 ³ /uL)	6.00	N/A	N/A	N/A	N/A
CV01HC054	50 µg (18-55 years)	MALE	38	1	1	WBC (10 ³ /uL)	6.10	N/A	N/A	N/A	N/A
CV01HC054	50 µg (18-55 years)	MALE	38	8	8	WBC (10 ³ /uL)	6.10	N/A	N/A	N/A	N/A
CV01HC054	50 µg (18-55 years)	MALE	38	29	27	WBC (10 ³ /uL)	7.00	N/A	N/A	N/A	N/A
CV01HC054	50 µg (18-55 years)	MALE	38	36	34	WBC (10 ³ /uL)	6.60	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	-1	-11	Hemoglobin (g/dL)	16.4	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	1	1	Hemoglobin (g/dL)	16.0	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	8	8	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	29	30	Hemoglobin (g/dL)	15.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
CV01KP001	25 µg (18-55 years)	MALE	46	36	38	Hemoglobin (g/dL)	16.0	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	-1	-11	PT (seconds)	10.2	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP001	25 µg (18-55 years)	MALE	46	-1	-11	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	-1	-11	Platelets (10 ³ /uL)	264	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	1	1	Platelets (10 ³ /uL)	186	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	8	8	Platelets (10 ³ /uL)	225	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	29	30	Platelets (10 ³ /uL)	183	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	36	38	Platelets (10 ³ /uL)	193	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	-1	-11	WBC (10 ³ /uL)	7.10	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	1	1	WBC (10 ³ /uL)	6.40	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	8	8	WBC (10 ³ /uL)	6.00	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	29	30	WBC (10 ³ /uL)	5.20	N/A	N/A	N/A	N/A
CV01KP001	25 µg (18-55 years)	MALE	46	36	38	WBC (10 ³ /uL)	5.80	N/A	N/A	N/A	N/A
CV01KP005	25 µg (18-55 years)	FEMALE	25	-1	-10	Hemoglobin (g/dL)	13.2	N/A	N/A	N/A	N/A
CV01KP005	25 µg (18-55 years)	FEMALE	25	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
CV01KP005	25 µg (18-55 years)	FEMALE	25	8	8	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
CV01KP005	25 µg (18-55 years)	FEMALE	25	29	30	Hemoglobin (g/dL)	13.4 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP005	25 µg (18-55 years)	FEMALE	25	36	38	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
CV01KP005	25 µg (18-55 years)	FEMALE	25	-1	-10	PT (seconds)	11.5 (Mild)	N/A	N/A	N/A	N/A
CV01KP005	25 µg (18-55 years)	FEMALE	25	-1	-10	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01KP005	25 µg (18-55 years)	FEMALE	25	-1	-10	Platelets (10 ³ /uL)	269	N/A	N/A	N/A	N/A
CV01KP005	25 µg (18-55 years)	FEMALE	25	1	1	Platelets (10 ³ /uL)	270	N/A	N/A	N/A	N/A
CV01KP005	25 µg (18-55 years)	FEMALE	25	8	8	Platelets (10 ³ /uL)	282	N/A	N/A	N/A	N/A
CV01KP005	25 µg (18-55 years)	FEMALE	25	29	30	Platelets (10 ³ /uL)	290	N/A	N/A	N/A	N/A
CV01KP005	25 µg (18-55 years)	FEMALE	25	36	38	Platelets (10 ³ /uL)	287	N/A	N/A	N/A	N/A
CV01KP005	25 µg (18-55 years)	FEMALE	25	-1	-10	WBC (10 ³ /uL)	4.50	N/A	N/A	N/A	N/A
CV01KP005	25 µg (18-55 years)	FEMALE	25	1	1	WBC (10 ³ /uL)	5.00	N/A	N/A	N/A	N/A
CV01KP005	25 µg (18-55 years)	FEMALE	25	8	8	WBC (10 ³ /uL)	4.70	N/A	N/A	N/A	N/A
CV01KP005	25 µg (18-55 years)	FEMALE	25	29	30	WBC (10 ³ /uL)	3.60	N/A	N/A	N/A	N/A
CV01KP005	25 µg (18-55 years)	FEMALE	25	36	38	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A
CV01KP006	25 µg (18-55 years)	FEMALE	32	-1	-10	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
CV01KP006	25 µg (18-55 years)	FEMALE	32	1	1	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP006	25 µg (18-55 years)	FEMALE	32	8	8	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01KP006	25 µg (18-55 years)	FEMALE	32	29	30	Hemoglobin (g/dL)	10.6 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP006	25 µg (18-55 years)	FEMALE	32	36	38	Hemoglobin (g/dL)	11.2 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP006	25 µg (18-55 years)	FEMALE	32	-1	-10	PT (seconds)	11.5 (Mild)	N/A	N/A	N/A	N/A
CV01KP006	25 µg (18-55 years)	FEMALE	32	-1	-10	PTT (seconds)	27.0	N/A	N/A	N/A	N/A
CV01KP006	25 µg (18-55 years)	FEMALE	32	-1	-10	Platelets (10 ³ /uL)	235	N/A	N/A	N/A	N/A
CV01KP006	25 µg (18-55 years)	FEMALE	32	1	1	Platelets (10 ³ /uL)	224	N/A	N/A	N/A	N/A
CV01KP006	25 µg (18-55 years)	FEMALE	32	8	8	Platelets (10 ³ /uL)	231	N/A	N/A	N/A	N/A
CV01KP006	25 µg (18-55 years)	FEMALE	32	29	30	Platelets (10 ³ /uL)	231	N/A	N/A	N/A	N/A
CV01KP006	25 µg (18-55 years)	FEMALE	32	36	38	Platelets (10 ³ /uL)	274	N/A	N/A	N/A	N/A
CV01KP006	25 µg (18-55 years)	FEMALE	32	-1	-10	WBC (10 ³ /uL)	5.40	N/A	N/A	N/A	N/A
CV01KP006	25 µg (18-55 years)	FEMALE	32	1	1	WBC (10 ³ /uL)	6.40	N/A	N/A	N/A	N/A
CV01KP006	25 µg (18-55 years)	FEMALE	32	8	8	WBC (10 ³ /uL)	5.30	N/A	N/A	N/A	N/A
CV01KP006	25 µg (18-55 years)	FEMALE	32	29	30	WBC (10 ³ /uL)	6.30	N/A	N/A	N/A	N/A
CV01KP006	25 µg (18-55 years)	FEMALE	32	36	38	WBC (10 ³ /uL)	5.20	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP007	25 µg (18-55 years)	FEMALE	44	-1	-10	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
CV01KP007	25 µg (18-55 years)	FEMALE	44	1	1	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
CV01KP007	25 µg (18-55 years)	FEMALE	44	8	8	Hemoglobin (g/dL)	11.6 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01KP007	25 µg (18-55 years)	FEMALE	44	29	30	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP007	25 µg (18-55 years)	FEMALE	44	36	38	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP007	25 µg (18-55 years)	FEMALE	44	-1	-10	PT (seconds)	9.7	N/A	N/A	N/A	N/A
CV01KP007	25 µg (18-55 years)	FEMALE	44	-1	-10	PTT (seconds)	26.0	N/A	N/A	N/A	N/A
CV01KP007	25 µg (18-55 years)	FEMALE	44	-1	-10	Platelets (10 ³ /uL)	278	N/A	N/A	N/A	N/A
CV01KP007	25 µg (18-55 years)	FEMALE	44	1	1	Platelets (10 ³ /uL)	317	N/A	N/A	N/A	N/A
CV01KP007	25 µg (18-55 years)	FEMALE	44	8	8	Platelets (10 ³ /uL)	319	N/A	N/A	N/A	N/A
CV01KP007	25 µg (18-55 years)	FEMALE	44	29	30	Platelets (10 ³ /uL)	295	N/A	N/A	N/A	N/A
CV01KP007	25 µg (18-55 years)	FEMALE	44	36	38	Platelets (10 ³ /uL)	295	N/A	N/A	N/A	N/A
CV01KP007	25 µg (18-55 years)	FEMALE	44	-1	-10	WBC (10 ³ /uL)	8.00	N/A	N/A	N/A	N/A
CV01KP007	25 µg (18-55 years)	FEMALE	44	1	1	WBC (10 ³ /uL)	5.30	N/A	N/A	N/A	N/A
CV01KP007	25 µg (18-55 years)	FEMALE	44	8	8	WBC (10 ³ /uL)	3.70	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP007	25 µg (18-55 years)	FEMALE	44	29	30	WBC (10 ³ /uL)	3.50 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP007	25 µg (18-55 years)	FEMALE	44	36	38	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01KP008	100 µg (18-55 years)	FEMALE	33	-1	-8	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
CV01KP008	100 µg (18-55 years)	FEMALE	33	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
CV01KP008	100 µg (18-55 years)	FEMALE	33	8	7	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
CV01KP008	100 µg (18-55 years)	FEMALE	33	29	29	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
CV01KP008	100 µg (18-55 years)	FEMALE	33	36	35	Hemoglobin (g/dL)	13.3 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
CV01KP008	100 µg (18-55 years)	FEMALE	33	-1	-8	PT (seconds)	10.2	N/A	N/A	N/A	N/A
CV01KP008	100 µg (18-55 years)	FEMALE	33	-1	-8	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01KP008	100 µg (18-55 years)	FEMALE	33	-1	-8	Platelets (10 ³ /uL)	248	N/A	N/A	N/A	N/A
CV01KP008	100 µg (18-55 years)	FEMALE	33	1	1	Platelets (10 ³ /uL)	245	N/A	N/A	N/A	N/A
CV01KP008	100 µg (18-55 years)	FEMALE	33	8	7	Platelets (10 ³ /uL)	251	N/A	N/A	N/A	N/A
CV01KP008	100 µg (18-55 years)	FEMALE	33	29	29	Platelets (10 ³ /uL)	235	N/A	N/A	N/A	N/A
CV01KP008	100 µg (18-55 years)	FEMALE	33	36	35	Platelets (10 ³ /uL)	272	N/A	N/A	N/A	N/A
CV01KP008	100 µg (18-55 years)	FEMALE	33	-1	-8	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP008	100 µg (18-55 years)	FEMALE	33	1	1	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A
CV01KP008	100 µg (18-55 years)	FEMALE	33	8	7	WBC (10 ³ /uL)	5.10	N/A	N/A	N/A	N/A
CV01KP008	100 µg (18-55 years)	FEMALE	33	29	29	WBC (10 ³ /uL)	3.90	N/A	N/A	N/A	N/A
CV01KP008	100 µg (18-55 years)	FEMALE	33	36	35	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A
CV01KP009	100 µg (18-55 years)	FEMALE	25	-1	-8	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
CV01KP009	100 µg (18-55 years)	FEMALE	25	1	1	Hemoglobin (g/dL)	11.1 (Mild)	N/A	N/A	N/A	N/A
CV01KP009	100 µg (18-55 years)	FEMALE	25	8	7	Hemoglobin (g/dL)	10.5 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01KP009	100 µg (18-55 years)	FEMALE	25	29	29	Hemoglobin (g/dL)	10.3 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP009	100 µg (18-55 years)	FEMALE	25	36	37	Hemoglobin (g/dL)	10.6 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP009	100 µg (18-55 years)	FEMALE	25	-1	-8	PT (seconds)	9.9	N/A	N/A	N/A	N/A
CV01KP009	100 µg (18-55 years)	FEMALE	25	-1	-8	PTT (seconds)	27.0	N/A	N/A	N/A	N/A
CV01KP009	100 µg (18-55 years)	FEMALE	25	-1	-8	Platelets (10 ³ /uL)	307	N/A	N/A	N/A	N/A
CV01KP009	100 µg (18-55 years)	FEMALE	25	1	1	Platelets (10 ³ /uL)	254	N/A	N/A	N/A	N/A
CV01KP009	100 µg (18-55 years)	FEMALE	25	8	7	Platelets (10 ³ /uL)	251	N/A	N/A	N/A	N/A
CV01KP009	100 µg (18-55 years)	FEMALE	25	29	29	Platelets (10 ³ /uL)	243	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP009	100 µg (18-55 years)	FEMALE	25	36	37	Platelets (10 ³ /uL)	297	N/A	N/A	N/A	N/A
CV01KP009	100 µg (18-55 years)	FEMALE	25	-1	-8	WBC (10 ³ /uL)	4.20	N/A	N/A	N/A	N/A
CV01KP009	100 µg (18-55 years)	FEMALE	25	1	1	WBC (10 ³ /uL)	3.40 (Mild)	N/A	N/A	N/A	N/A
CV01KP009	100 µg (18-55 years)	FEMALE	25	8	7	WBC (10 ³ /uL)	3.60	N/A	N/A	N/A	N/A
CV01KP009	100 µg (18-55 years)	FEMALE	25	29	29	WBC (10 ³ /uL)	3.30 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP009	100 µg (18-55 years)	FEMALE	25	36	37	WBC (10 ³ /uL)	3.80	N/A	N/A	N/A	N/A
CV01KP010	25 µg (18-55 years)	MALE	44	-1	-15	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
CV01KP010	25 µg (18-55 years)	MALE	44	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
CV01KP010	25 µg (18-55 years)	MALE	44	8	9	Hemoglobin (g/dL)	12.9 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01KP010	25 µg (18-55 years)	MALE	44	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP010	25 µg (18-55 years)	MALE	44	36	37	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A
CV01KP010	25 µg (18-55 years)	MALE	44	-1	-15	PT (seconds)	10.7	N/A	N/A	N/A	N/A
CV01KP010	25 µg (18-55 years)	MALE	44	-1	-15	PTT (seconds)	31.0	N/A	N/A	N/A	N/A
CV01KP010	25 µg (18-55 years)	MALE	44	-1	-15	Platelets (10 ³ /uL)	245	N/A	N/A	N/A	N/A
CV01KP010	25 µg (18-55 years)	MALE	44	1	1	Platelets (10 ³ /uL)	240	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP010	25 µg (18-55 years)	MALE	44	8	9	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A
CV01KP010	25 µg (18-55 years)	MALE	44	29	29	Platelets (10 ³ /uL)	272	N/A	N/A	N/A	N/A
CV01KP010	25 µg (18-55 years)	MALE	44	36	37	Platelets (10 ³ /uL)	272	N/A	N/A	N/A	N/A
CV01KP010	25 µg (18-55 years)	MALE	44	-1	-15	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01KP010	25 µg (18-55 years)	MALE	44	1	1	WBC (10 ³ /uL)	3.50 (Mild)	N/A	N/A	N/A	N/A
CV01KP010	25 µg (18-55 years)	MALE	44	8	9	WBC (10 ³ /uL)	3.20 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01KP010	25 µg (18-55 years)	MALE	44	29	29	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01KP010	25 µg (18-55 years)	MALE	44	36	37	WBC (10 ³ /uL)	4.10	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	-1	-15	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	1	1	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	8	9	Hemoglobin (g/dL)	15.4 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
CV01KP011	25 µg (18-55 years)	MALE	37	29	29	Hemoglobin (g/dL)	15.3 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
CV01KP011	25 µg (18-55 years)	MALE	37	36	37	Hemoglobin (g/dL)	15.5 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
CV01KP011	25 µg (18-55 years)	MALE	37	-1	-15	PT (seconds)	10.7	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	-1	-15	PTT (seconds)	32.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP011	25 µg (18-55 years)	MALE	37	-1	-15	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	1	1	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	8	9	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	29	29	Platelets (10 ³ /uL)	232	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	36	37	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	-1	-15	WBC (10 ³ /uL)	8.30	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	1	1	WBC (10 ³ /uL)	8.80	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	8	9	WBC (10 ³ /uL)	8.10	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	29	29	WBC (10 ³ /uL)	8.10	N/A	N/A	N/A	N/A
CV01KP011	25 µg (18-55 years)	MALE	37	36	37	WBC (10 ³ /uL)	7.50	N/A	N/A	N/A	N/A
CV01KP012	100 µg (18-55 years)	FEMALE	53	-1	-7	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
CV01KP012	100 µg (18-55 years)	FEMALE	53	1	1	Hemoglobin (g/dL)	12.5	N/A	N/A	N/A	N/A
CV01KP012	100 µg (18-55 years)	FEMALE	53	8	7	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
CV01KP012	100 µg (18-55 years)	FEMALE	53	29	29	Hemoglobin (g/dL)	11.5 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
CV01KP012	100 µg (18-55 years)	FEMALE	53	36	37	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP012	100 µg (18-55 years)	FEMALE	53	57	58	Hemoglobin (g/dL)	11.6 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP012	100 µg (18-55 years)	FEMALE	53	-1	-7	PT (seconds)	10.1	N/A	N/A	N/A	N/A
CV01KP012	100 µg (18-55 years)	FEMALE	53	-1	-7	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01KP012	100 µg (18-55 years)	FEMALE	53	-1	-7	Platelets (10 ³ /uL)	302	N/A	N/A	N/A	N/A
CV01KP012	100 µg (18-55 years)	FEMALE	53	1	1	Platelets (10 ³ /uL)	290	N/A	N/A	N/A	N/A
CV01KP012	100 µg (18-55 years)	FEMALE	53	8	7	Platelets (10 ³ /uL)	247	N/A	N/A	N/A	N/A
CV01KP012	100 µg (18-55 years)	FEMALE	53	29	29	Platelets (10 ³ /uL)	234	N/A	N/A	N/A	N/A
CV01KP012	100 µg (18-55 years)	FEMALE	53	36	37	Platelets (10 ³ /uL)	260	N/A	N/A	N/A	N/A
CV01KP012	100 µg (18-55 years)	FEMALE	53	-1	-7	WBC (10 ³ /uL)	5.80	N/A	N/A	N/A	N/A
CV01KP012	100 µg (18-55 years)	FEMALE	53	1	1	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A
CV01KP012	100 µg (18-55 years)	FEMALE	53	8	7	WBC (10 ³ /uL)	3.80	N/A	N/A	N/A	N/A
CV01KP012	100 µg (18-55 years)	FEMALE	53	29	29	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01KP012	100 µg (18-55 years)	FEMALE	53	36	37	WBC (10 ³ /uL)	4.50	N/A	N/A	N/A	N/A
CV01KP014	100 µg (18-55 years)	FEMALE	32	-1	-7	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
CV01KP014	100 µg (18-55 years)	FEMALE	32	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP014	100 µg (18-55 years)	FEMALE	32	8	7	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
CV01KP014	100 µg (18-55 years)	FEMALE	32	29	29	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
CV01KP014	100 µg (18-55 years)	FEMALE	32	36	37	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
CV01KP014	100 µg (18-55 years)	FEMALE	32	-1	-7	PT (seconds)	9.9	N/A	N/A	N/A	N/A
CV01KP014	100 µg (18-55 years)	FEMALE	32	-1	-7	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01KP014	100 µg (18-55 years)	FEMALE	32	-1	-7	Platelets (10 ³ /uL)	240	N/A	N/A	N/A	N/A
CV01KP014	100 µg (18-55 years)	FEMALE	32	1	1	Platelets (10 ³ /uL)	269	N/A	N/A	N/A	N/A
CV01KP014	100 µg (18-55 years)	FEMALE	32	8	7	Platelets (10 ³ /uL)	289	N/A	N/A	N/A	N/A
CV01KP014	100 µg (18-55 years)	FEMALE	32	29	29	Platelets (10 ³ /uL)	246	N/A	N/A	N/A	N/A
CV01KP014	100 µg (18-55 years)	FEMALE	32	36	37	Platelets (10 ³ /uL)	280	N/A	N/A	N/A	N/A
CV01KP014	100 µg (18-55 years)	FEMALE	32	-1	-7	WBC (10 ³ /uL)	7.20	N/A	N/A	N/A	N/A
CV01KP014	100 µg (18-55 years)	FEMALE	32	1	1	WBC (10 ³ /uL)	7.10	N/A	N/A	N/A	N/A
CV01KP014	100 µg (18-55 years)	FEMALE	32	8	7	WBC (10 ³ /uL)	7.20	N/A	N/A	N/A	N/A
CV01KP014	100 µg (18-55 years)	FEMALE	32	29	29	WBC (10 ³ /uL)	7.30	N/A	N/A	N/A	N/A
CV01KP014	100 µg (18-55 years)	FEMALE	32	36	37	WBC (10 ³ /uL)	6.90	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP015	25 µg (18-55 years)	FEMALE	34	-1	-14	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
CV01KP015	25 µg (18-55 years)	FEMALE	34	1	1	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
CV01KP015	25 µg (18-55 years)	FEMALE	34	8	9	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
CV01KP015	25 µg (18-55 years)	FEMALE	34	29	29	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
CV01KP015	25 µg (18-55 years)	FEMALE	34	36	37	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
CV01KP015	25 µg (18-55 years)	FEMALE	34	-1	-14	PT (seconds)	11.1	N/A	N/A	N/A	N/A
CV01KP015	25 µg (18-55 years)	FEMALE	34	-1	-14	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01KP015	25 µg (18-55 years)	FEMALE	34	-1	-14	Platelets (10 ³ /uL)	280	N/A	N/A	N/A	N/A
CV01KP015	25 µg (18-55 years)	FEMALE	34	1	1	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
CV01KP015	25 µg (18-55 years)	FEMALE	34	8	9	Platelets (10 ³ /uL)	253	N/A	N/A	N/A	N/A
CV01KP015	25 µg (18-55 years)	FEMALE	34	29	29	Platelets (10 ³ /uL)	231	N/A	N/A	N/A	N/A
CV01KP015	25 µg (18-55 years)	FEMALE	34	36	37	Platelets (10 ³ /uL)	255	N/A	N/A	N/A	N/A
CV01KP015	25 µg (18-55 years)	FEMALE	34	-1	-14	WBC (10 ³ /uL)	4.20	N/A	N/A	N/A	N/A
CV01KP015	25 µg (18-55 years)	FEMALE	34	1	1	WBC (10 ³ /uL)	2.90 (Mild)	N/A	N/A	N/A	N/A
CV01KP015	25 µg (18-55 years)	FEMALE	34	8	9	WBC (10 ³ /uL)	3.20 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP015	25 µg (18-55 years)	FEMALE	34	29	29	WBC (10 ³ /uL)	2.80 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP015	25 µg (18-55 years)	FEMALE	34	36	37	WBC (10 ³ /uL)	2.70 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP018	25 µg (18-55 years)	MALE	39	-1	-13	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
CV01KP018	25 µg (18-55 years)	MALE	39	1	1	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
CV01KP018	25 µg (18-55 years)	MALE	39	15	17	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP018	25 µg (18-55 years)	MALE	39	29	29	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
CV01KP018	25 µg (18-55 years)	MALE	39	36	37	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
CV01KP018	25 µg (18-55 years)	MALE	39	-1	-13	PT (seconds)	10.5	N/A	N/A	N/A	N/A
CV01KP018	25 µg (18-55 years)	MALE	39	-1	-13	PTT (seconds)	27.0	N/A	N/A	N/A	N/A
CV01KP018	25 µg (18-55 years)	MALE	39	-1	-13	Platelets (10 ³ /uL)	192	N/A	N/A	N/A	N/A
CV01KP018	25 µg (18-55 years)	MALE	39	1	1	Platelets (10 ³ /uL)	200	N/A	N/A	N/A	N/A
CV01KP018	25 µg (18-55 years)	MALE	39	15	17	Platelets (10 ³ /uL)	193	N/A	N/A	N/A	N/A
CV01KP018	25 µg (18-55 years)	MALE	39	29	29	Platelets (10 ³ /uL)	191	N/A	N/A	N/A	N/A
CV01KP018	25 µg (18-55 years)	MALE	39	36	37	Platelets (10 ³ /uL)	179	N/A	N/A	N/A	N/A
CV01KP018	25 µg (18-55 years)	MALE	39	-1	-13	WBC (10 ³ /uL)	5.30	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP018	25 µg (18-55 years)	MALE	39	1	1	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01KP018	25 µg (18-55 years)	MALE	39	15	17	WBC (10 ³ /uL)	3.80	N/A	N/A	N/A	N/A
CV01KP018	25 µg (18-55 years)	MALE	39	29	29	WBC (10 ³ /uL)	3.90	N/A	N/A	N/A	N/A
CV01KP018	25 µg (18-55 years)	MALE	39	36	37	WBC (10 ³ /uL)	4.20	N/A	N/A	N/A	N/A
CV01KP023	25 µg (18-55 years)	MALE	33	-1	-12	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
CV01KP023	25 µg (18-55 years)	MALE	33	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
CV01KP023	25 µg (18-55 years)	MALE	33	8	9	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
CV01KP023	25 µg (18-55 years)	MALE	33	29	29	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
CV01KP023	25 µg (18-55 years)	MALE	33	36	37	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
CV01KP023	25 µg (18-55 years)	MALE	33	-1	-12	PT (seconds)	10.7	N/A	N/A	N/A	N/A
CV01KP023	25 µg (18-55 years)	MALE	33	-1	-12	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01KP023	25 µg (18-55 years)	MALE	33	-1	-12	Platelets (10 ³ /uL)	313	N/A	N/A	N/A	N/A
CV01KP023	25 µg (18-55 years)	MALE	33	1	1	Platelets (10 ³ /uL)	264	N/A	N/A	N/A	N/A
CV01KP023	25 µg (18-55 years)	MALE	33	8	9	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A
CV01KP023	25 µg (18-55 years)	MALE	33	29	29	Platelets (10 ³ /uL)	273	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP023	25 µg (18-55 years)	MALE	33	36	37	Platelets (10 ³ /uL)	274	N/A	N/A	N/A	N/A
CV01KP023	25 µg (18-55 years)	MALE	33	-1	-12	WBC (10 ³ /uL)	5.40	N/A	N/A	N/A	N/A
CV01KP023	25 µg (18-55 years)	MALE	33	1	1	WBC (10 ³ /uL)	5.40	N/A	N/A	N/A	N/A
CV01KP023	25 µg (18-55 years)	MALE	33	8	9	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A
CV01KP023	25 µg (18-55 years)	MALE	33	29	29	WBC (10 ³ /uL)	4.50	N/A	N/A	N/A	N/A
CV01KP023	25 µg (18-55 years)	MALE	33	36	37	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01KP024	25 µg (18-55 years)	MALE	41	-1	-12	Hemoglobin (g/dL)	16.6	N/A	N/A	N/A	N/A
CV01KP024	25 µg (18-55 years)	MALE	41	1	1	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
CV01KP024	25 µg (18-55 years)	MALE	41	8	9	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
CV01KP024	25 µg (18-55 years)	MALE	41	29	29	Hemoglobin (g/dL)	15.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
CV01KP024	25 µg (18-55 years)	MALE	41	36	36	Hemoglobin (g/dL)	15.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
CV01KP024	25 µg (18-55 years)	MALE	41	-1	-12	PT (seconds)	10.0	N/A	N/A	N/A	N/A
CV01KP024	25 µg (18-55 years)	MALE	41	-1	-12	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01KP024	25 µg (18-55 years)	MALE	41	-1	-12	Platelets (10 ³ /uL)	298	N/A	N/A	N/A	N/A
CV01KP024	25 µg (18-55 years)	MALE	41	1	1	Platelets (10 ³ /uL)	285	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP024	25 µg (18-55 years)	MALE	41	8	9	Platelets (10 ³ /uL)	311	N/A	N/A	N/A	N/A
CV01KP024	25 µg (18-55 years)	MALE	41	29	29	Platelets (10 ³ /uL)	309	N/A	N/A	N/A	N/A
CV01KP024	25 µg (18-55 years)	MALE	41	36	36	Platelets (10 ³ /uL)	310	N/A	N/A	N/A	N/A
CV01KP024	25 µg (18-55 years)	MALE	41	-1	-12	WBC (10 ³ /uL)	6.00	N/A	N/A	N/A	N/A
CV01KP024	25 µg (18-55 years)	MALE	41	1	1	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A
CV01KP024	25 µg (18-55 years)	MALE	41	8	9	WBC (10 ³ /uL)	5.70	N/A	N/A	N/A	N/A
CV01KP024	25 µg (18-55 years)	MALE	41	29	29	WBC (10 ³ /uL)	5.80	N/A	N/A	N/A	N/A
CV01KP024	25 µg (18-55 years)	MALE	41	36	36	WBC (10 ³ /uL)	5.60	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	-1	-11	Hemoglobin (g/dL)	15.8	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	1	1	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	8	9	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
CV01KP027	25 µg (18-55 years)	MALE	53	29	29	Hemoglobin (g/dL)	15.7	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	36	37	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	-1	-11	PT (seconds)	10.2	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	-1	-11	PTT (seconds)	29.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP027	25 µg (18-55 years)	MALE	53	-1	-11	Platelets (10 ³ /uL)	286	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	1	1	Platelets (10 ³ /uL)	248	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	8	9	Platelets (10 ³ /uL)	251	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	29	29	Platelets (10 ³ /uL)	249	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	36	37	Platelets (10 ³ /uL)	257	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	-1	-11	WBC (10 ³ /uL)	6.30	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	1	1	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	8	9	WBC (10 ³ /uL)	5.80	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	29	29	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A
CV01KP027	25 µg (18-55 years)	MALE	53	36	37	WBC (10 ³ /uL)	3.50 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP028	25 µg (18-55 years)	FEMALE	28	-1	-11	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
CV01KP028	25 µg (18-55 years)	FEMALE	28	1	1	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
CV01KP028	25 µg (18-55 years)	FEMALE	28	8	9	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
CV01KP028	25 µg (18-55 years)	FEMALE	28	29	29	Hemoglobin (g/dL)	12.7 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
CV01KP028	25 µg (18-55 years)	FEMALE	28	36	37	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP028	25 µg (18-55 years)	FEMALE	28	-1	-11	PT (seconds)	10.4	N/A	N/A	N/A	N/A
CV01KP028	25 µg (18-55 years)	FEMALE	28	-1	-11	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01KP028	25 µg (18-55 years)	FEMALE	28	-1	-11	Platelets (10 ³ /uL)	241	N/A	N/A	N/A	N/A
CV01KP028	25 µg (18-55 years)	FEMALE	28	1	1	Platelets (10 ³ /uL)	249	N/A	N/A	N/A	N/A
CV01KP028	25 µg (18-55 years)	FEMALE	28	8	9	Platelets (10 ³ /uL)	293	N/A	N/A	N/A	N/A
CV01KP028	25 µg (18-55 years)	FEMALE	28	29	29	Platelets (10 ³ /uL)	224	N/A	N/A	N/A	N/A
CV01KP028	25 µg (18-55 years)	FEMALE	28	36	37	Platelets (10 ³ /uL)	257	N/A	N/A	N/A	N/A
CV01KP028	25 µg (18-55 years)	FEMALE	28	-1	-11	WBC (10 ³ /uL)	5.20	N/A	N/A	N/A	N/A
CV01KP028	25 µg (18-55 years)	FEMALE	28	1	1	WBC (10 ³ /uL)	5.00	N/A	N/A	N/A	N/A
CV01KP028	25 µg (18-55 years)	FEMALE	28	8	9	WBC (10 ³ /uL)	6.00	N/A	N/A	N/A	N/A
CV01KP028	25 µg (18-55 years)	FEMALE	28	29	29	WBC (10 ³ /uL)	5.30	N/A	N/A	N/A	N/A
CV01KP028	25 µg (18-55 years)	FEMALE	28	36	37	WBC (10 ³ /uL)	5.30	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	-1	-26	Hemoglobin (g/dL)	16.6	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	1	1	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	8	8	Hemoglobin (g/dL)	14.7 (Moderate)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP030	250 µg (18-55 years)	MALE	22	29	28	Hemoglobin (g/dL)	16.1 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
CV01KP030	250 µg (18-55 years)	MALE	22	36	35	Hemoglobin (g/dL)	16.2 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP030	250 µg (18-55 years)	MALE	22	-1	-26	PT (seconds)	10.4	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	-1	-26	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	-1	-26	Platelets (10 ³ /uL)	251	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	1	1	Platelets (10 ³ /uL)	223	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	8	8	Platelets (10 ³ /uL)	252	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	29	28	Platelets (10 ³ /uL)	195	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	36	35	Platelets (10 ³ /uL)	269	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	-1	-26	WBC (10 ³ /uL)	4.00	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	1	1	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	8	8	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	29	28	WBC (10 ³ /uL)	3.90	N/A	N/A	N/A	N/A
CV01KP030	250 µg (18-55 years)	MALE	22	36	35	WBC (10 ³ /uL)	3.90	N/A	N/A	N/A	N/A
CV01KP031	25 µg (18-55 years)	MALE	31	-1	-11	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP031	25 µg (18-55 years)	MALE	31	1	1	Hemoglobin (g/dL)	13.4 (Mild)	N/A	N/A	N/A	N/A
CV01KP031	25 µg (18-55 years)	MALE	31	8	9	Hemoglobin (g/dL)	13.6	N/A	N/A	N/A	N/A
CV01KP031	25 µg (18-55 years)	MALE	31	29	29	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
CV01KP031	25 µg (18-55 years)	MALE	31	36	37	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
CV01KP031	25 µg (18-55 years)	MALE	31	-1	-11	PT (seconds)	10.9	N/A	N/A	N/A	N/A
CV01KP031	25 µg (18-55 years)	MALE	31	-1	-11	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01KP031	25 µg (18-55 years)	MALE	31	-1	-11	Platelets (10 ³ /uL)	200	N/A	N/A	N/A	N/A
CV01KP031	25 µg (18-55 years)	MALE	31	1	1	Platelets (10 ³ /uL)	172	N/A	N/A	N/A	N/A
CV01KP031	25 µg (18-55 years)	MALE	31	8	9	Platelets (10 ³ /uL)	167	N/A	N/A	N/A	N/A
CV01KP031	25 µg (18-55 years)	MALE	31	29	29	Platelets (10 ³ /uL)	148	N/A	N/A	N/A	N/A
CV01KP031	25 µg (18-55 years)	MALE	31	36	37	Platelets (10 ³ /uL)	163	N/A	N/A	N/A	N/A
CV01KP031	25 µg (18-55 years)	MALE	31	-1	-11	WBC (10 ³ /uL)	7.70	N/A	N/A	N/A	N/A
CV01KP031	25 µg (18-55 years)	MALE	31	1	1	WBC (10 ³ /uL)	5.00	N/A	N/A	N/A	N/A
CV01KP031	25 µg (18-55 years)	MALE	31	8	9	WBC (10 ³ /uL)	5.40	N/A	N/A	N/A	N/A
CV01KP031	25 µg (18-55 years)	MALE	31	29	29	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP031	25 µg (18-55 years)	MALE	31	36	37	WBC (10 ³ /uL)	5.70	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	-1	-8	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	1	1	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	8	9	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
CV01KP032	25 µg (18-55 years)	MALE	27	29	29	Hemoglobin (g/dL)	14.9 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
CV01KP032	25 µg (18-55 years)	MALE	27	36	37	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	-1	-8	PT (seconds)	10.8	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	-1	-8	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	-1	-8	Platelets (10 ³ /uL)	327	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	1	1	Platelets (10 ³ /uL)	312	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	8	9	Platelets (10 ³ /uL)	324	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	29	29	Platelets (10 ³ /uL)	302	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	36	37	Platelets (10 ³ /uL)	335	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	-1	-8	WBC (10 ³ /uL)	8.10	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	1	1	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP032	25 µg (18-55 years)	MALE	27	8	9	WBC (10 ³ /uL)	6.80	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	29	29	WBC (10 ³ /uL)	6.10	N/A	N/A	N/A	N/A
CV01KP032	25 µg (18-55 years)	MALE	27	36	37	WBC (10 ³ /uL)	6.40	N/A	N/A	N/A	N/A
CV01KP033	250 µg (18-55 years)	FEMALE	29	-1	-22	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
CV01KP033	250 µg (18-55 years)	FEMALE	29	1	1	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
CV01KP033	250 µg (18-55 years)	FEMALE	29	8	8	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
CV01KP033	250 µg (18-55 years)	FEMALE	29	29	28	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
CV01KP033	250 µg (18-55 years)	FEMALE	29	36	35	Hemoglobin (g/dL)	11.6 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP033	250 µg (18-55 years)	FEMALE	29	57	56	Hemoglobin (g/dL)	11.5 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP033	250 µg (18-55 years)	FEMALE	29	-1	-22	PT (seconds)	10.7	N/A	N/A	N/A	N/A
CV01KP033	250 µg (18-55 years)	FEMALE	29	-1	-22	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01KP033	250 µg (18-55 years)	FEMALE	29	-1	-22	Platelets (10 ³ /uL)	234	N/A	N/A	N/A	N/A
CV01KP033	250 µg (18-55 years)	FEMALE	29	1	1	Platelets (10 ³ /uL)	209	N/A	N/A	N/A	N/A
CV01KP033	250 µg (18-55 years)	FEMALE	29	8	8	Platelets (10 ³ /uL)	200	N/A	N/A	N/A	N/A
CV01KP033	250 µg (18-55 years)	FEMALE	29	29	28	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP033	250 µg (18-55 years)	FEMALE	29	36	35	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A
CV01KP033	250 µg (18-55 years)	FEMALE	29	-1	-22	WBC (10 ³ /uL)	6.70	N/A	N/A	N/A	N/A
CV01KP033	250 µg (18-55 years)	FEMALE	29	1	1	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01KP033	250 µg (18-55 years)	FEMALE	29	8	8	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A
CV01KP033	250 µg (18-55 years)	FEMALE	29	29	28	WBC (10 ³ /uL)	4.10	N/A	N/A	N/A	N/A
CV01KP033	250 µg (18-55 years)	FEMALE	29	36	35	WBC (10 ³ /uL)	5.40	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	-1	-26	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	1	1	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	8	8	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP036	250 µg (18-55 years)	MALE	33	29	29	Hemoglobin (g/dL)	16.1	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	36	36	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP036	250 µg (18-55 years)	MALE	33	-1	-26	PT (seconds)	10.6	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	-1	-26	PTT (seconds)	25.0	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	-1	-26	Platelets (10 ³ /uL)	241	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	1	1	Platelets (10 ³ /uL)	266	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP036	250 µg (18-55 years)	MALE	33	8	8	Platelets (10 ³ /uL)	265	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	29	29	Platelets (10 ³ /uL)	287	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	36	36	Platelets (10 ³ /uL)	284	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	-1	-26	WBC (10 ³ /uL)	4.50	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	1	1	WBC (10 ³ /uL)	5.00	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	8	8	WBC (10 ³ /uL)	4.70	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	29	29	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01KP036	250 µg (18-55 years)	MALE	33	36	36	WBC (10 ³ /uL)	5.80	N/A	N/A	N/A	N/A
CV01KP037	250 µg (18-55 years)	FEMALE	19	-1	-21	Hemoglobin (g/dL)	13.5	N/A	N/A	N/A	N/A
CV01KP037	250 µg (18-55 years)	FEMALE	19	1	1	Hemoglobin (g/dL)	12.7	N/A	N/A	N/A	N/A
CV01KP037	250 µg (18-55 years)	FEMALE	19	8	8	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
CV01KP037	250 µg (18-55 years)	FEMALE	19	36	35	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP037	250 µg (18-55 years)	FEMALE	19	-1	-21	PT (seconds)	9.3	N/A	N/A	N/A	N/A
CV01KP037	250 µg (18-55 years)	FEMALE	19	-1	-21	PTT (seconds)	27.0	N/A	N/A	N/A	N/A
CV01KP037	250 µg (18-55 years)	FEMALE	19	-1	-21	Platelets (10 ³ /uL)	317	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP037	250 µg (18-55 years)	FEMALE	19	1	1	Platelets (10 ³ /uL)	278	N/A	N/A	N/A	N/A
CV01KP037	250 µg (18-55 years)	FEMALE	19	8	8	Platelets (10 ³ /uL)	281	N/A	N/A	N/A	N/A
CV01KP037	250 µg (18-55 years)	FEMALE	19	36	35	Platelets (10 ³ /uL)	301	N/A	N/A	N/A	N/A
CV01KP037	250 µg (18-55 years)	FEMALE	19	-1	-21	WBC (10 ³ /uL)	7.80	N/A	N/A	N/A	N/A
CV01KP037	250 µg (18-55 years)	FEMALE	19	1	1	WBC (10 ³ /uL)	7.30	N/A	N/A	N/A	N/A
CV01KP037	250 µg (18-55 years)	FEMALE	19	8	8	WBC (10 ³ /uL)	5.60	N/A	N/A	N/A	N/A
CV01KP037	250 µg (18-55 years)	FEMALE	19	36	35	WBC (10 ³ /uL)	6.10	N/A	N/A	N/A	N/A
CV01KP040	250 µg (18-55 years)	MALE	29	-1	-20	Hemoglobin (g/dL)	15.8	N/A	N/A	N/A	N/A
CV01KP040	250 µg (18-55 years)	MALE	29	1	1	Hemoglobin (g/dL)	16.7	N/A	N/A	N/A	N/A
CV01KP040	250 µg (18-55 years)	MALE	29	8	8	Hemoglobin (g/dL)	15.7 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
CV01KP040	250 µg (18-55 years)	MALE	29	29	28	Hemoglobin (g/dL)	16.2 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
CV01KP040	250 µg (18-55 years)	MALE	29	36	35	Hemoglobin (g/dL)	15.7 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
CV01KP040	250 µg (18-55 years)	MALE	29	-1	-20	PT (seconds)	10.4	N/A	N/A	N/A	N/A
CV01KP040	250 µg (18-55 years)	MALE	29	-1	-20	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01KP040	250 µg (18-55 years)	MALE	29	-1	-20	Platelets (10 ³ /uL)	199	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP040	250 µg (18-55 years)	MALE	29	1	1	Platelets (10 ³ /uL)	207	N/A	N/A	N/A	N/A
CV01KP040	250 µg (18-55 years)	MALE	29	8	8	Platelets (10 ³ /uL)	190	N/A	N/A	N/A	N/A
CV01KP040	250 µg (18-55 years)	MALE	29	29	28	Platelets (10 ³ /uL)	174	N/A	N/A	N/A	N/A
CV01KP040	250 µg (18-55 years)	MALE	29	36	35	Platelets (10 ³ /uL)	190	N/A	N/A	N/A	N/A
CV01KP040	250 µg (18-55 years)	MALE	29	-1	-20	WBC (10 ³ /uL)	5.10	N/A	N/A	N/A	N/A
CV01KP040	250 µg (18-55 years)	MALE	29	1	1	WBC (10 ³ /uL)	5.70	N/A	N/A	N/A	N/A
CV01KP040	250 µg (18-55 years)	MALE	29	8	8	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A
CV01KP040	250 µg (18-55 years)	MALE	29	29	28	WBC (10 ³ /uL)	5.40	N/A	N/A	N/A	N/A
CV01KP040	250 µg (18-55 years)	MALE	29	36	35	WBC (10 ³ /uL)	5.40	N/A	N/A	N/A	N/A
CV01KP041	250 µg (18-55 years)	FEMALE	32	-1	-25	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
CV01KP041	250 µg (18-55 years)	FEMALE	32	1	1	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
CV01KP041	250 µg (18-55 years)	FEMALE	32	8	8	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
CV01KP041	250 µg (18-55 years)	FEMALE	32	29	29	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
CV01KP041	250 µg (18-55 years)	FEMALE	32	36	37	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
CV01KP041	250 µg (18-55 years)	FEMALE	32	-1	-25	PT (seconds)	10.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP041	250 µg (18-55 years)	FEMALE	32	-1	-25	PTT (seconds)	27.0	N/A	N/A	N/A	N/A
CV01KP041	250 µg (18-55 years)	FEMALE	32	-1	-25	Platelets (10 ³ /uL)	242	N/A	N/A	N/A	N/A
CV01KP041	250 µg (18-55 years)	FEMALE	32	1	1	Platelets (10 ³ /uL)	245	N/A	N/A	N/A	N/A
CV01KP041	250 µg (18-55 years)	FEMALE	32	8	8	Platelets (10 ³ /uL)	248	N/A	N/A	N/A	N/A
CV01KP041	250 µg (18-55 years)	FEMALE	32	29	29	Platelets (10 ³ /uL)	216	N/A	N/A	N/A	N/A
CV01KP041	250 µg (18-55 years)	FEMALE	32	36	37	Platelets (10 ³ /uL)	261	N/A	N/A	N/A	N/A
CV01KP041	250 µg (18-55 years)	FEMALE	32	-1	-25	WBC (10 ³ /uL)	3.90	N/A	N/A	N/A	N/A
CV01KP041	250 µg (18-55 years)	FEMALE	32	1	1	WBC (10 ³ /uL)	4.00	N/A	N/A	N/A	N/A
CV01KP041	250 µg (18-55 years)	FEMALE	32	8	8	WBC (10 ³ /uL)	3.40 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01KP041	250 µg (18-55 years)	FEMALE	32	29	29	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01KP041	250 µg (18-55 years)	FEMALE	32	36	37	WBC (10 ³ /uL)	4.70	N/A	N/A	N/A	N/A
CV01KP048	250 µg (18-55 years)	MALE	23	-1	-24	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
CV01KP048	250 µg (18-55 years)	MALE	23	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
CV01KP048	250 µg (18-55 years)	MALE	23	8	8	Hemoglobin (g/dL)	13.9 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
CV01KP048	250 µg (18-55 years)	MALE	23	29	29	Hemoglobin (g/dL)	13.9 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP048	250 µg (18-55 years)	MALE	23	36	37	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP048	250 µg (18-55 years)	MALE	23	-1	-24	PT (seconds)	10.0	N/A	N/A	N/A	N/A
CV01KP048	250 µg (18-55 years)	MALE	23	-1	-24	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01KP048	250 µg (18-55 years)	MALE	23	-1	-24	Platelets (10 ³ /uL)	204	N/A	N/A	N/A	N/A
CV01KP048	250 µg (18-55 years)	MALE	23	1	1	Platelets (10 ³ /uL)	193	N/A	N/A	N/A	N/A
CV01KP048	250 µg (18-55 years)	MALE	23	8	8	Platelets (10 ³ /uL)	210	N/A	N/A	N/A	N/A
CV01KP048	250 µg (18-55 years)	MALE	23	29	29	Platelets (10 ³ /uL)	204	N/A	N/A	N/A	N/A
CV01KP048	250 µg (18-55 years)	MALE	23	36	37	Platelets (10 ³ /uL)	245	N/A	N/A	N/A	N/A
CV01KP048	250 µg (18-55 years)	MALE	23	-1	-24	WBC (10 ³ /uL)	5.40	N/A	N/A	N/A	N/A
CV01KP048	250 µg (18-55 years)	MALE	23	1	1	WBC (10 ³ /uL)	7.40	N/A	N/A	N/A	N/A
CV01KP048	250 µg (18-55 years)	MALE	23	8	8	WBC (10 ³ /uL)	6.50	N/A	N/A	N/A	N/A
CV01KP048	250 µg (18-55 years)	MALE	23	29	29	WBC (10 ³ /uL)	6.70	N/A	N/A	N/A	N/A
CV01KP048	250 µg (18-55 years)	MALE	23	36	37	WBC (10 ³ /uL)	6.70	N/A	N/A	N/A	N/A
CV01KP049	250 µg (18-55 years)	FEMALE	30	-1	-24	Hemoglobin (g/dL)	13.5	N/A	N/A	N/A	N/A
CV01KP049	250 µg (18-55 years)	FEMALE	30	1	1	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP049	250 µg (18-55 years)	FEMALE	30	8	8	Hemoglobin (g/dL)	11.4 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01KP049	250 µg (18-55 years)	FEMALE	30	29	29	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP049	250 µg (18-55 years)	FEMALE	30	36	37	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP049	250 µg (18-55 years)	FEMALE	30	-1	-24	PT (seconds)	10.5	N/A	N/A	N/A	N/A
CV01KP049	250 µg (18-55 years)	FEMALE	30	-1	-24	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01KP049	250 µg (18-55 years)	FEMALE	30	-1	-24	Platelets (10 ³ /uL)	298	N/A	N/A	N/A	N/A
CV01KP049	250 µg (18-55 years)	FEMALE	30	1	1	Platelets (10 ³ /uL)	243	N/A	N/A	N/A	N/A
CV01KP049	250 µg (18-55 years)	FEMALE	30	8	8	Platelets (10 ³ /uL)	247	N/A	N/A	N/A	N/A
CV01KP049	250 µg (18-55 years)	FEMALE	30	29	29	Platelets (10 ³ /uL)	210	N/A	N/A	N/A	N/A
CV01KP049	250 µg (18-55 years)	FEMALE	30	36	37	Platelets (10 ³ /uL)	255	N/A	N/A	N/A	N/A
CV01KP049	250 µg (18-55 years)	FEMALE	30	-1	-24	WBC (10 ³ /uL)	5.70	N/A	N/A	N/A	N/A
CV01KP049	250 µg (18-55 years)	FEMALE	30	1	1	WBC (10 ³ /uL)	4.70	N/A	N/A	N/A	N/A
CV01KP049	250 µg (18-55 years)	FEMALE	30	8	8	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01KP049	250 µg (18-55 years)	FEMALE	30	29	29	WBC (10 ³ /uL)	4.10	N/A	N/A	N/A	N/A
CV01KP049	250 µg (18-55 years)	FEMALE	30	36	37	WBC (10 ³ /uL)	3.80	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP053	250 µg (18-55 years)	FEMALE	31	-1	-21	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
CV01KP053	250 µg (18-55 years)	FEMALE	31	1	1	Hemoglobin (g/dL)	13.1	N/A	N/A	N/A	N/A
CV01KP053	250 µg (18-55 years)	FEMALE	31	8	8	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
CV01KP053	250 µg (18-55 years)	FEMALE	31	29	29	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP053	250 µg (18-55 years)	FEMALE	31	36	37	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP053	250 µg (18-55 years)	FEMALE	31	-1	-21	PT (seconds)	10.0	N/A	N/A	N/A	N/A
CV01KP053	250 µg (18-55 years)	FEMALE	31	-1	-21	PTT (seconds)	26.0	N/A	N/A	N/A	N/A
CV01KP053	250 µg (18-55 years)	FEMALE	31	-1	-21	Platelets (10 ³ /uL)	189	N/A	N/A	N/A	N/A
CV01KP053	250 µg (18-55 years)	FEMALE	31	1	1	Platelets (10 ³ /uL)	202	N/A	N/A	N/A	N/A
CV01KP053	250 µg (18-55 years)	FEMALE	31	8	8	Platelets (10 ³ /uL)	193	N/A	N/A	N/A	N/A
CV01KP053	250 µg (18-55 years)	FEMALE	31	29	29	Platelets (10 ³ /uL)	216	N/A	N/A	N/A	N/A
CV01KP053	250 µg (18-55 years)	FEMALE	31	36	37	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
CV01KP053	250 µg (18-55 years)	FEMALE	31	-1	-21	WBC (10 ³ /uL)	7.50	N/A	N/A	N/A	N/A
CV01KP053	250 µg (18-55 years)	FEMALE	31	1	1	WBC (10 ³ /uL)	6.60	N/A	N/A	N/A	N/A
CV01KP053	250 µg (18-55 years)	FEMALE	31	8	8	WBC (10 ³ /uL)	6.40	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP053	250 µg (18-55 years)	FEMALE	31	29	29	WBC (10 ³ /uL)	5.80	N/A	N/A	N/A	N/A
CV01KP053	250 µg (18-55 years)	FEMALE	31	36	37	WBC (10 ³ /uL)	6.90	N/A	N/A	N/A	N/A
CV01KP059	25 µg (≥71 years)	MALE	74	-1	-17	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
CV01KP059	25 µg (≥71 years)	MALE	74	1	1	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
CV01KP059	25 µg (≥71 years)	MALE	74	8	9	Hemoglobin (g/dL)	14.5 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP059	25 µg (≥71 years)	MALE	74	29	29	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP059	25 µg (≥71 years)	MALE	74	36	37	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP059	25 µg (≥71 years)	MALE	74	-1	-17	PT (seconds)	10.4	N/A	N/A	N/A	N/A
CV01KP059	25 µg (≥71 years)	MALE	74	-1	-17	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01KP059	25 µg (≥71 years)	MALE	74	-1	-17	Platelets (10 ³ /uL)	185	N/A	N/A	N/A	N/A
CV01KP059	25 µg (≥71 years)	MALE	74	1	1	Platelets (10 ³ /uL)	200	N/A	N/A	N/A	N/A
CV01KP059	25 µg (≥71 years)	MALE	74	8	9	Platelets (10 ³ /uL)	210	N/A	N/A	N/A	N/A
CV01KP059	25 µg (≥71 years)	MALE	74	29	29	Platelets (10 ³ /uL)	197	N/A	N/A	N/A	N/A
CV01KP059	25 µg (≥71 years)	MALE	74	36	37	Platelets (10 ³ /uL)	195	N/A	N/A	N/A	N/A
CV01KP059	25 µg (≥71 years)	MALE	74	-1	-17	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP059	25 µg (≥71 years)	MALE	74	1	1	WBC (10 ³ /uL)	6.60	N/A	N/A	N/A	N/A
CV01KP059	25 µg (≥71 years)	MALE	74	8	9	WBC (10 ³ /uL)	6.50	N/A	N/A	N/A	N/A
CV01KP059	25 µg (≥71 years)	MALE	74	29	29	WBC (10 ³ /uL)	6.00	N/A	N/A	N/A	N/A
CV01KP059	25 µg (≥71 years)	MALE	74	36	37	WBC (10 ³ /uL)	6.00	N/A	N/A	N/A	N/A
CV01KP060	25 µg (≥71 years)	FEMALE	75	-1	-17	Hemoglobin (g/dL)	13.2	N/A	N/A	N/A	N/A
CV01KP060	25 µg (≥71 years)	FEMALE	75	1	1	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
CV01KP060	25 µg (≥71 years)	FEMALE	75	8	9	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP060	25 µg (≥71 years)	FEMALE	75	29	29	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP060	25 µg (≥71 years)	FEMALE	75	36	37	Hemoglobin (g/dL)	12.7 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP060	25 µg (≥71 years)	FEMALE	75	-1	-17	PT (seconds)	9.9	N/A	N/A	N/A	N/A
CV01KP060	25 µg (≥71 years)	FEMALE	75	-1	-17	PTT (seconds)	27.0	N/A	N/A	N/A	N/A
CV01KP060	25 µg (≥71 years)	FEMALE	75	-1	-17	Platelets (10 ³ /uL)	260	N/A	N/A	N/A	N/A
CV01KP060	25 µg (≥71 years)	FEMALE	75	1	1	Platelets (10 ³ /uL)	250	N/A	N/A	N/A	N/A
CV01KP060	25 µg (≥71 years)	FEMALE	75	8	9	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
CV01KP060	25 µg (≥71 years)	FEMALE	75	29	29	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP060	25 µg (≥71 years)	FEMALE	75	36	37	Platelets (10 ³ /uL)	265	N/A	N/A	N/A	N/A
CV01KP060	25 µg (≥71 years)	FEMALE	75	-1	-17	WBC (10 ³ /uL)	4.50	N/A	N/A	N/A	N/A
CV01KP060	25 µg (≥71 years)	FEMALE	75	1	1	WBC (10 ³ /uL)	3.70	N/A	N/A	N/A	N/A
CV01KP060	25 µg (≥71 years)	FEMALE	75	8	9	WBC (10 ³ /uL)	4.50	N/A	N/A	N/A	N/A
CV01KP060	25 µg (≥71 years)	FEMALE	75	29	29	WBC (10 ³ /uL)	3.70	N/A	N/A	N/A	N/A
CV01KP060	25 µg (≥71 years)	FEMALE	75	36	37	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	-1	-17	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	1	1	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	8	9	Hemoglobin (g/dL)	14.3 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP061	25 µg (≥71 years)	MALE	72	29	29	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	36	37	Hemoglobin (g/dL)	14.0 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP061	25 µg (≥71 years)	MALE	72	-1	-17	PT (seconds)	10.0	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	-1	-17	PTT (seconds)	26.0	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	-1	-17	Platelets (10 ³ /uL)	203	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	1	1	Platelets (10 ³ /uL)	211	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP061	25 µg (≥71 years)	MALE	72	8	9	Platelets (10 ³ /uL)	230	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	29	29	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	36	37	Platelets (10 ³ /uL)	215	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	-1	-17	WBC (10 ³ /uL)	4.10	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	1	1	WBC (10 ³ /uL)	4.00	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	8	9	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	29	29	WBC (10 ³ /uL)	3.70	N/A	N/A	N/A	N/A
CV01KP061	25 µg (≥71 years)	MALE	72	36	37	WBC (10 ³ /uL)	3.20 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP062	25 µg (≥71 years)	MALE	72	-1	-17	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
CV01KP062	25 µg (≥71 years)	MALE	72	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
CV01KP062	25 µg (≥71 years)	MALE	72	8	9	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP062	25 µg (≥71 years)	MALE	72	29	29	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
CV01KP062	25 µg (≥71 years)	MALE	72	36	37	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP062	25 µg (≥71 years)	MALE	72	-1	-17	PT (seconds)	9.9	N/A	N/A	N/A	N/A
CV01KP062	25 µg (≥71 years)	MALE	72	-1	-17	PTT (seconds)	30.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP062	25 µg (≥71 years)	MALE	72	-1	-17	Platelets (10 ³ /uL)	276	N/A	N/A	N/A	N/A
CV01KP062	25 µg (≥71 years)	MALE	72	1	1	Platelets (10 ³ /uL)	273	N/A	N/A	N/A	N/A
CV01KP062	25 µg (≥71 years)	MALE	72	8	9	Platelets (10 ³ /uL)	282	N/A	N/A	N/A	N/A
CV01KP062	25 µg (≥71 years)	MALE	72	29	29	Platelets (10 ³ /uL)	311	N/A	N/A	N/A	N/A
CV01KP062	25 µg (≥71 years)	MALE	72	36	37	Platelets (10 ³ /uL)	303	N/A	N/A	N/A	N/A
CV01KP062	25 µg (≥71 years)	MALE	72	-1	-17	WBC (10 ³ /uL)	7.70	N/A	N/A	N/A	N/A
CV01KP062	25 µg (≥71 years)	MALE	72	1	1	WBC (10 ³ /uL)	5.70	N/A	N/A	N/A	N/A
CV01KP062	25 µg (≥71 years)	MALE	72	8	9	WBC (10 ³ /uL)	6.80	N/A	N/A	N/A	N/A
CV01KP062	25 µg (≥71 years)	MALE	72	29	29	WBC (10 ³ /uL)	6.70	N/A	N/A	N/A	N/A
CV01KP062	25 µg (≥71 years)	MALE	72	36	37	WBC (10 ³ /uL)	6.20	N/A	N/A	N/A	N/A
CV01KP063	25 µg (≥71 years)	MALE	72	-1	-14	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
CV01KP063	25 µg (≥71 years)	MALE	72	1	1	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
CV01KP063	25 µg (≥71 years)	MALE	72	8	9	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP063	25 µg (≥71 years)	MALE	72	29	29	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP063	25 µg (≥71 years)	MALE	72	36	37	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP063	25 µg (≥71 years)	MALE	72	-1	-14	PT (seconds)	10.1	N/A	N/A	N/A	N/A
CV01KP063	25 µg (≥71 years)	MALE	72	-1	-14	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01KP063	25 µg (≥71 years)	MALE	72	-1	-14	Platelets (10 ³ /uL)	207	N/A	N/A	N/A	N/A
CV01KP063	25 µg (≥71 years)	MALE	72	1	1	Platelets (10 ³ /uL)	213	N/A	N/A	N/A	N/A
CV01KP063	25 µg (≥71 years)	MALE	72	8	9	Platelets (10 ³ /uL)	228	N/A	N/A	N/A	N/A
CV01KP063	25 µg (≥71 years)	MALE	72	29	29	Platelets (10 ³ /uL)	232	N/A	N/A	N/A	N/A
CV01KP063	25 µg (≥71 years)	MALE	72	36	37	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A
CV01KP063	25 µg (≥71 years)	MALE	72	-1	-14	WBC (10 ³ /uL)	6.00	N/A	N/A	N/A	N/A
CV01KP063	25 µg (≥71 years)	MALE	72	1	1	WBC (10 ³ /uL)	5.40	N/A	N/A	N/A	N/A
CV01KP063	25 µg (≥71 years)	MALE	72	8	9	WBC (10 ³ /uL)	7.30	N/A	N/A	N/A	N/A
CV01KP063	25 µg (≥71 years)	MALE	72	29	29	WBC (10 ³ /uL)	5.10	N/A	N/A	N/A	N/A
CV01KP063	25 µg (≥71 years)	MALE	72	36	37	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01KP064	100 µg (≥71 years)	FEMALE	75	-1	-22	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
CV01KP064	100 µg (≥71 years)	FEMALE	75	1	1	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
CV01KP064	100 µg (≥71 years)	FEMALE	75	8	9	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP064	100 µg (≥71 years)	FEMALE	75	29	28	Hemoglobin (g/dL)	13.3 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP064	100 µg (≥71 years)	FEMALE	75	36	35	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP064	100 µg (≥71 years)	FEMALE	75	-1	-22	PT (seconds)	9.9	N/A	N/A	N/A	N/A
CV01KP064	100 µg (≥71 years)	FEMALE	75	-1	-22	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01KP064	100 µg (≥71 years)	FEMALE	75	-1	-22	Platelets (10 ³ /uL)	442	N/A	N/A	N/A	N/A
CV01KP064	100 µg (≥71 years)	FEMALE	75	-1	-15	Platelets (10 ³ /uL)	389	N/A	N/A	N/A	N/A
CV01KP064	100 µg (≥71 years)	FEMALE	75	1	1	Platelets (10 ³ /uL)	362	N/A	N/A	N/A	N/A
CV01KP064	100 µg (≥71 years)	FEMALE	75	8	9	Platelets (10 ³ /uL)	363	N/A	N/A	N/A	N/A
CV01KP064	100 µg (≥71 years)	FEMALE	75	29	28	Platelets (10 ³ /uL)	366	N/A	N/A	N/A	N/A
CV01KP064	100 µg (≥71 years)	FEMALE	75	36	35	Platelets (10 ³ /uL)	371	N/A	N/A	N/A	N/A
CV01KP064	100 µg (≥71 years)	FEMALE	75	-1	-22	WBC (10 ³ /uL)	5.70	N/A	N/A	N/A	N/A
CV01KP064	100 µg (≥71 years)	FEMALE	75	1	1	WBC (10 ³ /uL)	5.70	N/A	N/A	N/A	N/A
CV01KP064	100 µg (≥71 years)	FEMALE	75	8	9	WBC (10 ³ /uL)	6.30	N/A	N/A	N/A	N/A
CV01KP064	100 µg (≥71 years)	FEMALE	75	29	28	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A
CV01KP064	100 µg (≥71 years)	FEMALE	75	36	35	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP065	25 µg (≥71 years)	MALE	72	-1	-14	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
CV01KP065	25 µg (≥71 years)	MALE	72	1	1	Hemoglobin (g/dL)	13.5 (Mild)	N/A	N/A	N/A	N/A
CV01KP065	25 µg (≥71 years)	MALE	72	8	9	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP065	25 µg (≥71 years)	MALE	72	29	29	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
CV01KP065	25 µg (≥71 years)	MALE	72	36	37	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
CV01KP065	25 µg (≥71 years)	MALE	72	-1	-14	PT (seconds)	10.0	N/A	N/A	N/A	N/A
CV01KP065	25 µg (≥71 years)	MALE	72	-1	-14	PTT (seconds)	26.0	N/A	N/A	N/A	N/A
CV01KP065	25 µg (≥71 years)	MALE	72	-1	-14	Platelets (10 ³ /uL)	151	N/A	N/A	N/A	N/A
CV01KP065	25 µg (≥71 years)	MALE	72	1	1	Platelets (10 ³ /uL)	153	N/A	N/A	N/A	N/A
CV01KP065	25 µg (≥71 years)	MALE	72	8	9	Platelets (10 ³ /uL)	188	N/A	N/A	N/A	N/A
CV01KP065	25 µg (≥71 years)	MALE	72	29	29	Platelets (10 ³ /uL)	178	N/A	N/A	N/A	N/A
CV01KP065	25 µg (≥71 years)	MALE	72	36	37	Platelets (10 ³ /uL)	181	N/A	N/A	N/A	N/A
CV01KP065	25 µg (≥71 years)	MALE	72	-1	-14	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A
CV01KP065	25 µg (≥71 years)	MALE	72	1	1	WBC (10 ³ /uL)	3.60	N/A	N/A	N/A	N/A
CV01KP065	25 µg (≥71 years)	MALE	72	8	9	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP065	25 µg (≥71 years)	MALE	72	29	29	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A
CV01KP065	25 µg (≥71 years)	MALE	72	36	37	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01KP066	25 µg (≥71 years)	MALE	73	-1	-14	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
CV01KP066	25 µg (≥71 years)	MALE	73	1	1	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
CV01KP066	25 µg (≥71 years)	MALE	73	8	9	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP066	25 µg (≥71 years)	MALE	73	29	29	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
CV01KP066	25 µg (≥71 years)	MALE	73	36	37	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
CV01KP066	25 µg (≥71 years)	MALE	73	-1	-14	PT (seconds)	11.1	N/A	N/A	N/A	N/A
CV01KP066	25 µg (≥71 years)	MALE	73	-1	-14	PTT (seconds)	31.0	N/A	N/A	N/A	N/A
CV01KP066	25 µg (≥71 years)	MALE	73	-1	-14	Platelets (10 ³ /uL)	201	N/A	N/A	N/A	N/A
CV01KP066	25 µg (≥71 years)	MALE	73	1	1	Platelets (10 ³ /uL)	165	N/A	N/A	N/A	N/A
CV01KP066	25 µg (≥71 years)	MALE	73	8	9	Platelets (10 ³ /uL)	176	N/A	N/A	N/A	N/A
CV01KP066	25 µg (≥71 years)	MALE	73	29	29	Platelets (10 ³ /uL)	156	N/A	N/A	N/A	N/A
CV01KP066	25 µg (≥71 years)	MALE	73	36	37	Platelets (10 ³ /uL)	177	N/A	N/A	N/A	N/A
CV01KP066	25 µg (≥71 years)	MALE	73	-1	-14	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP066	25 µg (≥71 years)	MALE	73	1	1	WBC (10 ³ /uL)	4.10	N/A	N/A	N/A	N/A
CV01KP066	25 µg (≥71 years)	MALE	73	8	9	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01KP066	25 µg (≥71 years)	MALE	73	29	29	WBC (10 ³ /uL)	3.70	N/A	N/A	N/A	N/A
CV01KP066	25 µg (≥71 years)	MALE	73	36	37	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	-1	-15	Hemoglobin (g/dL)	11.9 (Mild)	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	1	1	Hemoglobin (g/dL)	12.1	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	8	9	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	29	29	Hemoglobin (g/dL)	11.6 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP067	100 µg (≥71 years)	FEMALE	73	36	36	Hemoglobin (g/dL)	11.7 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP067	100 µg (≥71 years)	FEMALE	73	-1	-15	PT (seconds)	10.1	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	-1	-15	PTT (seconds)	31.0	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	-1	-15	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	1	1	Platelets (10 ³ /uL)	191	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	8	9	Platelets (10 ³ /uL)	200	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	29	29	Platelets (10 ³ /uL)	202	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP067	100 µg (≥71 years)	FEMALE	73	36	36	Platelets (10 ³ /uL)	191	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	-1	-15	WBC (10 ³ /uL)	5.10	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	1	1	WBC (10 ³ /uL)	3.50 (Mild)	N/A	N/A	N/A	N/A
CV01KP067	100 µg (≥71 years)	FEMALE	73	8	9	WBC (10 ³ /uL)	3.30 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01KP067	100 µg (≥71 years)	FEMALE	73	29	29	WBC (10 ³ /uL)	3.30 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP067	100 µg (≥71 years)	FEMALE	73	36	36	WBC (10 ³ /uL)	3.40 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP068	25 µg (≥71 years)	FEMALE	73	-1	-15	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
CV01KP068	25 µg (≥71 years)	FEMALE	73	1	1	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
CV01KP068	25 µg (≥71 years)	FEMALE	73	8	9	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A
CV01KP068	25 µg (≥71 years)	FEMALE	73	29	29	Hemoglobin (g/dL)	14.9	N/A	N/A	N/A	N/A
CV01KP068	25 µg (≥71 years)	FEMALE	73	36	37	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A
CV01KP068	25 µg (≥71 years)	FEMALE	73	-1	-15	PT (seconds)	10.7	N/A	N/A	N/A	N/A
CV01KP068	25 µg (≥71 years)	FEMALE	73	-1	-15	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01KP068	25 µg (≥71 years)	FEMALE	73	-1	-15	Platelets (10 ³ /uL)	154	N/A	N/A	N/A	N/A
CV01KP068	25 µg (≥71 years)	FEMALE	73	1	1	Platelets (10 ³ /uL)	142	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP068	25 µg (≥71 years)	FEMALE	73	8	9	Platelets (10 ³ /uL)	152	N/A	N/A	N/A	N/A
CV01KP068	25 µg (≥71 years)	FEMALE	73	29	29	Platelets (10 ³ /uL)	137 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP068	25 µg (≥71 years)	FEMALE	73	36	37	Platelets (10 ³ /uL)	150	N/A	N/A	N/A	N/A
CV01KP068	25 µg (≥71 years)	FEMALE	73	-1	-15	WBC (10 ³ /uL)	6.10	N/A	N/A	N/A	N/A
CV01KP068	25 µg (≥71 years)	FEMALE	73	1	1	WBC (10 ³ /uL)	6.20	N/A	N/A	N/A	N/A
CV01KP068	25 µg (≥71 years)	FEMALE	73	8	9	WBC (10 ³ /uL)	6.40	N/A	N/A	N/A	N/A
CV01KP068	25 µg (≥71 years)	FEMALE	73	29	29	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01KP068	25 µg (≥71 years)	FEMALE	73	36	37	WBC (10 ³ /uL)	4.70	N/A	N/A	N/A	N/A
CV01KP069	25 µg (≥71 years)	MALE	73	-1	-15	Hemoglobin (g/dL)	13.5 (Mild)	N/A	N/A	N/A	N/A
CV01KP069	25 µg (≥71 years)	MALE	73	1	1	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
CV01KP069	25 µg (≥71 years)	MALE	73	8	9	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP069	25 µg (≥71 years)	MALE	73	29	29	Hemoglobin (g/dL)	13.3 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP069	25 µg (≥71 years)	MALE	73	36	37	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP069	25 µg (≥71 years)	MALE	73	-1	-15	PT (seconds)	10.0	N/A	N/A	N/A	N/A
CV01KP069	25 µg (≥71 years)	MALE	73	-1	-15	PTT (seconds)	26.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP069	25 µg (≥71 years)	MALE	73	-1	-15	Platelets (10 ³ /uL)	366	N/A	N/A	N/A	N/A
CV01KP069	25 µg (≥71 years)	MALE	73	1	1	Platelets (10 ³ /uL)	333	N/A	N/A	N/A	N/A
CV01KP069	25 µg (≥71 years)	MALE	73	8	9	Platelets (10 ³ /uL)	354	N/A	N/A	N/A	N/A
CV01KP069	25 µg (≥71 years)	MALE	73	29	29	Platelets (10 ³ /uL)	354	N/A	N/A	N/A	N/A
CV01KP069	25 µg (≥71 years)	MALE	73	36	37	Platelets (10 ³ /uL)	378	N/A	N/A	N/A	N/A
CV01KP069	25 µg (≥71 years)	MALE	73	-1	-15	WBC (10 ³ /uL)	6.50	N/A	N/A	N/A	N/A
CV01KP069	25 µg (≥71 years)	MALE	73	1	1	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01KP069	25 µg (≥71 years)	MALE	73	8	9	WBC (10 ³ /uL)	6.00	N/A	N/A	N/A	N/A
CV01KP069	25 µg (≥71 years)	MALE	73	29	29	WBC (10 ³ /uL)	5.80	N/A	N/A	N/A	N/A
CV01KP069	25 µg (≥71 years)	MALE	73	36	37	WBC (10 ³ /uL)	5.70	N/A	N/A	N/A	N/A
CV01KP071	100 µg (≥71 years)	FEMALE	72	-1	-21	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
CV01KP071	100 µg (≥71 years)	FEMALE	72	1	1	Hemoglobin (g/dL)	12.0 (Mild)	N/A	N/A	N/A	N/A
CV01KP071	100 µg (≥71 years)	FEMALE	72	8	8	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP071	100 µg (≥71 years)	FEMALE	72	29	28	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
CV01KP071	100 µg (≥71 years)	FEMALE	72	36	35	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP071	100 µg (≥71 years)	FEMALE	72	-1	-21	PT (seconds)	10.0	N/A	N/A	N/A	N/A
CV01KP071	100 µg (≥71 years)	FEMALE	72	-1	-21	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01KP071	100 µg (≥71 years)	FEMALE	72	-1	-21	Platelets (10 ³ /uL)	204	N/A	N/A	N/A	N/A
CV01KP071	100 µg (≥71 years)	FEMALE	72	1	1	Platelets (10 ³ /uL)	189	N/A	N/A	N/A	N/A
CV01KP071	100 µg (≥71 years)	FEMALE	72	8	8	Platelets (10 ³ /uL)	213	N/A	N/A	N/A	N/A
CV01KP071	100 µg (≥71 years)	FEMALE	72	29	28	Platelets (10 ³ /uL)	200	N/A	N/A	N/A	N/A
CV01KP071	100 µg (≥71 years)	FEMALE	72	36	35	Platelets (10 ³ /uL)	201	N/A	N/A	N/A	N/A
CV01KP071	100 µg (≥71 years)	FEMALE	72	-1	-21	WBC (10 ³ /uL)	3.70	N/A	N/A	N/A	N/A
CV01KP071	100 µg (≥71 years)	FEMALE	72	-1	-15	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01KP071	100 µg (≥71 years)	FEMALE	72	1	1	WBC (10 ³ /uL)	3.10 (Mild)	N/A	N/A	N/A	N/A
CV01KP071	100 µg (≥71 years)	FEMALE	72	8	8	WBC (10 ³ /uL)	3.80	N/A	N/A	N/A	N/A
CV01KP071	100 µg (≥71 years)	FEMALE	72	29	28	WBC (10 ³ /uL)	3.70	N/A	N/A	N/A	N/A
CV01KP071	100 µg (≥71 years)	FEMALE	72	36	35	WBC (10 ³ /uL)	3.20 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP072	25 µg (≥71 years)	MALE	71	-1	-13	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
CV01KP072	25 µg (≥71 years)	MALE	71	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP072	25 µg (≥71 years)	MALE	71	8	9	Hemoglobin (g/dL)	13.0 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01KP072	25 µg (≥71 years)	MALE	71	29	29	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
CV01KP072	25 µg (≥71 years)	MALE	71	36	37	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
CV01KP072	25 µg (≥71 years)	MALE	71	-1	-13	PT (seconds)	9.5	N/A	N/A	N/A	N/A
CV01KP072	25 µg (≥71 years)	MALE	71	-1	-13	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01KP072	25 µg (≥71 years)	MALE	71	-1	-13	Platelets (10 ³ /uL)	204	N/A	N/A	N/A	N/A
CV01KP072	25 µg (≥71 years)	MALE	71	1	1	Platelets (10 ³ /uL)	196	N/A	N/A	N/A	N/A
CV01KP072	25 µg (≥71 years)	MALE	71	8	9	Platelets (10 ³ /uL)	208	N/A	N/A	N/A	N/A
CV01KP072	25 µg (≥71 years)	MALE	71	29	29	Platelets (10 ³ /uL)	212	N/A	N/A	N/A	N/A
CV01KP072	25 µg (≥71 years)	MALE	71	36	37	Platelets (10 ³ /uL)	211	N/A	N/A	N/A	N/A
CV01KP072	25 µg (≥71 years)	MALE	71	-1	-13	WBC (10 ³ /uL)	5.40	N/A	N/A	N/A	N/A
CV01KP072	25 µg (≥71 years)	MALE	71	1	1	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A
CV01KP072	25 µg (≥71 years)	MALE	71	8	9	WBC (10 ³ /uL)	6.20	N/A	N/A	N/A	N/A
CV01KP072	25 µg (≥71 years)	MALE	71	29	29	WBC (10 ³ /uL)	5.20	N/A	N/A	N/A	N/A
CV01KP072	25 µg (≥71 years)	MALE	71	36	37	WBC (10 ³ /uL)	5.80	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP073	100 µg (≥71 years)	FEMALE	73	-1	-13	Hemoglobin (g/dL)	13.1	N/A	N/A	N/A	N/A
CV01KP073	100 µg (≥71 years)	FEMALE	73	1	1	Hemoglobin (g/dL)	13.1	N/A	N/A	N/A	N/A
CV01KP073	100 µg (≥71 years)	FEMALE	73	8	9	Hemoglobin (g/dL)	12.7 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP073	100 µg (≥71 years)	FEMALE	73	29	29	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP073	100 µg (≥71 years)	FEMALE	73	36	37	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP073	100 µg (≥71 years)	FEMALE	73	-1	-13	PT (seconds)	9.5	N/A	N/A	N/A	N/A
CV01KP073	100 µg (≥71 years)	FEMALE	73	-1	-13	PTT (seconds)	26.0	N/A	N/A	N/A	N/A
CV01KP073	100 µg (≥71 years)	FEMALE	73	-1	-13	Platelets (10 ³ /uL)	171	N/A	N/A	N/A	N/A
CV01KP073	100 µg (≥71 years)	FEMALE	73	1	1	Platelets (10 ³ /uL)	187	N/A	N/A	N/A	N/A
CV01KP073	100 µg (≥71 years)	FEMALE	73	8	9	Platelets (10 ³ /uL)	183	N/A	N/A	N/A	N/A
CV01KP073	100 µg (≥71 years)	FEMALE	73	29	29	Platelets (10 ³ /uL)	165	N/A	N/A	N/A	N/A
CV01KP073	100 µg (≥71 years)	FEMALE	73	36	37	Platelets (10 ³ /uL)	210	N/A	N/A	N/A	N/A
CV01KP073	100 µg (≥71 years)	FEMALE	73	-1	-13	WBC (10 ³ /uL)	4.20	N/A	N/A	N/A	N/A
CV01KP073	100 µg (≥71 years)	FEMALE	73	1	1	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A
CV01KP073	100 µg (≥71 years)	FEMALE	73	8	9	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP073	100 µg (≥71 years)	FEMALE	73	29	29	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01KP073	100 µg (≥71 years)	FEMALE	73	36	37	WBC (10 ³ /uL)	4.00	N/A	N/A	N/A	N/A
CV01KP075	100 µg (≥71 years)	FEMALE	72	-1	-19	Hemoglobin (g/dL)	13.0	N/A	N/A	N/A	N/A
CV01KP075	100 µg (≥71 years)	FEMALE	72	1	1	Hemoglobin (g/dL)	12.5	N/A	N/A	N/A	N/A
CV01KP075	100 µg (≥71 years)	FEMALE	72	8	8	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP075	100 µg (≥71 years)	FEMALE	72	29	29	Hemoglobin (g/dL)	12.6	N/A	N/A	N/A	N/A
CV01KP075	100 µg (≥71 years)	FEMALE	72	36	36	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP075	100 µg (≥71 years)	FEMALE	72	-1	-19	PT (seconds)	9.6	N/A	N/A	N/A	N/A
CV01KP075	100 µg (≥71 years)	FEMALE	72	-1	-19	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01KP075	100 µg (≥71 years)	FEMALE	72	-1	-19	Platelets (10 ³ /uL)	356	N/A	N/A	N/A	N/A
CV01KP075	100 µg (≥71 years)	FEMALE	72	1	1	Platelets (10 ³ /uL)	369	N/A	N/A	N/A	N/A
CV01KP075	100 µg (≥71 years)	FEMALE	72	8	8	Platelets (10 ³ /uL)	357	N/A	N/A	N/A	N/A
CV01KP075	100 µg (≥71 years)	FEMALE	72	29	29	Platelets (10 ³ /uL)	384	N/A	N/A	N/A	N/A
CV01KP075	100 µg (≥71 years)	FEMALE	72	36	36	Platelets (10 ³ /uL)	391	N/A	N/A	N/A	N/A
CV01KP075	100 µg (≥71 years)	FEMALE	72	-1	-19	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP075	100 µg (≥71 years)	FEMALE	72	1	1	WBC (10 ³ /uL)	6.60	N/A	N/A	N/A	N/A
CV01KP075	100 µg (≥71 years)	FEMALE	72	8	8	WBC (10 ³ /uL)	7.50	N/A	N/A	N/A	N/A
CV01KP075	100 µg (≥71 years)	FEMALE	72	29	29	WBC (10 ³ /uL)	8.00	N/A	N/A	N/A	N/A
CV01KP075	100 µg (≥71 years)	FEMALE	72	36	36	WBC (10 ³ /uL)	5.60	N/A	N/A	N/A	N/A
CV01KP076	100 µg (≥71 years)	MALE	73	-1	-20	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
CV01KP076	100 µg (≥71 years)	MALE	73	1	1	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
CV01KP076	100 µg (≥71 years)	MALE	73	8	8	Hemoglobin (g/dL)	13.7 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP076	100 µg (≥71 years)	MALE	73	29	28	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP076	100 µg (≥71 years)	MALE	73	36	35	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
CV01KP076	100 µg (≥71 years)	MALE	73	-1	-20	PT (seconds)	10.6	N/A	N/A	N/A	N/A
CV01KP076	100 µg (≥71 years)	MALE	73	-1	-20	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01KP076	100 µg (≥71 years)	MALE	73	-1	-20	Platelets (10 ³ /uL)	195	N/A	N/A	N/A	N/A
CV01KP076	100 µg (≥71 years)	MALE	73	1	1	Platelets (10 ³ /uL)	186	N/A	N/A	N/A	N/A
CV01KP076	100 µg (≥71 years)	MALE	73	8	8	Platelets (10 ³ /uL)	194	N/A	N/A	N/A	N/A
CV01KP076	100 µg (≥71 years)	MALE	73	29	28	Platelets (10 ³ /uL)	188	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP076	100 µg (≥71 years)	MALE	73	36	35	Platelets (10 ³ /uL)	201	N/A	N/A	N/A	N/A
CV01KP076	100 µg (≥71 years)	MALE	73	-1	-20	WBC (10 ³ /uL)	5.00	N/A	N/A	N/A	N/A
CV01KP076	100 µg (≥71 years)	MALE	73	1	1	WBC (10 ³ /uL)	4.10	N/A	N/A	N/A	N/A
CV01KP076	100 µg (≥71 years)	MALE	73	8	8	WBC (10 ³ /uL)	5.30	N/A	N/A	N/A	N/A
CV01KP076	100 µg (≥71 years)	MALE	73	29	28	WBC (10 ³ /uL)	4.10	N/A	N/A	N/A	N/A
CV01KP076	100 µg (≥71 years)	MALE	73	36	35	WBC (10 ³ /uL)	4.70	N/A	N/A	N/A	N/A
CV01KP077	100 µg (≥71 years)	FEMALE	72	-1	-20	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
CV01KP077	100 µg (≥71 years)	FEMALE	72	1	1	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
CV01KP077	100 µg (≥71 years)	FEMALE	72	8	8	Hemoglobin (g/dL)	11.0 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01KP077	100 µg (≥71 years)	FEMALE	72	29	28	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
CV01KP077	100 µg (≥71 years)	FEMALE	72	36	35	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP077	100 µg (≥71 years)	FEMALE	72	-1	-20	PT (seconds)	10.7	N/A	N/A	N/A	N/A
CV01KP077	100 µg (≥71 years)	FEMALE	72	-1	-20	PTT (seconds)	29.0	N/A	N/A	N/A	N/A
CV01KP077	100 µg (≥71 years)	FEMALE	72	-1	-20	Platelets (10 ³ /uL)	242	N/A	N/A	N/A	N/A
CV01KP077	100 µg (≥71 years)	FEMALE	72	1	1	Platelets (10 ³ /uL)	257	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP077	100 µg (≥71 years)	FEMALE	72	8	8	Platelets (10 ³ /uL)	234	N/A	N/A	N/A	N/A
CV01KP077	100 µg (≥71 years)	FEMALE	72	29	28	Platelets (10 ³ /uL)	252	N/A	N/A	N/A	N/A
CV01KP077	100 µg (≥71 years)	FEMALE	72	36	35	Platelets (10 ³ /uL)	224	N/A	N/A	N/A	N/A
CV01KP077	100 µg (≥71 years)	FEMALE	72	-1	-20	WBC (10 ³ /uL)	5.80	N/A	N/A	N/A	N/A
CV01KP077	100 µg (≥71 years)	FEMALE	72	1	1	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A
CV01KP077	100 µg (≥71 years)	FEMALE	72	8	8	WBC (10 ³ /uL)	6.60	N/A	N/A	N/A	N/A
CV01KP077	100 µg (≥71 years)	FEMALE	72	29	28	WBC (10 ³ /uL)	6.50	N/A	N/A	N/A	N/A
CV01KP077	100 µg (≥71 years)	FEMALE	72	36	35	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	-1	-19	Hemoglobin (g/dL)	12.2	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	1	1	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	8	8	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01KP078	100 µg (≥71 years)	FEMALE	73	29	29	Hemoglobin (g/dL)	12.2 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP078	100 µg (≥71 years)	FEMALE	73	36	36	Hemoglobin (g/dL)	11.9 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP078	100 µg (≥71 years)	FEMALE	73	-1	-19	PT (seconds)	9.8	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	-1	-19	PTT (seconds)	28.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP078	100 µg (≥71 years)	FEMALE	73	-1	-19	Platelets (10 ³ /uL)	281	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	1	1	Platelets (10 ³ /uL)	318	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	8	8	Platelets (10 ³ /uL)	303	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	29	29	Platelets (10 ³ /uL)	306	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	36	36	Platelets (10 ³ /uL)	333	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	-1	-19	WBC (10 ³ /uL)	4.00	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	1	1	WBC (10 ³ /uL)	4.50	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	8	8	WBC (10 ³ /uL)	4.20	N/A	N/A	N/A	N/A
CV01KP078	100 µg (≥71 years)	FEMALE	73	29	29	WBC (10 ³ /uL)	3.40 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01KP078	100 µg (≥71 years)	FEMALE	73	36	36	WBC (10 ³ /uL)	3.50 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP081	100 µg (≥71 years)	MALE	72	-1	-20	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
CV01KP081	100 µg (≥71 years)	MALE	72	1	1	Hemoglobin (g/dL)	15.2	N/A	N/A	N/A	N/A
CV01KP081	100 µg (≥71 years)	MALE	72	8	8	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP081	100 µg (≥71 years)	MALE	72	29	28	Hemoglobin (g/dL)	14.9 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP081	100 µg (≥71 years)	MALE	72	36	35	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP081	100 µg (≥71 years)	MALE	72	-1	-20	PT (seconds)	10.2	N/A	N/A	N/A	N/A
CV01KP081	100 µg (≥71 years)	MALE	72	-1	-20	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01KP081	100 µg (≥71 years)	MALE	72	-1	-20	Platelets (10 ³ /uL)	211	N/A	N/A	N/A	N/A
CV01KP081	100 µg (≥71 years)	MALE	72	1	1	Platelets (10 ³ /uL)	213	N/A	N/A	N/A	N/A
CV01KP081	100 µg (≥71 years)	MALE	72	8	8	Platelets (10 ³ /uL)	213	N/A	N/A	N/A	N/A
CV01KP081	100 µg (≥71 years)	MALE	72	29	28	Platelets (10 ³ /uL)	197	N/A	N/A	N/A	N/A
CV01KP081	100 µg (≥71 years)	MALE	72	36	35	Platelets (10 ³ /uL)	225	N/A	N/A	N/A	N/A
CV01KP081	100 µg (≥71 years)	MALE	72	-1	-20	WBC (10 ³ /uL)	6.10	N/A	N/A	N/A	N/A
CV01KP081	100 µg (≥71 years)	MALE	72	1	1	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A
CV01KP081	100 µg (≥71 years)	MALE	72	8	8	WBC (10 ³ /uL)	5.60	N/A	N/A	N/A	N/A
CV01KP081	100 µg (≥71 years)	MALE	72	29	28	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A
CV01KP081	100 µg (≥71 years)	MALE	72	36	35	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01KP085	100 µg (≥71 years)	MALE	71	-1	-18	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
CV01KP085	100 µg (≥71 years)	MALE	71	1	1	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
CV01KP085	100 µg (≥71 years)	MALE	71	8	8	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP085	100 µg (≥71 years)	MALE	71	29	29	Hemoglobin (g/dL)	15.3 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP085	100 µg (≥71 years)	MALE	71	36	36	Hemoglobin (g/dL)	15.4 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP085	100 µg (≥71 years)	MALE	71	-1	-18	PT (seconds)	9.8	N/A	N/A	N/A	N/A
CV01KP085	100 µg (≥71 years)	MALE	71	-1	-18	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01KP085	100 µg (≥71 years)	MALE	71	-1	-18	Platelets (10 ³ /uL)	144	N/A	N/A	N/A	N/A
CV01KP085	100 µg (≥71 years)	MALE	71	1	1	Platelets (10 ³ /uL)	104 (Moderate)	N/A	N/A	N/A	N/A
CV01KP085	100 µg (≥71 years)	MALE	71	8	8	Platelets (10 ³ /uL)	125 (Mild)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01KP085	100 µg (≥71 years)	MALE	71	36	36	Platelets (10 ³ /uL)	141	N/A	N/A	N/A	N/A
CV01KP085	100 µg (≥71 years)	MALE	71	-1	-18	WBC (10 ³ /uL)	6.40	N/A	N/A	N/A	N/A
CV01KP085	100 µg (≥71 years)	MALE	71	1	1	WBC (10 ³ /uL)	5.40	N/A	N/A	N/A	N/A
CV01KP085	100 µg (≥71 years)	MALE	71	8	8	WBC (10 ³ /uL)	6.50	N/A	N/A	N/A	N/A
CV01KP085	100 µg (≥71 years)	MALE	71	29	29	WBC (10 ³ /uL)	5.60	N/A	N/A	N/A	N/A
CV01KP085	100 µg (≥71 years)	MALE	71	36	36	WBC (10 ³ /uL)	5.60	N/A	N/A	N/A	N/A
CV01KP092	50 µg (18-55 years)	MALE	35	-1	-13	Hemoglobin (g/dL)	16.0	N/A	N/A	N/A	N/A
CV01KP092	50 µg (18-55 years)	MALE	35	1	1	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP092	50 µg (18-55 years)	MALE	35	8	8	Hemoglobin (g/dL)	14.2 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP092	50 µg (18-55 years)	MALE	35	29	27	Hemoglobin (g/dL)	13.7 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP092	50 µg (18-55 years)	MALE	35	36	34	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
CV01KP092	50 µg (18-55 years)	MALE	35	-1	-13	PT (seconds)	10.4	N/A	N/A	N/A	N/A
CV01KP092	50 µg (18-55 years)	MALE	35	-1	-13	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01KP092	50 µg (18-55 years)	MALE	35	-1	-13	Platelets (10 ³ /uL)	246	N/A	N/A	N/A	N/A
CV01KP092	50 µg (18-55 years)	MALE	35	1	1	Platelets (10 ³ /uL)	230	N/A	N/A	N/A	N/A
CV01KP092	50 µg (18-55 years)	MALE	35	8	8	Platelets (10 ³ /uL)	210	N/A	N/A	N/A	N/A
CV01KP092	50 µg (18-55 years)	MALE	35	29	27	Platelets (10 ³ /uL)	188	N/A	N/A	N/A	N/A
CV01KP092	50 µg (18-55 years)	MALE	35	36	34	Platelets (10 ³ /uL)	223	N/A	N/A	N/A	N/A
CV01KP092	50 µg (18-55 years)	MALE	35	-1	-13	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01KP092	50 µg (18-55 years)	MALE	35	1	1	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A
CV01KP092	50 µg (18-55 years)	MALE	35	8	8	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01KP092	50 µg (18-55 years)	MALE	35	29	27	WBC (10 ³ /uL)	3.80	N/A	N/A	N/A	N/A
CV01KP092	50 µg (18-55 years)	MALE	35	36	34	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP094	50 µg (18-55 years)	FEMALE	54	-1	-9	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
CV01KP094	50 µg (18-55 years)	FEMALE	54	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
CV01KP094	50 µg (18-55 years)	FEMALE	54	8	8	Hemoglobin (g/dL)	12.8 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP094	50 µg (18-55 years)	FEMALE	54	29	27	Hemoglobin (g/dL)	13.4 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP094	50 µg (18-55 years)	FEMALE	54	36	34	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP094	50 µg (18-55 years)	FEMALE	54	-1	-9	PT (seconds)	10.2	N/A	N/A	N/A	N/A
CV01KP094	50 µg (18-55 years)	FEMALE	54	-1	-9	PTT (seconds)	30.0	N/A	N/A	N/A	N/A
CV01KP094	50 µg (18-55 years)	FEMALE	54	-1	-9	Platelets (10 ³ /uL)	242	N/A	N/A	N/A	N/A
CV01KP094	50 µg (18-55 years)	FEMALE	54	1	1	Platelets (10 ³ /uL)	250	N/A	N/A	N/A	N/A
CV01KP094	50 µg (18-55 years)	FEMALE	54	8	8	Platelets (10 ³ /uL)	232	N/A	N/A	N/A	N/A
CV01KP094	50 µg (18-55 years)	FEMALE	54	29	27	Platelets (10 ³ /uL)	237	N/A	N/A	N/A	N/A
CV01KP094	50 µg (18-55 years)	FEMALE	54	36	34	Platelets (10 ³ /uL)	268	N/A	N/A	N/A	N/A
CV01KP094	50 µg (18-55 years)	FEMALE	54	-1	-9	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A
CV01KP094	50 µg (18-55 years)	FEMALE	54	1	1	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01KP094	50 µg (18-55 years)	FEMALE	54	8	8	WBC (10 ³ /uL)	4.90	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP094	50 µg (18-55 years)	FEMALE	54	29	27	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01KP094	50 µg (18-55 years)	FEMALE	54	36	34	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01KP095	50 µg (18-55 years)	MALE	23	-1	-9	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
CV01KP095	50 µg (18-55 years)	MALE	23	1	1	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
CV01KP095	50 µg (18-55 years)	MALE	23	8	8	Hemoglobin (g/dL)	15.5 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP095	50 µg (18-55 years)	MALE	23	29	27	Hemoglobin (g/dL)	16.5	N/A	N/A	N/A	N/A
CV01KP095	50 µg (18-55 years)	MALE	23	36	34	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP095	50 µg (18-55 years)	MALE	23	-1	-9	PT (seconds)	10.5	N/A	N/A	N/A	N/A
CV01KP095	50 µg (18-55 years)	MALE	23	-1	-9	PTT (seconds)	32.0	N/A	N/A	N/A	N/A
CV01KP095	50 µg (18-55 years)	MALE	23	-1	-9	Platelets (10 ³ /uL)	259	N/A	N/A	N/A	N/A
CV01KP095	50 µg (18-55 years)	MALE	23	1	1	Platelets (10 ³ /uL)	285	N/A	N/A	N/A	N/A
CV01KP095	50 µg (18-55 years)	MALE	23	8	8	Platelets (10 ³ /uL)	256	N/A	N/A	N/A	N/A
CV01KP095	50 µg (18-55 years)	MALE	23	29	27	Platelets (10 ³ /uL)	243	N/A	N/A	N/A	N/A
CV01KP095	50 µg (18-55 years)	MALE	23	36	34	Platelets (10 ³ /uL)	266	N/A	N/A	N/A	N/A
CV01KP095	50 µg (18-55 years)	MALE	23	-1	-9	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP095	50 µg (18-55 years)	MALE	23	1	1	WBC (10 ³ /uL)	6.50	N/A	N/A	N/A	N/A
CV01KP095	50 µg (18-55 years)	MALE	23	8	8	WBC (10 ³ /uL)	7.20	N/A	N/A	N/A	N/A
CV01KP095	50 µg (18-55 years)	MALE	23	29	27	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A
CV01KP095	50 µg (18-55 years)	MALE	23	36	34	WBC (10 ³ /uL)	6.80	N/A	N/A	N/A	N/A
CV01KP096	50 µg (18-55 years)	MALE	29	-1	-9	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
CV01KP096	50 µg (18-55 years)	MALE	29	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
CV01KP096	50 µg (18-55 years)	MALE	29	8	8	Hemoglobin (g/dL)	14.0 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP096	50 µg (18-55 years)	MALE	29	29	27	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
CV01KP096	50 µg (18-55 years)	MALE	29	36	36	Hemoglobin (g/dL)	13.3 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
CV01KP096	50 µg (18-55 years)	MALE	29	-1	-9	PT (seconds)	10.7	N/A	N/A	N/A	N/A
CV01KP096	50 µg (18-55 years)	MALE	29	-1	-9	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01KP096	50 µg (18-55 years)	MALE	29	-1	-9	Platelets (10 ³ /uL)	239	N/A	N/A	N/A	N/A
CV01KP096	50 µg (18-55 years)	MALE	29	1	1	Platelets (10 ³ /uL)	212	N/A	N/A	N/A	N/A
CV01KP096	50 µg (18-55 years)	MALE	29	8	8	Platelets (10 ³ /uL)	210	N/A	N/A	N/A	N/A
CV01KP096	50 µg (18-55 years)	MALE	29	29	27	Platelets (10 ³ /uL)	232	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP096	50 µg (18-55 years)	MALE	29	36	36	Platelets (10 ³ /uL)	235	N/A	N/A	N/A	N/A
CV01KP096	50 µg (18-55 years)	MALE	29	-1	-9	WBC (10 ³ /uL)	5.90	N/A	N/A	N/A	N/A
CV01KP096	50 µg (18-55 years)	MALE	29	1	1	WBC (10 ³ /uL)	5.50	N/A	N/A	N/A	N/A
CV01KP096	50 µg (18-55 years)	MALE	29	8	8	WBC (10 ³ /uL)	6.20	N/A	N/A	N/A	N/A
CV01KP096	50 µg (18-55 years)	MALE	29	29	27	WBC (10 ³ /uL)	5.20	N/A	N/A	N/A	N/A
CV01KP096	50 µg (18-55 years)	MALE	29	36	36	WBC (10 ³ /uL)	6.20	N/A	N/A	N/A	N/A
CV01KP097	50 µg (18-55 years)	MALE	31	-1	-9	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
CV01KP097	50 µg (18-55 years)	MALE	31	1	1	Hemoglobin (g/dL)	14.9	N/A	N/A	N/A	N/A
CV01KP097	50 µg (18-55 years)	MALE	31	8	8	Hemoglobin (g/dL)	13.9 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP097	50 µg (18-55 years)	MALE	31	29	27	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
CV01KP097	50 µg (18-55 years)	MALE	31	36	34	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP097	50 µg (18-55 years)	MALE	31	-1	-9	PT (seconds)	9.9	N/A	N/A	N/A	N/A
CV01KP097	50 µg (18-55 years)	MALE	31	-1	-9	PTT (seconds)	27.0	N/A	N/A	N/A	N/A
CV01KP097	50 µg (18-55 years)	MALE	31	-1	-9	Platelets (10 ³ /uL)	212	N/A	N/A	N/A	N/A
CV01KP097	50 µg (18-55 years)	MALE	31	1	1	Platelets (10 ³ /uL)	211	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP097	50 µg (18-55 years)	MALE	31	8	8	Platelets (10 ³ /uL)	208	N/A	N/A	N/A	N/A
CV01KP097	50 µg (18-55 years)	MALE	31	29	27	Platelets (10 ³ /uL)	244	N/A	N/A	N/A	N/A
CV01KP097	50 µg (18-55 years)	MALE	31	36	34	Platelets (10 ³ /uL)	235	N/A	N/A	N/A	N/A
CV01KP097	50 µg (18-55 years)	MALE	31	-1	-9	WBC (10 ³ /uL)	5.70	N/A	N/A	N/A	N/A
CV01KP097	50 µg (18-55 years)	MALE	31	1	1	WBC (10 ³ /uL)	4.70	N/A	N/A	N/A	N/A
CV01KP097	50 µg (18-55 years)	MALE	31	8	8	WBC (10 ³ /uL)	4.50	N/A	N/A	N/A	N/A
CV01KP097	50 µg (18-55 years)	MALE	31	29	27	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01KP097	50 µg (18-55 years)	MALE	31	36	34	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A
CV01KP098	50 µg (18-55 years)	FEMALE	43	-1	-8	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A
CV01KP098	50 µg (18-55 years)	FEMALE	43	1	1	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
CV01KP098	50 µg (18-55 years)	FEMALE	43	8	8	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
CV01KP098	50 µg (18-55 years)	FEMALE	43	29	27	Hemoglobin (g/dL)	13.7 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
CV01KP098	50 µg (18-55 years)	FEMALE	43	36	34	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
CV01KP098	50 µg (18-55 years)	FEMALE	43	-1	-8	PT (seconds)	10.7	N/A	N/A	N/A	N/A
CV01KP098	50 µg (18-55 years)	FEMALE	43	-1	-8	PTT (seconds)	25.0	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP098	50 µg (18-55 years)	FEMALE	43	-1	-8	Platelets (10 ³ /uL)	279	N/A	N/A	N/A	N/A
CV01KP098	50 µg (18-55 years)	FEMALE	43	1	1	Platelets (10 ³ /uL)	258	N/A	N/A	N/A	N/A
CV01KP098	50 µg (18-55 years)	FEMALE	43	8	8	Platelets (10 ³ /uL)	245	N/A	N/A	N/A	N/A
CV01KP098	50 µg (18-55 years)	FEMALE	43	29	27	Platelets (10 ³ /uL)	254	N/A	N/A	N/A	N/A
CV01KP098	50 µg (18-55 years)	FEMALE	43	36	34	Platelets (10 ³ /uL)	248	N/A	N/A	N/A	N/A
CV01KP098	50 µg (18-55 years)	FEMALE	43	-1	-8	WBC (10 ³ /uL)	7.10	N/A	N/A	N/A	N/A
CV01KP098	50 µg (18-55 years)	FEMALE	43	1	1	WBC (10 ³ /uL)	6.50	N/A	N/A	N/A	N/A
CV01KP098	50 µg (18-55 years)	FEMALE	43	8	8	WBC (10 ³ /uL)	7.00	N/A	N/A	N/A	N/A
CV01KP098	50 µg (18-55 years)	FEMALE	43	29	27	WBC (10 ³ /uL)	6.40	N/A	N/A	N/A	N/A
CV01KP098	50 µg (18-55 years)	FEMALE	43	36	34	WBC (10 ³ /uL)	7.30	N/A	N/A	N/A	N/A
CV01KP101	50 µg (18-55 years)	MALE	39	-1	-8	Hemoglobin (g/dL)	13.4 (Mild)	N/A	N/A	N/A	N/A
CV01KP101	50 µg (18-55 years)	MALE	39	1	1	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
CV01KP101	50 µg (18-55 years)	MALE	39	8	8	Hemoglobin (g/dL)	12.2 (Moderate)	RELATED	N/A	NC- DOSE NOT CHANGED	No
CV01KP101	50 µg (18-55 years)	MALE	39	29	27	Hemoglobin (g/dL)	13.0 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No
CV01KP101	50 µg (18-55 years)	MALE	39	36	34	Hemoglobin (g/dL)	13.1 (Mild)	RELATED	N/A	NA- NOT APPLICABLE	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01KP101	50 µg (18-55 years)	MALE	39	-1	-8	PT (seconds)	10.1	N/A	N/A	N/A	N/A
CV01KP101	50 µg (18-55 years)	MALE	39	-1	-8	PTT (seconds)	28.0	N/A	N/A	N/A	N/A
CV01KP101	50 µg (18-55 years)	MALE	39	-1	-8	Platelets (10 ³ /uL)	229	N/A	N/A	N/A	N/A
CV01KP101	50 µg (18-55 years)	MALE	39	1	1	Platelets (10 ³ /uL)	250	N/A	N/A	N/A	N/A
CV01KP101	50 µg (18-55 years)	MALE	39	8	8	Platelets (10 ³ /uL)	239	N/A	N/A	N/A	N/A
CV01KP101	50 µg (18-55 years)	MALE	39	29	27	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
CV01KP101	50 µg (18-55 years)	MALE	39	36	34	Platelets (10 ³ /uL)	245	N/A	N/A	N/A	N/A
CV01KP101	50 µg (18-55 years)	MALE	39	-1	-8	WBC (10 ³ /uL)	4.50	N/A	N/A	N/A	N/A
CV01KP101	50 µg (18-55 years)	MALE	39	1	1	WBC (10 ³ /uL)	5.40	N/A	N/A	N/A	N/A
CV01KP101	50 µg (18-55 years)	MALE	39	8	8	WBC (10 ³ /uL)	4.70	N/A	N/A	N/A	N/A
CV01KP101	50 µg (18-55 years)	MALE	39	29	27	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01KP101	50 µg (18-55 years)	MALE	39	36	34	WBC (10 ³ /uL)	4.60	N/A	N/A	N/A	N/A
CV01VR002	50 µg (≥71 years)	MALE	74	-1	-39	Hemoglobin (g/dL)	15.7	N/A	N/A	N/A	N/A
CV01VR002	50 µg (≥71 years)	MALE	74	1	1	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
CV01VR002	50 µg (≥71 years)	MALE	74	8	7	Hemoglobin (g/dL)	14.5 (Mild)	NOT RELATED	Hgb within institutional normal range	NC- DOSE NOT CHANGED	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR002	50 µg (≥71 years)	MALE	74	29	27	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
CV01VR002	50 µg (≥71 years)	MALE	74	36	35	Hemoglobin (g/dL)	14.3 (Mild)	NOT RELATED	Hemoglobin is within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR002	50 µg (≥71 years)	MALE	74	-1	-39	PT (seconds)	13.3	N/A	N/A	N/A	N/A
CV01VR002	50 µg (≥71 years)	MALE	74	-1	-39	PTT (seconds)	32.0	N/A	N/A	N/A	N/A
CV01VR002	50 µg (≥71 years)	MALE	74	-1	-39	Platelets (10 ³ /uL)	216	N/A	N/A	N/A	N/A
CV01VR002	50 µg (≥71 years)	MALE	74	1	1	Platelets (10 ³ /uL)	196	N/A	N/A	N/A	N/A
CV01VR002	50 µg (≥71 years)	MALE	74	8	7	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A
CV01VR002	50 µg (≥71 years)	MALE	74	29	27	Platelets (10 ³ /uL)	209	N/A	N/A	N/A	N/A
CV01VR002	50 µg (≥71 years)	MALE	74	36	35	Platelets (10 ³ /uL)	222	N/A	N/A	N/A	N/A
CV01VR002	50 µg (≥71 years)	MALE	74	-1	-39	WBC (10 ³ /uL)	6.11	N/A	N/A	N/A	N/A
CV01VR002	50 µg (≥71 years)	MALE	74	1	1	WBC (10 ³ /uL)	5.05	N/A	N/A	N/A	N/A
CV01VR002	50 µg (≥71 years)	MALE	74	8	7	WBC (10 ³ /uL)	5.98	N/A	N/A	N/A	N/A
CV01VR002	50 µg (≥71 years)	MALE	74	29	27	WBC (10 ³ /uL)	5.06	N/A	N/A	N/A	N/A
CV01VR002	50 µg (≥71 years)	MALE	74	36	35	WBC (10 ³ /uL)	7.37	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR003	50 µg (56-70 years)	FEMALE	56	-1	-36	Hemoglobin (g/dL)	12.7	N/A	N/A	N/A	N/A
CV01VR003	50 µg (56-70 years)	FEMALE	56	1	1	Hemoglobin (g/dL)	13.2	N/A	N/A	N/A	N/A
CV01VR003	50 µg (56-70 years)	FEMALE	56	8	7	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	Hgb within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR003	50 µg (56-70 years)	FEMALE	56	29	31	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	hemoglobin within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR003	50 µg (56-70 years)	FEMALE	56	36	37	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	Hemoglobin within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR003	50 µg (56-70 years)	FEMALE	56	-1	-36	PT (seconds)	13.6	N/A	N/A	N/A	N/A
CV01VR003	50 µg (56-70 years)	FEMALE	56	-1	-36	PTT (seconds)	32.8	N/A	N/A	N/A	N/A
CV01VR003	50 µg (56-70 years)	FEMALE	56	-1	-36	Platelets (10 ³ /uL)	237	N/A	N/A	N/A	N/A
CV01VR003	50 µg (56-70 years)	FEMALE	56	1	1	Platelets (10 ³ /uL)	215	N/A	N/A	N/A	N/A
CV01VR003	50 µg (56-70 years)	FEMALE	56	8	7	Platelets (10 ³ /uL)	237	N/A	N/A	N/A	N/A
CV01VR003	50 µg (56-70 years)	FEMALE	56	29	31	Platelets (10 ³ /uL)	248	N/A	N/A	N/A	N/A
CV01VR003	50 µg (56-70 years)	FEMALE	56	36	37	Platelets (10 ³ /uL)	275	N/A	N/A	N/A	N/A
CV01VR003	50 µg (56-70 years)	FEMALE	56	-1	-36	WBC (10 ³ /uL)	5.56	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR003	50 µg (56-70 years)	FEMALE	56	1	1	WBC (10 ³ /uL)	5.41	N/A	N/A	N/A	N/A
CV01VR003	50 µg (56-70 years)	FEMALE	56	8	7	WBC (10 ³ /uL)	6.04	N/A	N/A	N/A	N/A
CV01VR003	50 µg (56-70 years)	FEMALE	56	29	31	WBC (10 ³ /uL)	5.91	N/A	N/A	N/A	N/A
CV01VR003	50 µg (56-70 years)	FEMALE	56	36	37	WBC (10 ³ /uL)	5.81	N/A	N/A	N/A	N/A
CV01VR005	50 µg (56-70 years)	MALE	63	-1	-37	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
CV01VR005	50 µg (56-70 years)	MALE	63	1	1	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
CV01VR005	50 µg (56-70 years)	MALE	63	8	7	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Hgb within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR005	50 µg (56-70 years)	MALE	63	29	27	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	hemoglobin within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR005	50 µg (56-70 years)	MALE	63	36	33	Hemoglobin (g/dL)	15.0 (Mild)	NOT RELATED	hemoglobin is within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR005	50 µg (56-70 years)	MALE	63	-1	-37	PT (seconds)	13.4	N/A	N/A	N/A	N/A
CV01VR005	50 µg (56-70 years)	MALE	63	-1	-37	PTT (seconds)	32.8	N/A	N/A	N/A	N/A
CV01VR005	50 µg (56-70 years)	MALE	63	-1	-37	Platelets (10 ³ /uL)	229	N/A	N/A	N/A	N/A
CV01VR005	50 µg (56-70 years)	MALE	63	1	1	Platelets (10 ³ /uL)	206	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR005	50 µg (56-70 years)	MALE	63	8	7	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A
CV01VR005	50 µg (56-70 years)	MALE	63	29	27	Platelets (10 ³ /uL)	206	N/A	N/A	N/A	N/A
CV01VR005	50 µg (56-70 years)	MALE	63	36	33	Platelets (10 ³ /uL)	223	N/A	N/A	N/A	N/A
CV01VR005	50 µg (56-70 years)	MALE	63	-1	-37	WBC (10 ³ /uL)	7.20	N/A	N/A	N/A	N/A
CV01VR005	50 µg (56-70 years)	MALE	63	1	1	WBC (10 ³ /uL)	7.12	N/A	N/A	N/A	N/A
CV01VR005	50 µg (56-70 years)	MALE	63	8	7	WBC (10 ³ /uL)	7.63	N/A	N/A	N/A	N/A
CV01VR005	50 µg (56-70 years)	MALE	63	29	27	WBC (10 ³ /uL)	6.33	N/A	N/A	N/A	N/A
CV01VR005	50 µg (56-70 years)	MALE	63	36	33	WBC (10 ³ /uL)	6.72	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	-1	-35	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	1	1	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	8	7	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	hgb within INR	NC- DOSE NOT CHANGED	No
CV01VR006	50 µg (56-70 years)	MALE	65	29	31	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	hemoglobin within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR006	50 µg (56-70 years)	MALE	65	36	37	Hemoglobin (g/dL)	14.9 (Mild)	NOT RELATED	hemoglobin is within institutional normal range	NC- DOSE NOT CHANGED	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR006	50 µg (56-70 years)	MALE	65	57	59	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	-1	-35	PT (seconds)	14.0	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	-1	-35	PTT (seconds)	30.9	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	-1	-35	Platelets (10 ³ /uL)	174	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	1	1	Platelets (10 ³ /uL)	153	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	8	7	Platelets (10 ³ /uL)	160	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	29	31	Platelets (10 ³ /uL)	164	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	36	37	Platelets (10 ³ /uL)	148	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	57	59	Platelets (10 ³ /uL)	170	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	-1	-35	WBC (10 ³ /uL)	4.80	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	1	1	WBC (10 ³ /uL)	3.87	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	8	7	WBC (10 ³ /uL)	4.47	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	29	31	WBC (10 ³ /uL)	4.53	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	36	37	WBC (10 ³ /uL)	4.28	N/A	N/A	N/A	N/A
CV01VR006	50 µg (56-70 years)	MALE	65	57	59	WBC (10 ³ /uL)	5.58	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR008	50 µg (56-70 years)	MALE	64	-1	-35	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
CV01VR008	50 µg (56-70 years)	MALE	64	-1	-27	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
CV01VR008	50 µg (56-70 years)	MALE	64	1	1	Hemoglobin (g/dL)	15.8	N/A	N/A	N/A	N/A
CV01VR008	50 µg (56-70 years)	MALE	64	8	7	Hemoglobin (g/dL)	15.8	N/A	N/A	N/A	N/A
CV01VR008	50 µg (56-70 years)	MALE	64	29	31	Hemoglobin (g/dL)	15.4 (Mild)	NOT RELATED	Hemoglobin within institutional normal limits	NC- DOSE NOT CHANGED	No
CV01VR008	50 µg (56-70 years)	MALE	64	36	37	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	hemoglobin is within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR008	50 µg (56-70 years)	MALE	64	-1	-35	PT (seconds)	13.7	N/A	N/A	N/A	N/A
CV01VR008	50 µg (56-70 years)	MALE	64	-1	-35	PTT (seconds)	29.6	N/A	N/A	N/A	N/A
CV01VR008	50 µg (56-70 years)	MALE	64	-1	-35	Platelets (10 ³ /uL)	195	N/A	N/A	N/A	N/A
CV01VR008	50 µg (56-70 years)	MALE	64	-1	-27	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
CV01VR008	50 µg (56-70 years)	MALE	64	1	1	Platelets (10 ³ /uL)	220	N/A	N/A	N/A	N/A
CV01VR008	50 µg (56-70 years)	MALE	64	8	7	Platelets (10 ³ /uL)	220	N/A	N/A	N/A	N/A
CV01VR008	50 µg (56-70 years)	MALE	64	29	31	Platelets (10 ³ /uL)	208	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR008	50 µg (56-70 years)	MALE	64	36	37	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A
CV01VR008	50 µg (56-70 years)	MALE	64	-1	-35	WBC (10 ³ /uL)	10.57	N/A	N/A	N/A	N/A
CV01VR008	50 µg (56-70 years)	MALE	64	-1	-27	WBC (10 ³ /uL)	6.30	N/A	N/A	N/A	N/A
CV01VR008	50 µg (56-70 years)	MALE	64	1	1	WBC (10 ³ /uL)	5.29	N/A	N/A	N/A	N/A
CV01VR008	50 µg (56-70 years)	MALE	64	8	7	WBC (10 ³ /uL)	5.52	N/A	N/A	N/A	N/A
CV01VR008	50 µg (56-70 years)	MALE	64	29	31	WBC (10 ³ /uL)	4.64	N/A	N/A	N/A	N/A
CV01VR008	50 µg (56-70 years)	MALE	64	36	37	WBC (10 ³ /uL)	5.61	N/A	N/A	N/A	N/A
CV01VR009	50 µg (56-70 years)	FEMALE	68	-1	-36	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
CV01VR009	50 µg (56-70 years)	FEMALE	68	1	1	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
CV01VR009	50 µg (56-70 years)	FEMALE	68	8	7	Hemoglobin (g/dL)	12.2 (Mild)	NOT RELATED	hgb within INR	NC- DOSE NOT CHANGED	No
CV01VR009	50 µg (56-70 years)	FEMALE	68	29	27	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	Hgb within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR009	50 µg (56-70 years)	FEMALE	68	36	35	Hemoglobin (g/dL)	11.8 (Mild)	NOT RELATED	Hemoglobin is within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR009	50 µg (56-70 years)	FEMALE	68	-1	-36	PT (seconds)	14.0	N/A	N/A	N/A	N/A
CV01VR009	50 µg (56-70 years)	FEMALE	68	-1	-36	PTT (seconds)	34.3	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR009	50 µg (56-70 years)	FEMALE	68	-1	-36	Platelets (10 ³ /uL)	270	N/A	N/A	N/A	N/A
CV01VR009	50 µg (56-70 years)	FEMALE	68	1	1	Platelets (10 ³ /uL)	258	N/A	N/A	N/A	N/A
CV01VR009	50 µg (56-70 years)	FEMALE	68	8	7	Platelets (10 ³ /uL)	252	N/A	N/A	N/A	N/A
CV01VR009	50 µg (56-70 years)	FEMALE	68	29	27	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
CV01VR009	50 µg (56-70 years)	FEMALE	68	36	35	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
CV01VR009	50 µg (56-70 years)	FEMALE	68	-1	-36	WBC (10 ³ /uL)	6.37	N/A	N/A	N/A	N/A
CV01VR009	50 µg (56-70 years)	FEMALE	68	1	1	WBC (10 ³ /uL)	4.38	N/A	N/A	N/A	N/A
CV01VR009	50 µg (56-70 years)	FEMALE	68	8	7	WBC (10 ³ /uL)	5.34	N/A	N/A	N/A	N/A
CV01VR009	50 µg (56-70 years)	FEMALE	68	29	27	WBC (10 ³ /uL)	5.61	N/A	N/A	N/A	N/A
CV01VR009	50 µg (56-70 years)	FEMALE	68	36	35	WBC (10 ³ /uL)	4.76	N/A	N/A	N/A	N/A
CV01VR011	50 µg (56-70 years)	MALE	66	-1	-34	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A
CV01VR011	50 µg (56-70 years)	MALE	66	1	1	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
CV01VR011	50 µg (56-70 years)	MALE	66	8	7	Hemoglobin (g/dL)	14.5 (Mild)	NOT RELATED	Hgb within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR011	50 µg (56-70 years)	MALE	66	29	31	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	hemoglobin within institutional normal range	NC- DOSE NOT CHANGED	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR011	50 µg (56-70 years)	MALE	66	36	37	Hemoglobin (g/dL)	14.2 (Mild)	NOT RELATED	hemoglobin is within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR011	50 µg (56-70 years)	MALE	66	-1	-34	PT (seconds)	14.2	N/A	N/A	N/A	N/A
CV01VR011	50 µg (56-70 years)	MALE	66	-1	-34	PTT (seconds)	30.3	N/A	N/A	N/A	N/A
CV01VR011	50 µg (56-70 years)	MALE	66	-1	-34	Platelets (10 ³ /uL)	228	N/A	N/A	N/A	N/A
CV01VR011	50 µg (56-70 years)	MALE	66	1	1	Platelets (10 ³ /uL)	215	N/A	N/A	N/A	N/A
CV01VR011	50 µg (56-70 years)	MALE	66	8	7	Platelets (10 ³ /uL)	228	N/A	N/A	N/A	N/A
CV01VR011	50 µg (56-70 years)	MALE	66	29	31	Platelets (10 ³ /uL)	224	N/A	N/A	N/A	N/A
CV01VR011	50 µg (56-70 years)	MALE	66	36	37	Platelets (10 ³ /uL)	256	N/A	N/A	N/A	N/A
CV01VR011	50 µg (56-70 years)	MALE	66	-1	-34	WBC (10 ³ /uL)	6.26	N/A	N/A	N/A	N/A
CV01VR011	50 µg (56-70 years)	MALE	66	1	1	WBC (10 ³ /uL)	5.88	N/A	N/A	N/A	N/A
CV01VR011	50 µg (56-70 years)	MALE	66	8	7	WBC (10 ³ /uL)	5.95	N/A	N/A	N/A	N/A
CV01VR011	50 µg (56-70 years)	MALE	66	29	31	WBC (10 ³ /uL)	6.34	N/A	N/A	N/A	N/A
CV01VR011	50 µg (56-70 years)	MALE	66	36	37	WBC (10 ³ /uL)	6.01	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	-1	-36	Hemoglobin (g/dL)	14.9	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR013	50 µg (≥71 years)	MALE	73	-1	-30	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	1	1	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	8	7	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	hgb within INR	NC- DOSE NOT CHANGED	No
CV01VR013	50 µg (≥71 years)	MALE	73	29	27	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	36	33	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	-1	-36	PT (seconds)	14.0	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	-1	-36	PTT (seconds)	28.1	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	-1	-36	Platelets (10 ³ /uL)	158	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	-1	-30	Platelets (10 ³ /uL)	173	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	1	1	Platelets (10 ³ /uL)	175	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	8	7	Platelets (10 ³ /uL)	187	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	29	27	Platelets (10 ³ /uL)	176	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	36	33	Platelets (10 ³ /uL)	193	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	-1	-36	WBC (10 ³ /uL)	5.30	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	-1	-30	WBC (10 ³ /uL)	5.21	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR013	50 µg (≥71 years)	MALE	73	1	1	WBC (10 ³ /uL)	4.91	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	8	7	WBC (10 ³ /uL)	5.09	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	29	27	WBC (10 ³ /uL)	6.25	N/A	N/A	N/A	N/A
CV01VR013	50 µg (≥71 years)	MALE	73	36	33	WBC (10 ³ /uL)	5.91	N/A	N/A	N/A	N/A
CV01VR014	50 µg (≥71 years)	MALE	74	-1	-35	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
CV01VR014	50 µg (≥71 years)	MALE	74	1	1	Hemoglobin (g/dL)	13.6	N/A	N/A	N/A	N/A
CV01VR014	50 µg (≥71 years)	MALE	74	8	7	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	anemia due to blood draws	NC- DOSE NOT CHANGED	No
CV01VR014	50 µg (≥71 years)	MALE	74	29	27	Hemoglobin (g/dL)	13.3 (Mild)	NOT RELATED	anemia due to blood draws	NC- DOSE NOT CHANGED	No
CV01VR014	50 µg (≥71 years)	MALE	74	36	33	Hemoglobin (g/dL)	13.3 (Mild)	NOT RELATED	anemia due to blood draws	NC- DOSE NOT CHANGED	No
CV01VR014	50 µg (≥71 years)	MALE	74	-1	-35	PT (seconds)	13.6	N/A	N/A	N/A	N/A
CV01VR014	50 µg (≥71 years)	MALE	74	-1	-35	PTT (seconds)	31.3	N/A	N/A	N/A	N/A
CV01VR014	50 µg (≥71 years)	MALE	74	-1	-35	Platelets (10 ³ /uL)	178	N/A	N/A	N/A	N/A
CV01VR014	50 µg (≥71 years)	MALE	74	1	1	Platelets (10 ³ /uL)	154	N/A	N/A	N/A	N/A
CV01VR014	50 µg (≥71 years)	MALE	74	8	7	Platelets (10 ³ /uL)	168	N/A	N/A	N/A	N/A
CV01VR014	50 µg (≥71 years)	MALE	74	29	27	Platelets (10 ³ /uL)	163	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR014	50 µg (≥71 years)	MALE	74	36	33	Platelets (10 ³ /uL)	163	N/A	N/A	N/A	N/A
CV01VR014	50 µg (≥71 years)	MALE	74	-1	-35	WBC (10 ³ /uL)	8.31	N/A	N/A	N/A	N/A
CV01VR014	50 µg (≥71 years)	MALE	74	1	1	WBC (10 ³ /uL)	6.43	N/A	N/A	N/A	N/A
CV01VR014	50 µg (≥71 years)	MALE	74	8	7	WBC (10 ³ /uL)	7.33	N/A	N/A	N/A	N/A
CV01VR014	50 µg (≥71 years)	MALE	74	29	27	WBC (10 ³ /uL)	6.13	N/A	N/A	N/A	N/A
CV01VR014	50 µg (≥71 years)	MALE	74	36	33	WBC (10 ³ /uL)	6.12	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	-1	-34	Hemoglobin (g/dL)	11.5 (Mild)	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	-1	-22	Hemoglobin (g/dL)	12.1	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	1	1	Hemoglobin (g/dL)	12.2	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	8	7	Hemoglobin (g/dL)	11.3 (Mild)	NOT RELATED	within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR016	50 µg (56-70 years)	FEMALE	60	29	27	Hemoglobin (g/dL)	12.2	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	36	35	Hemoglobin (g/dL)	11.3 (Mild)	NOT RELATED	hemoglobin within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR016	50 µg (56-70 years)	FEMALE	60	-1	-34	PT (seconds)	13.7	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	-1	-34	PTT (seconds)	32.5	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR016	50 µg (56-70 years)	FEMALE	60	-1	-34	Platelets (10 ³ /uL)	177	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	-1	-22	Platelets (10 ³ /uL)	192	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	1	1	Platelets (10 ³ /uL)	181	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	8	7	Platelets (10 ³ /uL)	190	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	29	27	Platelets (10 ³ /uL)	189	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	36	35	Platelets (10 ³ /uL)	199	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	-1	-34	WBC (10 ³ /uL)	3.97	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	-1	-22	WBC (10 ³ /uL)	4.40	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	1	1	WBC (10 ³ /uL)	4.16	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	8	7	WBC (10 ³ /uL)	4.02	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	29	27	WBC (10 ³ /uL)	4.44	N/A	N/A	N/A	N/A
CV01VR016	50 µg (56-70 years)	FEMALE	60	36	35	WBC (10 ³ /uL)	4.89	N/A	N/A	N/A	N/A
CV01VR017	50 µg (56-70 years)	FEMALE	59	-1	-34	Hemoglobin (g/dL)	12.5	N/A	N/A	N/A	N/A
CV01VR017	50 µg (56-70 years)	FEMALE	59	1	1	Hemoglobin (g/dL)	12.6	N/A	N/A	N/A	N/A
CV01VR017	50 µg (56-70 years)	FEMALE	59	8	7	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	within institutional normal range	NC- DOSE NOT CHANGED	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR017	50 µg (56-70 years)	FEMALE	59	29	27	Hemoglobin (g/dL)	12.2 (Mild)	NOT RELATED	hemoglobin within institutional range	NC- DOSE NOT CHANGED	No
CV01VR017	50 µg (56-70 years)	FEMALE	59	36	35	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	hemoglobin is within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR017	50 µg (56-70 years)	FEMALE	59	-1	-34	PT (seconds)	13.5	N/A	N/A	N/A	N/A
CV01VR017	50 µg (56-70 years)	FEMALE	59	-1	-34	PTT (seconds)	31.2	N/A	N/A	N/A	N/A
CV01VR017	50 µg (56-70 years)	FEMALE	59	-1	-34	Platelets (10 ³ /uL)	248	N/A	N/A	N/A	N/A
CV01VR017	50 µg (56-70 years)	FEMALE	59	1	1	Platelets (10 ³ /uL)	248	N/A	N/A	N/A	N/A
CV01VR017	50 µg (56-70 years)	FEMALE	59	8	7	Platelets (10 ³ /uL)	228	N/A	N/A	N/A	N/A
CV01VR017	50 µg (56-70 years)	FEMALE	59	29	27	Platelets (10 ³ /uL)	247	N/A	N/A	N/A	N/A
CV01VR017	50 µg (56-70 years)	FEMALE	59	36	35	Platelets (10 ³ /uL)	282	N/A	N/A	N/A	N/A
CV01VR017	50 µg (56-70 years)	FEMALE	59	-1	-34	WBC (10 ³ /uL)	5.35	N/A	N/A	N/A	N/A
CV01VR017	50 µg (56-70 years)	FEMALE	59	1	1	WBC (10 ³ /uL)	4.81	N/A	N/A	N/A	N/A
CV01VR017	50 µg (56-70 years)	FEMALE	59	8	7	WBC (10 ³ /uL)	4.44	N/A	N/A	N/A	N/A
CV01VR017	50 µg (56-70 years)	FEMALE	59	29	27	WBC (10 ³ /uL)	4.94	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR017	50 µg (56-70 years)	FEMALE	59	36	35	WBC (10 ³ /uL)	4.30	N/A	N/A	N/A	N/A
CV01VR018	50 µg (≥71 years)	MALE	83	-1	-35	Hemoglobin (g/dL)	15.2	N/A	N/A	N/A	N/A
CV01VR018	50 µg (≥71 years)	MALE	83	1	1	Hemoglobin (g/dL)	16.4	N/A	N/A	N/A	N/A
CV01VR018	50 µg (≥71 years)	MALE	83	8	7	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Hgb within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR018	50 µg (≥71 years)	MALE	83	29	27	Hemoglobin (g/dL)	15.3 (Mild)	NOT RELATED	hemoglobin within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR018	50 µg (≥71 years)	MALE	83	36	33	Hemoglobin (g/dL)	15.4 (Mild)	NOT RELATED	Hemoglobin within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR018	50 µg (≥71 years)	MALE	83	-1	-35	PT (seconds)	14.6	N/A	N/A	N/A	N/A
CV01VR018	50 µg (≥71 years)	MALE	83	-1	-35	PTT (seconds)	30.6	N/A	N/A	N/A	N/A
CV01VR018	50 µg (≥71 years)	MALE	83	-1	-35	Platelets (10 ³ /uL)	167	N/A	N/A	N/A	N/A
CV01VR018	50 µg (≥71 years)	MALE	83	1	1	Platelets (10 ³ /uL)	182	N/A	N/A	N/A	N/A
CV01VR018	50 µg (≥71 years)	MALE	83	8	7	Platelets (10 ³ /uL)	182	N/A	N/A	N/A	N/A
CV01VR018	50 µg (≥71 years)	MALE	83	29	27	Platelets (10 ³ /uL)	173	N/A	N/A	N/A	N/A
CV01VR018	50 µg (≥71 years)	MALE	83	36	33	Platelets (10 ³ /uL)	183	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR018	50 µg (≥71 years)	MALE	83	-1	-35	WBC (10 ³ /uL)	6.47	N/A	N/A	N/A	N/A
CV01VR018	50 µg (≥71 years)	MALE	83	1	1	WBC (10 ³ /uL)	6.47	N/A	N/A	N/A	N/A
CV01VR018	50 µg (≥71 years)	MALE	83	8	7	WBC (10 ³ /uL)	5.53	N/A	N/A	N/A	N/A
CV01VR018	50 µg (≥71 years)	MALE	83	29	27	WBC (10 ³ /uL)	6.69	N/A	N/A	N/A	N/A
CV01VR018	50 µg (≥71 years)	MALE	83	36	33	WBC (10 ³ /uL)	6.81	N/A	N/A	N/A	N/A
CV01VR021	50 µg (≥71 years)	MALE	73	-1	-32	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
CV01VR021	50 µg (≥71 years)	MALE	73	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
CV01VR021	50 µg (≥71 years)	MALE	73	8	7	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	anemia due to blood draws	NC- DOSE NOT CHANGED	No
CV01VR021	50 µg (≥71 years)	MALE	73	29	27	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	hemoglobin within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR021	50 µg (≥71 years)	MALE	73	36	35	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	anemia due to blood draws	NC- DOSE NOT CHANGED	No
CV01VR021	50 µg (≥71 years)	MALE	73	57	55	Hemoglobin (g/dL)	14.7 (Mild)	NOT RELATED	Hgb within institutional normal range	NA- NOT APPLICABLE	No
CV01VR021	50 µg (≥71 years)	MALE	73	-1	-32	PT (seconds)	12.7	N/A	N/A	N/A	N/A
CV01VR021	50 µg (≥71 years)	MALE	73	-1	-32	PTT (seconds)	28.4	N/A	N/A	N/A	N/A
CV01VR021	50 µg (≥71 years)	MALE	73	-1	-32	Platelets (10 ³ /uL)	220	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR021	50 µg (≥71 years)	MALE	73	1	1	Platelets (10 ³ /uL)	256	N/A	N/A	N/A	N/A
CV01VR021	50 µg (≥71 years)	MALE	73	8	7	Platelets (10 ³ /uL)	211	N/A	N/A	N/A	N/A
CV01VR021	50 µg (≥71 years)	MALE	73	29	27	Platelets (10 ³ /uL)	268	N/A	N/A	N/A	N/A
CV01VR021	50 µg (≥71 years)	MALE	73	36	35	Platelets (10 ³ /uL)	241	N/A	N/A	N/A	N/A
CV01VR021	50 µg (≥71 years)	MALE	73	57	55	Platelets (10 ³ /uL)	295	N/A	N/A	N/A	N/A
CV01VR021	50 µg (≥71 years)	MALE	73	-1	-32	WBC (10 ³ /uL)	6.77	N/A	N/A	N/A	N/A
CV01VR021	50 µg (≥71 years)	MALE	73	1	1	WBC (10 ³ /uL)	6.04	N/A	N/A	N/A	N/A
CV01VR021	50 µg (≥71 years)	MALE	73	8	7	WBC (10 ³ /uL)	6.12	N/A	N/A	N/A	N/A
CV01VR021	50 µg (≥71 years)	MALE	73	29	27	WBC (10 ³ /uL)	6.47	N/A	N/A	N/A	N/A
CV01VR021	50 µg (≥71 years)	MALE	73	36	35	WBC (10 ³ /uL)	7.53	N/A	N/A	N/A	N/A
CV01VR021	50 µg (≥71 years)	MALE	73	57	55	WBC (10 ³ /uL)	8.80	N/A	N/A	N/A	N/A
CV01VR024	50 µg (56-70 years)	MALE	60	-1	-28	Hemoglobin (g/dL)	16.9	N/A	N/A	N/A	N/A
CV01VR024	50 µg (56-70 years)	MALE	60	1	1	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A
CV01VR024	50 µg (56-70 years)	MALE	60	8	7	Hemoglobin (g/dL)	15.6 (Mild)	NOT RELATED	hgb within INR	NC- DOSE NOT CHANGED	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR024	50 µg (56-70 years)	MALE	60	29	31	Hemoglobin (g/dL)	16.0 (Mild)	NOT RELATED	hemoglobin within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR024	50 µg (56-70 years)	MALE	60	36	37	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A
CV01VR024	50 µg (56-70 years)	MALE	60	-1	-28	PT (seconds)	13.1	N/A	N/A	N/A	N/A
CV01VR024	50 µg (56-70 years)	MALE	60	-1	-28	PTT (seconds)	31.9	N/A	N/A	N/A	N/A
CV01VR024	50 µg (56-70 years)	MALE	60	-1	-28	Platelets (10 ³ /uL)	264	N/A	N/A	N/A	N/A
CV01VR024	50 µg (56-70 years)	MALE	60	1	1	Platelets (10 ³ /uL)	262	N/A	N/A	N/A	N/A
CV01VR024	50 µg (56-70 years)	MALE	60	8	7	Platelets (10 ³ /uL)	249	N/A	N/A	N/A	N/A
CV01VR024	50 µg (56-70 years)	MALE	60	29	31	Platelets (10 ³ /uL)	224	N/A	N/A	N/A	N/A
CV01VR024	50 µg (56-70 years)	MALE	60	36	37	Platelets (10 ³ /uL)	260	N/A	N/A	N/A	N/A
CV01VR024	50 µg (56-70 years)	MALE	60	-1	-28	WBC (10 ³ /uL)	7.27	N/A	N/A	N/A	N/A
CV01VR024	50 µg (56-70 years)	MALE	60	1	1	WBC (10 ³ /uL)	11.98 (Mild)	N/A	N/A	N/A	N/A
CV01VR024	50 µg (56-70 years)	MALE	60	8	7	WBC (10 ³ /uL)	9.81	N/A	N/A	N/A	N/A
CV01VR024	50 µg (56-70 years)	MALE	60	29	31	WBC (10 ³ /uL)	6.82	N/A	N/A	N/A	N/A
CV01VR024	50 µg (56-70 years)	MALE	60	36	37	WBC (10 ³ /uL)	8.15	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR028	50 µg (56-70 years)	FEMALE	61	-1	-29	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
CV01VR028	50 µg (56-70 years)	FEMALE	61	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
CV01VR028	50 µg (56-70 years)	FEMALE	61	8	7	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	hgb within INR	NC- DOSE NOT CHANGED	No
CV01VR028	50 µg (56-70 years)	FEMALE	61	29	27	Hemoglobin (g/dL)	14.5 (Mild)	NOT RELATED	Hgb within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR028	50 µg (56-70 years)	FEMALE	61	36	33	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	hemoglobin within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR028	50 µg (56-70 years)	FEMALE	61	-1	-29	PT (seconds)	14.0	N/A	N/A	N/A	N/A
CV01VR028	50 µg (56-70 years)	FEMALE	61	-1	-29	PTT (seconds)	31.6	N/A	N/A	N/A	N/A
CV01VR028	50 µg (56-70 years)	FEMALE	61	-1	-29	Platelets (10 ³ /uL)	188	N/A	N/A	N/A	N/A
CV01VR028	50 µg (56-70 years)	FEMALE	61	1	1	Platelets (10 ³ /uL)	184	N/A	N/A	N/A	N/A
CV01VR028	50 µg (56-70 years)	FEMALE	61	8	7	Platelets (10 ³ /uL)	205	N/A	N/A	N/A	N/A
CV01VR028	50 µg (56-70 years)	FEMALE	61	29	27	Platelets (10 ³ /uL)	170	N/A	N/A	N/A	N/A
CV01VR028	50 µg (56-70 years)	FEMALE	61	36	33	Platelets (10 ³ /uL)	194	N/A	N/A	N/A	N/A
CV01VR028	50 µg (56-70 years)	FEMALE	61	-1	-29	WBC (10 ³ /uL)	5.68	N/A	N/A	N/A	N/A
CV01VR028	50 µg (56-70 years)	FEMALE	61	1	1	WBC (10 ³ /uL)	7.56	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR028	50 µg (56-70 years)	FEMALE	61	8	7	WBC (10 ³ /uL)	5.56	N/A	N/A	N/A	N/A
CV01VR028	50 µg (56-70 years)	FEMALE	61	29	27	WBC (10 ³ /uL)	5.54	N/A	N/A	N/A	N/A
CV01VR028	50 µg (56-70 years)	FEMALE	61	36	33	WBC (10 ³ /uL)	6.64	N/A	N/A	N/A	N/A
CV01VR030	50 µg (≥71 years)	FEMALE	78	-1	-28	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
CV01VR030	50 µg (≥71 years)	FEMALE	78	1	1	Hemoglobin (g/dL)	13.5	N/A	N/A	N/A	N/A
CV01VR030	50 µg (≥71 years)	FEMALE	78	8	7	Hemoglobin (g/dL)	13.4 (Mild)	NOT RELATED	hgb within INR	NC- DOSE NOT CHANGED	No
CV01VR030	50 µg (≥71 years)	FEMALE	78	29	27	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	Hgb within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR030	50 µg (≥71 years)	FEMALE	78	36	35	Hemoglobin (g/dL)	12.8 (Mild)	NOT RELATED	Hemoglobin is within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR030	50 µg (≥71 years)	FEMALE	78	-1	-28	PT (seconds)	13.9	N/A	N/A	N/A	N/A
CV01VR030	50 µg (≥71 years)	FEMALE	78	-1	-28	PTT (seconds)	33.3	N/A	N/A	N/A	N/A
CV01VR030	50 µg (≥71 years)	FEMALE	78	-1	-28	Platelets (10 ³ /uL)	355	N/A	N/A	N/A	N/A
CV01VR030	50 µg (≥71 years)	FEMALE	78	1	1	Platelets (10 ³ /uL)	321	N/A	N/A	N/A	N/A
CV01VR030	50 µg (≥71 years)	FEMALE	78	8	7	Platelets (10 ³ /uL)	350	N/A	N/A	N/A	N/A
CV01VR030	50 µg (≥71 years)	FEMALE	78	29	27	Platelets (10 ³ /uL)	327	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR030	50 µg (≥71 years)	FEMALE	78	36	35	Platelets (10 ³ /uL)	342	N/A	N/A	N/A	N/A
CV01VR030	50 µg (≥71 years)	FEMALE	78	-1	-28	WBC (10 ³ /uL)	7.43	N/A	N/A	N/A	N/A
CV01VR030	50 µg (≥71 years)	FEMALE	78	1	1	WBC (10 ³ /uL)	7.14	N/A	N/A	N/A	N/A
CV01VR030	50 µg (≥71 years)	FEMALE	78	8	7	WBC (10 ³ /uL)	5.82	N/A	N/A	N/A	N/A
CV01VR030	50 µg (≥71 years)	FEMALE	78	29	27	WBC (10 ³ /uL)	6.53	N/A	N/A	N/A	N/A
CV01VR030	50 µg (≥71 years)	FEMALE	78	36	35	WBC (10 ³ /uL)	5.08	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	-1	-24	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	1	1	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	8	7	Hemoglobin (g/dL)	13.7 (Mild)	NOT RELATED	Hgb within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR035	50 µg (≥71 years)	FEMALE	77	29	27	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	Hemoglobin within institutional normal limits	NC- DOSE NOT CHANGED	No
CV01VR035	50 µg (≥71 years)	FEMALE	77	36	35	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	hemoglobin is within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR035	50 µg (≥71 years)	FEMALE	77	-1	-24	PT (seconds)	13.7	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	-1	-24	PTT (seconds)	31.2	N/A	N/A	N/A	N/A

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR035	50 µg (≥71 years)	FEMALE	77	-1	-24	Platelets (10 ³ /uL)	199	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	1	1	Platelets (10 ³ /uL)	215	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	8	7	Platelets (10 ³ /uL)	196	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	29	27	Platelets (10 ³ /uL)	192	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	36	35	Platelets (10 ³ /uL)	207	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	-1	-24	WBC (10 ³ /uL)	5.75	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	1	1	WBC (10 ³ /uL)	5.35	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	8	7	WBC (10 ³ /uL)	5.54	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	29	27	WBC (10 ³ /uL)	5.13	N/A	N/A	N/A	N/A
CV01VR035	50 µg (≥71 years)	FEMALE	77	36	35	WBC (10 ³ /uL)	5.30	N/A	N/A	N/A	N/A
CV01VR037	50 µg (≥71 years)	FEMALE	74	-1	-24	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A
CV01VR037	50 µg (≥71 years)	FEMALE	74	1	1	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
CV01VR037	50 µg (≥71 years)	FEMALE	74	8	7	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	Hgb within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR037	50 µg (≥71 years)	FEMALE	74	29	27	Hemoglobin (g/dL)	14.5 (Mild)	NOT RELATED	hemoglobin within institutional normal range	NC- DOSE NOT CHANGED	No

Subject ID	Treatment Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
CV01VR037	50 µg (≥71 years)	FEMALE	74	36	35	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	hemoglobin is within institutional normal range	NC- DOSE NOT CHANGED	No
CV01VR037	50 µg (≥71 years)	FEMALE	74	-1	-24	PT (seconds)	12.8	N/A	N/A	N/A	N/A
CV01VR037	50 µg (≥71 years)	FEMALE	74	-1	-24	PTT (seconds)	31.0	N/A	N/A	N/A	N/A
CV01VR037	50 µg (≥71 years)	FEMALE	74	-1	-24	Platelets (10 ³ /uL)	272	N/A	N/A	N/A	N/A
CV01VR037	50 µg (≥71 years)	FEMALE	74	1	1	Platelets (10 ³ /uL)	246	N/A	N/A	N/A	N/A
CV01VR037	50 µg (≥71 years)	FEMALE	74	8	7	Platelets (10 ³ /uL)	235	N/A	N/A	N/A	N/A
CV01VR037	50 µg (≥71 years)	FEMALE	74	29	27	Platelets (10 ³ /uL)	318	N/A	N/A	N/A	N/A
CV01VR037	50 µg (≥71 years)	FEMALE	74	36	35	Platelets (10 ³ /uL)	260	N/A	N/A	N/A	N/A
CV01VR037	50 µg (≥71 years)	FEMALE	74	-1	-24	WBC (10 ³ /uL)	8.07	N/A	N/A	N/A	N/A
CV01VR037	50 µg (≥71 years)	FEMALE	74	1	1	WBC (10 ³ /uL)	6.50	N/A	N/A	N/A	N/A
CV01VR037	50 µg (≥71 years)	FEMALE	74	8	7	WBC (10 ³ /uL)	6.80	N/A	N/A	N/A	N/A
CV01VR037	50 µg (≥71 years)	FEMALE	74	29	27	WBC (10 ³ /uL)	7.77	N/A	N/A	N/A	N/A
CV01VR037	50 µg (≥71 years)	FEMALE	74	36	35	WBC (10 ³ /uL)	5.60	N/A	N/A	N/A	N/A